PaxMedica, Inc. Common Stock (PXMD) S-1 19 Dec 22 IPO registration Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Sep. 30, 2022
Document and Entity Information [Abstract]
Document Type	S-1
Entity Registrant Name	PAXMEDICA, INC.
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Central Index Key	0001811623
Amendment Flag	false

Balance Sheets

Balance Sheets	Dec. 31, 2020 USD ($)
Current assets
Cash	$ 1,123,625
Total current assets	1,123,625
Total assets	1,123,625
Current liabilities
Accounts payable	346,094
Accounts payable - related party	102,803
Accrued expenses	578,524
Accrued interest	55,175
Notes payable, net of discount of $0 and $2,550,780	611,641
Warrant liability	4,057,927
Total current liabilities	5,752,164
Total liabilities	5,752,164
Commitments and contingencies
Stockholders' deficit
Preferred stock	270
Common stock, par value $0.0001; 20,000,000 shares authorized at December 31, 2021 and 2020; 6,913,492 and 5,775,898 shares issued and outstanding at December 31, 2021 and 2020, respectively	578
Additional paid-in capital	4,079,891
Accumulated deficit	(8,709,278)
Total stockholders' equity (deficit)	(4,628,539)
Total liabilities, and stockholders' equity (deficit)	$ 1,123,625

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
CONDENSED BALANCE SHEETS
Notes payable, Discount	$ 0	$ 2,550,780
Preferred shares, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred shares, shares authorized (in shares)	2,696,439	2,696,439
Preferred shares, shares issued (in shares)	2,696,439	2,696,439
Preferred shares, shares outstanding (in shares)	2,696,439	2,696,439
Preferred shares, aggregate liquidation preference	$ 2,808,148	$ 2,808,148
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	20,000,000	20,000,000
Common stock, shares issued (in shares)	6,913,492	5,775,898
Common stock, shares outstanding (in shares)	6,913,492	5,775,898

Statements of Operations

Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating expenses
General and administrative	$ 4,973,245	$ 4,629,070
Research and development	2,224,555	936,776
Total operating expenses	7,197,800	5,565,846
Loss from operations	(7,197,800)	(5,565,846)
Other income (expense):
Interest expense	(2,805,856)	(609,458)
Loss on issuance of debt		(53,541)
Loss on extinguishment of debt		(23,284)
Gain on conversion of notes	59,890
Change in fair value of SAFE	175,783
Change in fair value warrant liability	(458,558)	(1,569,383)
Change in fair value of derivative		(4,496)
Other income	2,665
Other expense	(5,095)
Total other expense	(3,031,171)	(2,260,162)
Net loss	(10,228,971)	(7,826,008)
Less: Accrued preferred unit and stock dividend		(19,442)
Less: Deemed dividend - beneficial conversion feature on preferred stock		(1,452,422)
Net loss attributable to common stockholders	$ (10,228,971)	$ (9,297,872)
Basic weighted average number of shares outstanding	6,666,005	5,775,898
Diluted weighted average number of shares outstanding	6,666,005	5,775,898
Basic net loss per share attributable to common stockholders	$ (1.53)	$ (1.61)
Diluted net loss per share attributable to common stockholders	$ (1.53)	$ (1.61)

Statements of Stockholders' Def

Statements of Stockholders' Deficit - USD ($)	Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Preferred Units	Common Units	Total
Beginning balance at Dec. 31, 2019				$ (863,828)			$ (863,828)
Increase (Decrease) in Stockholders' Equity
Stock-based compensation			$ 2,262,093				$ 2,262,093
Accrued preferred unit and stock dividend					$ 19,442
Accrued preferred unit and stock dividend (in Units)				(19,442)	38,884		(19,442)
Beneficial conversion feature in connection with notes payable			462,920				$ 462,920
Conversion of preferred units to preferred stock	$ 267		1,340,916				1,341,183
Conversion of preferred units to preferred stock (in shares)	2,667,353
Conversion of common units to common stock		$ 578	(578)
Conversion of common units to common stock (in shares)		5,775,898
Net income (loss)				$ (7,826,008)			(7,826,008)
Ending balance at Dec. 31, 2020	$ 270	$ 578	4,079,891	(8,709,278)			(4,628,539)
Ending balance (in shares) at Dec. 31, 2020	2,696,439	5,775,898
Beginning balance at Dec. 31, 2019					$ 765,527
Beginning balance (in Units) at Dec. 31, 2019					1,516,041	5,775,898
Increase (Decrease) in Stockholders' Equity
Contribution from TardiMed					$ 470,000
Contribution from TardiMed (in Units)					940,000
Investor contributions					$ 50,000
Investor contributions (in Units)					100,000
Non-cash contribution from TardiMed	$ 3		14,540		$ 36,214		14,543
Non-cash contribution from TardiMed (in Units)	29,086				72,428
Conversion of preferred units to preferred stock					$ (1,341,183)
Conversion of preferred units to preferred stock (in units)					(2,667,353)
Conversion of common units to common stock (in units)						(5,775,898)
Common stock issued in connection with conversion of notes payable		$ 113	3,412,669				3,412,782
Issuance of common stock in connection with conversion of notes payable (in shares)		1,137,594
Stock-based compensation			1,110,874				1,110,874
Net income (loss)				(16,462,227)			(16,462,227)
Ending balance at Sep. 30, 2021		$ 691	8,603,434	(25,171,505)			(16,567,110)
Ending balance (in shares) at Sep. 30, 2021		6,913,492
Beginning balance at Dec. 31, 2020	$ 270	$ 578	4,079,891	(8,709,278)			(4,628,539)
Beginning balance (in shares) at Dec. 31, 2020	2,696,439	5,775,898
Increase (Decrease) in Stockholders' Equity
Common stock issued in connection with conversion of notes payable		$ 113	3,412,669				$ 3,412,782
Issuance of common stock in connection with conversion of notes payable (in shares)		1,137,594					1,137,594
Stock-based compensation			1,335,865				$ 1,335,865
Net income (loss)				(10,228,971)			(10,228,971)
Ending balance at Dec. 31, 2021	$ 270	$ 691	8,828,425	(18,938,249)			(10,108,863)
Ending balance (in shares) at Dec. 31, 2021	2,696,439	6,913,492
Beginning balance at Jun. 30, 2021		$ 691	8,331,310	(22,060,863)			(13,728,592)
Beginning balance (in shares) at Jun. 30, 2021		6,913,492
Increase (Decrease) in Stockholders' Equity
Stock-based compensation			272,124				272,124
Net income (loss)				(3,110,642)			(3,110,642)
Ending balance at Sep. 30, 2021		$ 691	8,603,434	(25,171,505)			(16,567,110)
Ending balance (in shares) at Sep. 30, 2021		6,913,492
Beginning balance at Dec. 31, 2021	$ 270	$ 691	8,828,425	(18,938,249)			(10,108,863)
Beginning balance (in shares) at Dec. 31, 2021	2,696,439	6,913,492
Increase (Decrease) in Stockholders' Equity
Common stock issued in connection with conversion of notes payable		$ 24	1,159,476				1,159,500
Issuance of common stock in connection with conversion of notes payable (in shares)		238,094
Stock-based compensation			1,377,165				1,377,165
Net income (loss)				(9,581,119)			(9,581,119)
Ending balance at Sep. 30, 2022		$ 1,178	30,906,477	(28,519,368)			2,388,302
Ending balance (in shares) at Sep. 30, 2022		11,779,475
Beginning balance at Jun. 30, 2022		$ 691	9,158,437	(17,055,755)			(7,896,357)
Beginning balance (in shares) at Jun. 30, 2022		6,913,492
Increase (Decrease) in Stockholders' Equity
Common stock issued in connection with conversion of notes payable		$ 24	1,159,476				1,159,500
Issuance of common stock in connection with conversion of notes payable (in shares)		238,094
Stock-based compensation			1,047,153				1,047,153
Net income (loss)				(11,463,613)			(11,463,613)
Ending balance at Sep. 30, 2022		$ 1,178	$ 30,906,477	$ (28,519,368)			$ 2,388,302
Ending balance (in shares) at Sep. 30, 2022		11,779,475

Statements of Cash Flows

Statements of Cash Flows	12 Months Ended
	Dec. 31, 2020 USD ($)
Cash flows from operating activities
Net loss	$ (7,826,008)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	2,262,093
Amortization of debt discount	551,752
Loss on issuance of debt	53,541
Loss on extinguishment of debt	23,284
Change in fair value warrant liability	1,569,383
Change in fair value of derivative	4,496
Non-cash contribution from TardiMed	50,757
Changes in assets and liabilities:
Accounts payable	305,071
Accounts payable - related party	87,478
Accrued expenses	511,624
Accrued interest	57,707
Net cash used in operating activities	(2,348,822)
Cash flows from financing activities
Contribution from TardiMed	470,000
Proceeds from notes payable	2,927,500
Third party investor contributions	50,000
Net cash provided by financing activities	3,447,500
Net increase in cash	1,098,678
Cash, beginning of period	24,947
Cash, end of period	1,123,625
Non-cash financing activities:
Deemed dividend - beneficial conversion feature on preferred stock	1,452,422
Conversion of preferred units to preferred stock	1,341,183
Beneficial conversion feature in connection with notes payable	462,920
Accrued preferred unit and stock dividend	$ 19,442

Organization and description of

Organization and description of business operations	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Organization and description of business operations
Organization and description of business operations	Note 1. Organization and description of business operations PaxMedica, Inc. (the “Company”) is a clinical stage biopharmaceutical company organized as a Delaware limited liability company on April 5, 2018 (“Inception”) to focus on the development of drug candidates for the treatment of autism spectrum disorder (ASD), Fragile X syndrome tremor-ataxia (FXTAS) and Human African Trypanosomiasis (HAT). Initial Public Offering On August 9, 2022, the Company entered into an underwriting agreement relating to the public offering of its common stock, par value $0.0001 per share. The Company agreed to sell 1,545,454 shares of its common stock to the underwriters, at a purchase price per share of $4.83 (the offering price to the public of $5.25 per share minus the underwriters’ discount), pursuant to the Company’s registration statement on Form S-1 (File No. 333-239676), as amended, under the Securities Act of 1933, that was filed by the Company under Rule 462(b) under the Securities Act. The Company also granted the underwriters a 45 - day option to purchase up to 231,818 additional shares of common stock to cover over-allotments. On August 30, 2022, the Company received net proceeds from its public offering of approximately $6.0 million, net of underwriter fees and commissions of approximately $0.8 million, and offering costs of approximately $1.4 million. In connection with its public offering the Company issued 108,181 warrants to purchase shares of the Company’s common stock with an exercise price of $6.5625 per share. Going concern, liquidity and capital resources The Company has no product revenues, incurred operating losses since inception, and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. The Company had an accumulated deficit of approximately $28.5 million at September 30, 2022, a net loss of approximately $9.6 million, and approximately $3.0 million of net cash used in operating activities for the nine months ended September 30, 2022. 2022 Notes During the second and third quarters of 2022, the Company entered into senior secured convertible promissory notes (the “2022 Notes”) with a principal balance totaling approximately $1.5 million. The 2022 Notes contain an original issue discount totaling $0.3 million and the Company received net proceeds of approximately $1.2 million (See Note 6). Series X Preferred Stock On August 2, 2022, the Company issued 3,200 shares of Series X preferred stock, par value $0.0001 per share at a purchase price of $100 per share. The Company received net proceeds of approximately $0.3 million, net of fees. (See Note 8). Going Concern The accompanying condensed financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern. The Company’s future liquidity and capital funding requirements will depend on numerous factors, including: ● its ability to raise additional funds to finance its operations; ● the outcome, costs and timing of clinical trial results for the Company’s current or future product candidates; ● the emergence and effect of competing or complementary products; ● its ability to maintain, expand and defend the scope of its intellectual property portfolio, including the amount and timing of any payments the Company may be required to make, or that it may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights; ● its ability to retain its current employees and the need and ability to hire additional management and scientific and medical personnel; and ● the terms and timing of any collaborative, licensing or other arrangements that it has or may establish. The Company will likely need to raise substantial additional funds through one or more of the following: issuance of additional debt or equity, or the completion of a licensing transaction for one or more of the Company’s pipeline assets. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. This could affect future development and business activities and potential future clinical studies and/or other future ventures. Failure to obtain additional equity or debt financing will have a material, adverse impact on the Company’s business operations. There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or debt financings will likely have a dilutive effect on the holdings of the Company’s existing stockholders. Accordingly, there are material risks and uncertainties that raise substantial doubt about the Company’s ability to continue as a going concern for the next twelve months from the issuance of these condensed financial statements. The accompanying condensed financial statements do not include any adjustments that result from the outcome of these uncertainties. The COVID-19 global pandemic has been unprecedented and unpredictable, is likely to continue to result in significant national and global economic disruption, which may adversely affect our business. Based on the Company’s current assessment, the Company does not expect any material impact on its long-term development timeline and its liquidity due to the worldwide spread of the COVID-19 virus. However, the Company is continuing to assess the effect on its operations by monitoring the spread of COVID-19 and the resulting global pandemic and the actions implemented to combat the virus throughout the world.	Note 1. Organization and description of business operations PaxMedica, Inc. (Formerly Purinix Pharmaceuticals LLC) (the “Company”) is a clinical stage biopharmaceutical company organized as a Delaware limited liability company on April 5, 2018 (“Inception”) to focus on the development of drug candidates for the treatment of autism spectrum disorder (ASD), Fragile X syndrome tremor-ataxia (FXTAS) and Human African Trypanosomiasis (HAT). On April 15, 2020, Purinix Pharmaceuticals LLC converted from a limited liability company (“ LLC”) to a Delaware corporation and changed its name to PaxMedica, Inc., resulting in a new capital structure consisting of two classes of stock: common and preferred, each having a par value of $0.0001 . The Company has authorized 20,000,000 shares of common stock and 2,696,439 shares of preferred stock. This conversion resulted in conversion of the current members’ LLC interests into an aggregate of 2,696,439 shares of preferred stock, which are convertible into 1,557,435 shares of common stock, and 5,775,898 shares of common stock of the Company. On July 22, 2020, the Company filed with the state of Delaware a certificate of amendment for its certificate of incorporation and effected a 1-for- 0.5775898 reverse stock split of its common stock. All share and per share information in the accompanying financial statements and footnotes has been retroactively adjusted for the effects of the reverse split for all periods presented. Going concern, liquidity and capital resources The Company has no product revenues, incurred operating losses since inception, and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. The Company had an accumulated deficit of approximately $18.9 million at December 31, 2021, a net loss of approximately $10.2 million, and approximately $5.5 million of net cash used in operating activities for the year ended December 31, 2021. On March 19, 2021, the Company entered into a Simple Agreement for Future Equity (“SAFE”) with an investor and received proceeds of $5.0 million. Under the terms of the SAFE, the investor has rights to certain shares of the Company’s common and preferred stock at a discount to the price at which those securities might be issued (See Note 6). The accompanying financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern. The Company’s future liquidity and capital funding requirements will depend on numerous factors, including: ● its ability to raise additional funds to finance its operations; ● the outcome, costs and timing of clinical trial results for the Company’s current or future product candidates; ● the emergence and effect of competing or complementary products; ● its ability to maintain, expand and defend the scope of its intellectual property portfolio, including the amount and timing of any payments the Company may be required to make, or that it may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights; ● its ability to retain its current employees and the need and ability to hire additional management and scientific and medical personnel; and ● the terms and timing of any collaborative, licensing or other arrangements that it has or may establish. The Company will likely need to raise substantial additional funds through one or more of the following: issuance of additional debt or equity, or the completion of a licensing transaction for one or more of the Company’s pipeline assets. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. This could affect future development and business activities and potential future clinical studies and/or other future ventures. Failure to obtain additional equity or debt financing will have a material, adverse impact on the Company’s business operations. There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or debt financings will likely have a dilutive effect on the holdings of the Company’s existing stockholders. Accordingly, there are material risks and uncertainties that raise substantial doubt about the Company’s ability to continue as a going concern for the next twelve months from the issuance of these financial statements. The accompanying financial statements do not include any adjustments that result from the outcome of these uncertainties. The COVID-19 global pandemic has been unprecedented and unpredictable, is likely to continue to result in significant national and global economic disruption, which may adversely affect our business. Based on the Company’s current assessment, the Company does not expect any material impact on its long-term development timeline and its liquidity due to the worldwide spread of the COVID-19 virus. However, the Company is continuing to assess the effect on its operations by monitoring the spread of COVID-19 and the resulting global pandemic and the actions implemented to combat the virus throughout the world.

Significant accounting policies

Significant accounting policies	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Significant accounting policies
Significant accounting policies	Note 2. Significant accounting policies Basis of presentation The accompanying unaudited condensed financial statements are presented in U.S. dollars and in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected through December 31, 2022. The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the registration statement on Form S-1/A filed by the Company with the SEC on August 8, 2022. Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed financial statements relate to the valuation of convertible notes, valuation of warrants, valuation of the Simple Agreement For Equity (“SAFE”) liability and valuation of equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. Cash, cash equivalents and short-term investments The Company considers all highly liquid investments with an original maturity of three months or less at the date of acquisition to be cash equivalents. As of September 30, 2022 and December 31, 2021, the Company had no cash equivalents or short-term investments. Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash high credit quality financial institutions, which may at times, be in excess of federal insured limits. The Company believes it is not exposed to any significant losses due to credit risk on cash. Fair value of financial instruments The Company accounts for financial instruments under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification 820 (“ASC 820”), Fair Value Measurements. This statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements, ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels as follows: Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and Level 3 - assets and liabilities whose significant value drivers are unobservable. Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment. During the nine months ended September 30, 2022, the Company issued certain of the 2022 Notes and warrants in connection with the 2022 Notes. The 2022 Notes and warrants were classified as liabilities and measured at fair value on the issuance date, with changes in fair value recognized as other expense on the statements of operations and disclosed in the condensed financial statements During the year ended December 31, 2021, the Company entered into its SAFE agreement and classified the SAFE as a liability measured at cost on the issuance date, with changes in fair value recognized as other income on the statement of operations. The carrying amounts of the Company’s financial assets and liabilities, such as accounts payable, approximate fair value due to the short-term nature of these instruments. Convertible Notes In accordance with Accounting Standards Codification 825, Financial Instruments (“ASC 825”), the Company has elected the fair value option for recognition of its 2022 Notes. In accordance with ASC 825, the Company recognizes these 2022 Notes at fair value with changes in fair value recognized in the condensed statements of operations. The fair value option may be applied instrument by instrument, but it is irrevocable. As a result of applying the fair value option, direct costs and fees related to the convertible notes were recognized in general and administrative expense. Accrued interest for the 2022 Notes has been included in the change in fair value of convertible notes in the condensed statements of operations. Warrant Liability The Company accounts for certain common stock warrants outstanding as a liability at fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statements of operations. The fair value of the warrants issued by the Company have been estimated using the Monte Carlo simulation. As of September 30, 2022, there are no warrant liabilities (See Note 3). Simple Agreement for Future Equity The Company accounts for a SAFE as a liability at fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until a triggering event, equity financing or a liquidity/dissolution occurs, and any change in fair value is recognized in the Company’s statements of operations. The fair value of the SAFE has been estimated using the Backsolve method which utilizes the Option Pricing Method. As of September 30, 2022, the SAFE liability has been converted to 100,000 shares of Series X preferred stock (See Note 8). Research and development Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Accrued Outsourcing Costs Substantial portions of the Company’s preclinical studies and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors (collectively “CROs”). These CROs generally bill monthly or quarterly for services performed, or bill based upon milestone achievement. For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining. Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources a substantial portion of its clinical trial activities, utilizing external entities such as CROs, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies. For each clinical trial that the Company conducts, certain clinical trial costs are expensed immediately, while others are expensed over time based on the number of patients in the trial, the attrition rate at which patients leave the trial, and/or the period over which clinical investigators or CROs are expected to provide services. The Company’s estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives. Stock-Based Compensation The Company expenses stock-based compensation to employees, non-employees and board members over the requisite service period based on the estimated grant-date fair value of the awards and actual forfeitures. The Company accounts for forfeitures as they occur. Stock-based awards with graded vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. All stock-based compensation costs are recorded in general and administrative costs in the statements of operations. Loss Per Share Basic net loss per share (“EPS”) of common stock is computed by dividing net loss allocated to common shareholders by the weighted average number of common shares outstanding during the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity. The Company’s common stock equivalents have been excluded from the computation of diluted loss per share for the three and nine months ended September 30, 2022 and 2021, as the effect would be to reduce the loss per share. Therefore, the weighted average common stock outstanding used to calculate both basic and diluted loss per share is the same for the three and nine months ended September 30, 2022 and 2021. The following securities were excluded from the computation of diluted net loss per share attributable to common shareholders for the nine months ended September 30, 2022 and 2021, because including them would have been anti-dilutive: ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ 2022 2021 Preferred stock — 1,557,435 Series X preferred stock ​ 863,162 ​ — Unvested restricted stock units 1,582,220 1,377,999 Common stock warrants 587,497 1,034,176 SAFE investment — 414,808 Convertible notes 37,259 — Total 3,070,138 4,384,418 ​ Income taxes ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company’s condensed financial statements. The Company believes that its income tax positions and deductions would be sustained on audit and does not anticipate any adjustments that would result in material changes to its financial position. Recent accounting pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This ASU is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company adopted this standard on January 1, 2022, and the adoption did not have a material impact on the Company’s condensed financial statements or disclosures. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The Company adopted this standard on January 1, 2022, and the adoption did not have a material impact on the Company’s condensed financial statements or disclosures.	Note 2. Significant accounting policies Basis of presentation The Company’s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and include all adjustments necessary for the fair presentation of its balance sheets, results of operations and cash flows for the period presented. Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to the valuation of warrants, valuation of the SAFE liability and valuation of equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. Cash, cash equivalents and short-term investments The Company considers all highly liquid investments with an original maturity of three months or less at the date of acquisition to be cash equivalents. As of December 31, 2021 and 2020, the Company had no cash equivalents or short-term investments . Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash high credit quality financial institutions, which may at times, be in excess of federal insured limits. The Company believes it is not exposed to any significant losses due to credit risk on cash. Risks and Uncertainties The Company operates in a dynamic and highly competitive industry and is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, contract manufacturer and contract research organizations, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. The Company believes that changes in any of the following areas could have a material adverse effect on the Company’s future financial position, results of operations, or cash flows; ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Company’s products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company’s ability to attract and retain employees necessary to support its growth. Fair value of financial instruments The Company accounts for financial instruments under FASB Accounting Standards Codification 820 (“ASC 820”), Fair Value Measurements. This statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements, ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels as follows: Level 1 — quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 — observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and Level 3 — assets and liabilities whose significant value drivers are unobservable. Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment. During the year ended December 31, 2021, the Company entered into its SAFE agreement and classified the SAFE as a liability measured at cost on the issuance date, with changes in fair value recognized as other income on the statement of operations. During the year ended December 31, 2020, the Company issued convertible notes and warrants in connection with the notes. The notes and warrants were classified as liabilities and measured at fair value on the issuance date, with changes in fair value recognized as other expense on the statements of operations and disclosed in the financial statements. The carrying amounts of the Company’s financial assets and liabilities, such as accounts payable, approximate fair value due to the short-term nature of these instruments. Warrant Liability The Company accounts for certain common stock warrants outstanding as a liability at fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statements of operations. The fair value of the warrants issued by the Company has been estimated using the Monte Carlo simulation. Simple Agreement for Future Equity The Company accounts for a SAFE as a liability at fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until a triggering event, equity financing or a liquidity/dissolution occurs, and any change in fair value is recognized in the Company’s statements of operations. The fair value of the SAFE has been estimated using the Backsolve method which utilizes the Option Pricing Method. Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to interest rate, market, or foreign currency risks. The Company evaluates all of its financial instruments, including notes payable, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the statement of operations each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s balance sheet. During the year ended December 31, 2020, the Company entered into note agreements that were determined to have embedded derivative instruments in the form of contingent interest. The notes are recognized at the value of proceeds received after allocating issuance proceeds to the separable instruments issued with the notes and to the bifurcated contingent interest. The notes are subsequently measured at amortized cost using the effective interest method to accrete interest over their term to bring the notes’ initial carrying value to their principal balance at maturity. The bifurcated contingent interest is initially measured at fair value which is included in the notes payable balance on the accompanying balance sheets and subsequently measured at fair value with changes in fair value recognized as a component of other income (expense) in the statements of operations. The notes were converted during the year ended December 31, 2021 (See Note 5). Research and development Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Accrued Outsourcing Costs Substantial portions of the Company’s preclinical studies and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors (collectively “CROs”). These CROs generally bill monthly or quarterly for services performed, or bill based upon milestone achievement. For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining. Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources a substantial portion of its clinical trial activities, utilizing external entities such as CROs, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies. For each clinical trial that the Company conducts, certain clinical trial costs are expensed immediately, while others are expensed over time based on the number of patients in the trial, the attrition rate at which patients leave the trial, and/or the period over which clinical investigators or CROs are expected to provide services. The Company’s estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives. Convertible Financial Instruments The Company bifurcates conversion options from their host instruments and accounts for them as free standing derivative financial instruments if certain criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable GAAP. When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, discounts are recorded for the intrinsic value of conversion options embedded in the instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the instrument. Stock-Based Compensation The Company expenses stock-based compensation to employees, non-employees and board members over the requisite service period based on the estimated grant-date fair value of the awards and actual forfeitures. The Company accounts for forfeitures as they occur. Stock-based awards with graded vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. All stock-based compensation costs are recorded in general and administrative costs in the statements of operations. Loss Per Share Basic net loss per share (“EPS”) of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity. Since the Company has net losses, basic and diluted net loss per share is the same. Securities that could potentially dilute loss per share in the future were not included in the computation of diluted loss per share at December 31, 2021 and 2020, because their inclusion would be anti-dilutive are as follows: ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2021 2020 Preferred stock 1,557,435 1,557,435 Unvested restricted stock units — 1,377,999 Common stock warrants 1,034,176 1,034,176 Convertible notes — 1,034,177 SAFE investment (1) 414,808 — Total 3,006,419 5,003,787 (1) SAFE investment As of December 31, 2021, the Company’s price per share of $12.05 was calculated by dividing the post money valuation of $150 million by 12,444,251 shares of common stock outstanding. The 12,444,251 shares of common stock outstanding was calculated in accord with the agreement and includes 6,913,492 of common shares outstanding, 2,703,776 of IPO shares, 1,377,999 of restricted stock units, 1,034,176 of common stock warrants and 414,808 of SAFE shares. The SAFE investment shares of 414,808 (included in the table above) were calculated using the SAFE investment of $5.0 million divided by $12.05 per share. Income taxes From April 5, 2018 (Inception) through April 14, 2020, the Company was organized as an LLC and subject to the provisions of Subchapter K of the Internal Revenue Code. As such, the Company was not viewed as a taxpaying entity in any jurisdiction and did not require a provision for income taxes for this period. Each member was responsible for the tax liability, if any, related to its proportionate share of the Company’s taxable losses for this period. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company’s financial statements. The Company believes that its income tax positions and deductions would be sustained on audit and does not anticipate any adjustments that would result in material changes to its financial position. The Company converted to a C-Corporation on April 15, 2020 and therefore the Company is subject to examination starting in 2020. The Company’s tax year, 2021 and 2020 federal tax returns remain subject to examination by the Internal Revenue Service. Given the Company’s historical losses, the conversion to a C-Corporation did not have a material impact on the Company financial statements. Recent accounting pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This ASU is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company adopted this standard on January 1, 2022, and the adoption did not have a material impact on the Company’s financial statements or disclosures. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: (1) how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The Company adopted this standard on January 1, 2022, and the adoption did not have a material impact on the Company’s financial statements or disclosures.

Fair Value Measurements

Fair Value Measurements	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Fair Value Measurements
Fair Value Measurements	Note 3. Fair Value Measurements Convertible Notes During the second and third quarters of 2022, the Company issued the 2022 Notes. The fair value of the 2022 Notes on the issuance dates and as of September 30, 2022 were estimated using a Monte Carlo simulation to capture the path dependencies intrinsic to their terms. The significant unobservable inputs used in the fair value measurement of the Company’s convertible notes are the common stock price, volatility, and risk-free interest rates. Significant changes in these inputs may result in significantly lower or higher fair value measurement. The Company elected the fair value option when recording its 2022 Notes (See Note 2) and the notes were classified as liabilities and measured at fair value on the issuance date, with changes in fair value recognized as other income (expense) on the statements of operations and disclosed in the condensed financial statements. On August 26, 2022, two holders of the 2022 Notes converted their notes to 238,094 shares of the Company’s common stock and one holder of the 2022 Notes converted its note to 2,555 shares of Series X preferred stock. A summary of significant unobservable inputs (Level 3 inputs) used in measuring the 2022 Notes upon the issuance dates, conversion dates and during three and nine months ended September 30, 2022 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ​ ​ ​ ​ ​ ​ August 3, 2022 - ​ ended September ​ Nine months ended ​ ​ July 8, 2022 August 5, 2022 30, 2022 September 30, 2022 Dividend yield 0 % 0 % 0 % 0 % Expected price volatility 57.0 % 57.0 % 57.0 % 57.0% - 57.2 % Risk free interest rate 2.96 % 3.14 %- 3.29 % 2.8 %- 4.05 % 2.8 %- 4.05 % Expected term (in years) 1.0 1.0 0.7 - 0.9 ​ 0.7 - 0.9 ​ ​ Simple Agreement for Future Equity On March 19, 2021, the Company entered into a SAFE agreement with an investor. At issuance date, the Company classified the cash received of $5.0 million as a liability, with changes in fair value recognized as other income (expense) on the statements of operations and disclosed in the condensed financial statements (See Note 5). On August 2, 2022 the SAFE was converted to 100,000 shares of Series X preferred stock (See Note 8). A summary of significant unobservable inputs (Level 3 inputs) used in measuring the SAFE on the conversion date of August 2, 2022, and the period January 1, 2022 through August 2, 2022 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1, ​ ​ August 2, ​ 2022 - August ​ ​ 2022 2, 2022 Dividend yield 0 % 0 % Expected price volatility 50.0 % 50.0 % Risk free interest rate 3.08 % 1.35% - 3.08 % Expected term (in years) 1.5 0.8 - 1.5 ​ ​ Warrants During the nine months ended September 30, 2022, the Company issued 195,140 common stock warrants in connection with its 2022 Notes (See Note 6). During the year ended December 31, 2020, the Company issued 1,034,176 common stock warrants in association with its 2020 convertible notes (the “2020 Notes”) issued during 2020. The warrants were classified as liabilities and measured at fair value on the grant date, with changes in fair value recognized as other income (expense) on the statements of operations and disclosed in the condensed financial statements. On August 26, 2022, 750,000 warrants issued in connection with the 2020 Notes were exchanged for 350,000 shares of common stock and 1,250 shares of Series X preferred stock (see below). On August 26, 2022, 479,316 liability classified warrants were reclassified to equity. As of September 30, 2022, there are no liability classified warrants. Warrant Exchange On August 3, 2022, the Company entered into a warrant exchange agreement (the “Warrant Exchange Agreement”) with a holder of certain warrants to purchase the Company’s common stock. The warrants were issued in connection with the Company’s 2020 Notes. Pursuant to the Warrant Exchange Agreement, the Company exchanged 750,000 warrants for 350,000 shares of common stock and 1,250 shares of Series X preferred stock at the consummation of the Company’s initial public offering (See Note 8). A summary of significant unobservable inputs (Level 3 inputs) used in measuring warrants on issuance date, August 26, 2022, and during the period January 1, 2022 through August 26, 2022, is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1 2022 - ​ ​ July 2022 August 26, 2022 August 26, 2022 Dividend yield 0 % 0 % 0 % Expected price volatility 57.0 % 57.0 % 57.0% - 105.0 % Risk free interest rate 2.70 % - 2.82 % 2.39% - 3.40 % 0.17% - 3.40 % Expected term (in years) 5.0 ​ 0.1 - 4.9 0.1 - 4.0 ​ ​ Significant changes in the expected price volatility and expected term would result in significantly lower or higher fair value measurement of the warrants, respectively. The following tables classify the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of September 30, 2022 and December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value measured at September 30, 2022 ​ ​ ​ ​ Quoted prices in active ​ Significant other ​ Significant ​ ​ Total carrying value at ​ markets ​ observable inputs ​ unobservable inputs ​ September 30, 2022 (Level 1) (Level 2) (Level 3) Liabilities: ​ ​ ​ ​ Convertible notes ​ $ 156,486 ​ $ — ​ $ — ​ $ 156,486 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value measured at December 31, 2021 ​ ​ ​ ​ Quoted prices in active ​ Significant other ​ Significant ​ ​ Total carrying value at ​ markets ​ observable inputs ​ unobservable inputs ​ December 31, 2021 (Level 1) (Level 2) (Level 3) Liabilities: ​ ​ ​ ​ SAFE liability ​ $ 4,824,217 ​ $ — ​ $ — ​ $ 4,824,217 Warrant liability ​ $ 4,516,485 ​ $ — ​ $ — ​ $ 4,516,485 ​ For the three and nine months ended September 30, 2022, there was a change of approximately $3.3 million and $1.8 million in Level 3 liabilities measured at fair value, respectively. The fair value of the convertible notes may change significantly as additional data is obtained, impacting the Company’s assumptions used to estimate the fair value of the liabilities. In evaluating this information, considerable judgment is required to interpret the data used to develop the assumptions and estimates. The estimates of fair value may not be indicative of the amounts that could be realized in a current market exchange. Accordingly, the use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts, and such changes could materially impact the Company’s results of operations in future periods. The following table presents changes in Level 3 liabilities measured at fair value for the nine months ended September 30, 2022. Unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to unobservable (e.g., changes in unobservable long-dated volatilities) inputs. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Convertible Notes SAFE Liability Warrant Liability Balance at December 31, 2021 ​ $ — ​ $ 4,824,217 ​ $ 4,516,485 Issuance of convertible notes and warrants ​ 1,353,720 ​ — ​ 278,494 Conversion of SAFE liability to Series X preferred stock ​ ​ — ​ ​ (10,000,000) ​ ​ — Issuance of common stock in connection with conversion of notes payable ​ ​ (1,159,500) ​ ​ — ​ ​ — Issuance of Series X preferred stock in connection with conversion of notes payable ​ ​ (296,819) ​ ​ — ​ ​ — Warrants exchanged for shares of common stock and Series X preferred stock ​ ​ — ​ ​ — ​ ​ (2,009,207) Loss on extinguishment of debt ​ ​ 3,940 ​ ​ — ​ ​ — Change in fair value ​ 255,145 ​ (163,025) ​ (1,873,192) Reclassification of warrants to equity ​ ​ — ​ ​ — ​ ​ (912,580) Loss on conversion of SAFE ​ ​ — ​ ​ 5,338,808 ​ ​ — Balance at September 30, 2022 ​ $ 156,486 ​ $ — ​ $ — ​	Note 3. Fair Value Measurements Simple Agreement for Future Equity On March 19, 2021, the Company entered into a SAFE agreement with an investor. At issuance date, the Company classified the cash received of $5.0 million as a liability, with changes in fair value recognized as other expense on the statements of operations and disclosed in the financial statements. (See Note 6). A summary of significant unobservable inputs (Level 3 inputs) used in measuring the SAFE during the year ended December 31, 2021, is as follows: ​ ​ ​ ​ ​ ​ Year Ended ​ ​ December 31, 2021 Dividend yield — ​ Expected price volatility 50.0 % Risk free interest rate 0.06 % – 0.07 % Expected term (in years) 1.0 – 5.0 ​ ​ Warrants During the year ended December 31, 2020, the Company issued 1,034,176 common stock warrants in association with its convertible notes. As of December 31, 2021, 1,034,176 warrants were outstanding. The warrants were classified as liabilities and measured at fair value on the grant date, with changes in fair value recognized as other expense on the statements of operations and disclosed in the financial statements. A summary of significant unobservable inputs (Level 3 inputs) used in measuring warrants during the years ended December 31, 2021 and 2020, is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, ​ 2021 2020 Dividend yield ​ — ​ — ​ Expected price volatility 76.8 % – 112.1 % 108.7 % – 114.4 % Risk free interest rate 0.05 % – 1.09 % 0.10 % – 0.38 % Expected term (in years) 1.0 – 5.0 1.0 – 5.0 ​ ​ Significant changes in the expected price volatility and expected term would result in significantly lower or higher fair value measurement of the warrants, respectively. Contingent Interest During the year ended December 31, 2020, the Company recorded a derivative liability resulting from the contingent interest feature within its convertible notes. The Company recorded contingent interest on its convertible notes due to the interest rate increasing from 10% to 15% per annum, if the Company has not consummated a Qualified Offering on or before the date that is 9 months from the note issuance dates (See Note 5). The fair value of the contingent interest was estimated using the Monte Carlo simulation model on the dates the notes were issued and was subsequently revalued. During the year ended December 31, 2021, all of the Company’s notes were converted into 1,137,594 shares of the Company’s common stock, and the Company recognized a gain on the derivative liability of approximately $60,000 . As of December 31, 2021, there is no derivative liability. The following table reflects the assumptions used in the Monte Carlo simulation model at the notes issuance dates and during the year ended December 31, 2020: ​ ​ ​ ​ ​ ​ Year Ended ​ ​ December 31, 2020 Contingent interest rate 15.0 % Interest rate 10.0 % Expected term 0.8 – 1.0 ​ ​ Significant changes in the expected term and contingent interest rate would result in significantly lower or higher fair value measurement of the contingent interest derivative, respectively. The following tables classify the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of December 31, 2021 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value measured at December 31, 2021 ​ ​ Total carrying ​ Quoted prices in ​ Significant other ​ Significant ​ ​ value at ​ active markets ​ observable inputs ​ unobservable inputs ​ December 31, 2021 (Level 1) (Level 2) (Level 3) Liabilities: ​ ​ ​ ​ SAFE liability ​ $ 4,824,217 ​ $ — ​ $ — ​ $ 4,824,217 Warrant liability ​ $ 4,516,485 ​ $ — ​ $ — ​ $ 4,516,485 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value measured at December 31, 2020 ​ ​ Total carrying ​ Quoted prices in ​ Significant other ​ Significant ​ ​ value at ​ active markets ​ observable inputs ​ unobservable inputs ​ December 31, 2020 (Level 1) (Level 2) (Level 3) Liabilities: ​ ​ ​ ​ Warrant liability ​ $ 4,057,927 ​ $ — ​ $ — ​ $ 4,057,927 Contingent Interest ​ $ 59,890 ​ $ — ​ $ — ​ $ 59,890 ​ For the years ended December 31, 2021 and 2020, there was a change of approximately $0.3 million and $1.6 million, respectively, in Level 3 liabilities measured at fair value. The fair value of the warrant liability and SAFE liability may change significantly as additional data is obtained, impacting the Company’s assumptions used to estimate the fair value of the liabilities. In evaluating this information, considerable judgment is required to interpret the data used to develop the assumptions and estimates. The estimates of fair value may not be indicative of the amounts that could be realized in a current market exchange. Accordingly, the use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts, and such changes could materially impact the Company’s results of operations in future periods. The following table presents changes in Level 3 liabilities measured at fair value for the years ended December 31, 2021 and 2020. Unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to unobservable (e.g., changes in unobservable long-dated volatilities) inputs. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ SAFE Liability Warrant Liability Contingent Interest Balance at December 31, 2019 ​ $ — ​ $ — ​ $ — Issuance of warrants in connection with convertible notes ​ — ​ 2,488,544 ​ — Contingent interest in connection with notes payable ​ — ​ — ​ 55,394 Change in fair value ​ — ​ 1,569,383 ​ 4,496 Balance at December 31, 2020 ​ $ — ​ $ 4,057,927 ​ $ 59,890 Gain on conversion of notes ​ — ​ — ​ (59,890) Issuance of SAFE ​ 5,000,000 ​ — ​ — Change in fair value ​ (175,783) ​ 458,558 ​ — Balance at December 31, 2021 ​ $ 4,824,217 ​ $ 4,516,485 ​ $ — ​

Accrued Expenses

Accrued Expenses	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Accrued Expenses
Accrued Expenses	Note 4. Accrued Expenses The Company’s accrued expenses as of September 30, 2022 and December 31, 2021 consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2022 ​ 2021 ​ (Unaudited) ​ ​ Employee and related expenses ​ $ 50,335 ​ $ 680,026 Directors and officers insurance ​ ​ 385,362 ​ ​ — Professional fees ​ ​ 153,995 ​ ​ — Research and development ​ 24,758 ​ — Total accrued expenses ​ $ 614,450 ​ $ 680,026 ​	Note 4. Accrued Expenses The Company’s accrued expenses as of December 31, 2021 and 2020 consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2021 2020 Accrued expenses: ​ ​ ​ ​ Employee and related expenses ​ $ 680,026 ​ $ 499,752 Research and development ​ — ​ 4,000 Professional fees ​ — ​ 74,772 Total accrued expenses ​ $ 680,026 ​ $ 578,524 ​

Notes Payable

Notes Payable	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Convertible promissory notes
Notes Payable	Note 6. Convertible promissory notes During the second and third quarters of 2022, the Company entered into its 2022 Notes with a principal balance totaling approximately $1.5 million. The 2022 Notes contain an original issue discount totaling $0.2 million and the Company received net proceeds of approximately $1.2 million (net of financing fees of approximately $0.1 million). The 2022 Notes bear interest at 10% per annum and mature 12 months from the issuance date. The notes are secured by all assets and personal property of the Company. The note holders have the right to convert all or any portion of the outstanding principal balance and accrued interest into shares of the Company’s common stock, up to a beneficial ownership limitation of 9.99% of the number of shares of common stock outstanding at the time of conversion. The per share conversion price is equal to the lessor of (i) $7.00 or (ii) 80% of the qualified offering price of the Company’s common stock resulting from the listing for trading of its common stock on a qualified exchange. In connection with the notes, the Company issued common stock warrants to purchase 195,140 shares of the Company’s common stock. The warrants have an exercise price of the lessor of (i) $7.00 or (ii) 80% of the qualified offering price and expire five years from the issuance date. As a result of the issuance of the common stock warrants, the exercise price of the Company’s existing warrants was adjusted to an exercise of $3.00 per share. On August 26, 2022, upon the consummation of the Company’s initial public offering, the conversion price of the 2022 Notes and the exercise price of the warrants is calculated at 80% of $5.25 per share (the offering price) or $4.20 per share. On August 3, 2022, the Company entered into a conversion agreement with certain holders of the 2022 Notes, pursuant to which the holders agreed to convert $1.0 million of the principal balance at the consummation of the Company’s initial public offering at the conversion price of $4.20 per share. On August 26, 2022, the holders of the 2022 Notes converted the notes fair value of approximately $1.2 million to 238,094 shares of the Company’s common stock. On August 3, 2022, the Company entered into a conversion agreement with an additional holder of the 2022 Notes, pursuant to which the holder agreed to convert $255,555 of the principal balance at the consummation of the Company’s initial public offering into 2,555 shares of Series X preferred stock. On August 26, 2022, the note holder converted the notes fair value of $0.3 million to 2,555 shares of Series X preferred stock (See Note 8). As of September 30, 2022, the outstanding principal balance of the 2022 Notes was approximately $0.2 million. For the nine months ended September 30, 2022, the Company recorded a loss on issuance of debt of $0.4 million, and a fair value loss of $0.25 million that is included in the change in fair value of notes, in the accompanying condensed statements of operations. The Company recognized interest expense as a component of the change in fair value of the notes during the nine months ended September 30, 2022 (See Note 2).	Note 5. Notes Payable Notes payable at December 31, 2020 consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unamortized Notes ​ ​ Principal ​ Contingent ​ Debt ​ Payable as of Issuance date ​ Balance ​ Interest ​ Discount ​ December 31, 2020 October 26, 2020 ​ $ 2,250,000 ​ $ 43,445 ​ $ (1,843,151) ​ $ 450,295 October 29, 2020 ​ 750,000 ​ 14,470 ​ (620,548) ​ 143,922 November 6, 2020 ​ 102,532 ​ 1,974 ​ (87,082) ​ 17,424 ​ ​ $ 3,102,532 ​ $ 59,890 ​ $ (2,550,780) ​ $ 611,641 ​ Unsecured Convertible Promissory Notes In July, 2020, the Company issued unsecured convertible promissory notes in an aggregate principal amount of $100,000 with an interest rate of 8% per annum. The notes mature 12 months from the date of issuance and provide for conversion into shares of the Company’s common stock on the earlier of a Qualified Financing or if the Company engages in a Change of Control. Upon a Qualified Offering, the notes will convert into shares of the Company’s common stock at a conversion price equal to 75% of the per share purchase price in such Qualified Financing. The principal amount and accrued but unpaid interest under each note will automatically convert into shares of the Company’s common stock at the stated conversion price per share. If the Company engages in a Change of Control, the principal amount and all accrued but unpaid interest on the notes will automatically be converted into shares of the Company’s common stock at a conversion price equal to 75% of the price per share of the common stock set forth in the definitive agreements related to the Change of Control. Further, in the event that the Change of Control is a transaction wholly for cash, all principal and accrued but unpaid interest will convert into shares of the Company’s common stock at a price per share equal to 75% of the Company’s Enterprise Value as set forth and agreed to in the definitive agreements related to the Change of Control. During the year ended December 31, 2020, the unsecured convertible promissory notes were converted into senior secured convertible promissory notes (see below). Senior Secured Convertible Promissory Notes and Warrants On October 26, 2020, the Company issued a senior secured convertible promissory note with a principal balance of $2,250,000 . The Company recorded an original issue discount of $172,500 and received net proceeds totaling $2,077,500 . The note accrues interest at a rate of 10% per annum (which increases to 15% per annum if the Company has not consummated a Qualified Offering on or before July 26, 2021), and matures on October 26, 2021. The note holder has the right to convert all or any portion of the outstanding principal and interest into shares of the Company’s common stock at a conversion price equal to the lesser of (i) $3.00 or (ii) 90% of the stock price in a Qualified Offering. On October 29, 2020, the Company issued a senior secured convertible promissory note with a principal balance of $750,000 . The note accrues interest at a rate of 10% per annum (which increases to 15% per annum if the Company has not consummated a Qualified Offering on or before July 29, 2021), and matures on October 29, 2021. The note holder has the right to convert all or any portion of the outstanding principal and interest into shares of the Company’s common stock at a conversion price equal to the lesser of (i) $3.00 or (ii) 90% of the stock price in a Qualified Offering. On November 6, 2020, the Company entered into note exchange agreements with the holders of the unsecured convertible promissory notes. The note holders surrendered the July 2020 notes and entered into senior secured convertible promissory notes dated November 6, 2020. The senior secured convertible promissory notes have a principal balance of approximately $102,500 , accrue interest at a rate of 10% per annum (which increases to 15% per annum if the Company has not consummated a Qualified Offering on or before August 6, 2021), and mature on November 6, 2021. The note holders have the right to convert all or any portion of the outstanding principal and interest into shares of the Company’s common stock at a conversion price equal to the lesser of (i) $3.00 or (ii) 90% of the stock price in a Qualified Offering. In connection with the issuance of the senior secured convertible promissory notes, the Company issued the note holders common stock purchase warrants, providing the holders with the right to purchase 1,034,176 shares of the Company’s common stock at December 31, 2020. The purchase price of one share of common stock under the warrant shall be the same as the conversion price of the senior secured convertible promissory notes, and 517,088 of the common stock purchase warrants expire five years from the issuance date, and 517,088 of the common stock warrants expire thirty calendar days after the consummation of a Qualified Offering. As of December 31, 2020, the carrying value of the senior secured convertible notes was comprised of the following: ​ ​ ​ ​ Principal value of convertible notes $ 3,102,532 Original issue discount ​ (172,500) Discount resulting from allocation of proceeds to warrant liability ​ (2,488,544) Discount resulting from beneficial conversion feature ​ (462,920) Amortization of discount ​ 551,752 Loss on issuance of debt ​ 53,541 Loss on extinguishment of debt ​ 23,284 Change in fair value of derivative ​ 4,496 Net carrying value of senior secured convertible notes ​ $ 611,641 ​ During the year ended December 31, 2021, the Company converted all of its senior secured promissory notes into 1,137,594 shares of its common stock. In connection with the note conversions, the Company recorded interest expense totaling $2.6 million, and recognized a gain of approximately $60,000 related to the contingent interest feature (see Note 3). As of December 31, 2021, there were no convertible notes outstanding.

Simple Agreement for Future Equ

Simple Agreement for Future Equity ("SAFE")	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Simple Agreement for Future Equity ("SAFE").
Simple Agreement for Future Equity ("SAFE")	Note 5. Simple Agreement for Future Equity (“SAFE”) During the year ended December 31, 2021, the Company entered into a SAFE with an investor, and received proceeds of $5.0 million. Under the terms of the SAFE, the investor has the right to participate in future equity financings of the Company. The number of shares to be received by the SAFE investor was based on a 50% discount of the pricing in the triggering equity financing and includes a post money valuation cap of $150.0 million. In a liquidity or dissolution event, the investors right to receive cash out was junior to payment of outstanding indebtedness and creditor claims, on par for other SAFE agreements and/or preferred stock, and senior to payments for common stock. The SAFE had no interest rate or maturity date, the SAFE investor had no voting rights prior to conversion, and if the Company paid a dividend on outstanding shares of common stock while the SAFE was outstanding, the SAFE investor would have received the same dividend. On August 2, 2022, the fair value of the SAFE was approximately $ 4.7 million and the SAFE was converted into 100,000 shares of Series X preferred stock. During the three and nine months ended September 30, 2022, the Company recognized a $5.3 million loss on conversion of the SAFE (See Note 8).	Note 6. Simple Agreement for Future Equity (“SAFE”) During the year ended December 31, 2021, the Company entered into a SAFE with an investor, and received proceeds of $5.0 million. Under the terms of the SAFE, the investor has the right to participate in future equity financings of the Company. The number of shares to be received by the SAFE investor is based on a 50% discount of the pricing in the triggering equity financing and includes a post money valuation cap of $150.0 million. In a liquidity or dissolution event, the investors right to receive cash out is junior to payment of outstanding indebtedness and creditor claims, on par for other SAFE agreements and/or preferred stock, and senior to payments for common stock. The SAFE has no interest rate or maturity date, the SAFE investor has no voting rights prior to conversion, and if the Company pays a dividend on outstanding shares of common stock while the SAFE is outstanding, the SAFE investor will receive the same dividend. As of December 31, 2021, the SAFE had not yet converted as a qualifying financing had not yet occurred. Pursuant to the guidance under ASC 480, Distinguishing Liabilities from Equity , the Company determined that the value of the SAFE should be recorded as a liability in the accompanying balance sheets (See Note 3).

Stockholders' Deficit

Stockholders' Deficit	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Preferred and common stock
Stockholders' Deficit	Note 8. Preferred and common stock Amendment to Certificate of Incorporation On August 30, 2022, the Company filed an amendment (the “Amendment”) to its certificate of incorporation (the “Certificate”) with the Secretary of State of the State of Delaware in connection with the completion of the Company’s initial public offering. The Amendment amends the Company’s Certificate to, among other things: (i) authorize 200,000,000 shares of common stock and (ii) authorize 10,000,000 shares of preferred stock, 500,000 of which are designated as Series X Preferred Stock. In connection with the initial public offering, the Board waived any lock-up restrictions contained in the Series X Certificate of Designations. Series X Preferred Stock On August 1, 2022, the Company authorized 500,000 shares of Series X preferred stock, par value 0.0001 per share. The stated value of the Series X preferred stock is $100 per share. The holders of the Series X preferred stock have no voting rights and are not entitled to dividends. The Series X preferred stock is convertible into shares of the Company’s common stock and is subject to a beneficial ownership limitation of 9.99% of the number of shares of common stock outstanding at the time of conversion. On August 2, 2022, the Company issued 3,200 shares of Series X preferred stock in a private placement, at a purchase price of $100 per share, and received net proceeds of approximately $0.3 million, after deducting expenses (the “Series X Private Placement”). The Series X Private Placement constituted a qualified offering under the terms of the SAFE and the $5.0 million outstanding under the SAFE automatically converted into 100,000 shares of Series X preferred stock (See Note 5). On August 26, 2022, the Company issued 2,555 shares of its Series X preferred stock in connection with the conversion of certain 2022 Notes (See Note 6). The 2,555 shares of Series X preferred stock are convertible into shares of common stock at the initial offering price of $5.25 per share, subject to the beneficial ownership limitation. On the August 26, 2022, in connection with its Warrant Exchange Agreement (See Note 3), the Company exchanged 750,000 warrants for 350,000 shares of its common stock and 1,250 shares of its Series X preferred stock. On August 26, 2022, upon the consummation of the Company’s initial public offering, 61,689 shares of the Series X preferred stock were converted into 1,175,000 shares of the Company’s common stock. As of September 30, 2022, 45,316 shares of Series X preferred stock remain outstanding. Series Seed Preferred Stock On August 5, 2022, the Company entered into exchange agreements with the holders of the Company’s Series Seed preferred stock, par value $0.0001 per share. The Company and the holders exchanged all shares of outstanding Series Seed preferred stock into 1,557,435 shares of common stock immediately prior to the effectiveness of its registration statement filed in connection with the Company’s initial public offering.	Note 7. Stockholders’ Deficit Preferred Units During the year ended December 31, 2020, TardiMed contributed approximately $470,000 in exchange for 940,000 preferred units, which are convertible into 542,934 shares of the Company’s common stock. During the year ended December 31, 2021, there were no contributions from TardiMed. On March 2, 2020, a third-party investor contributed $50,000 in exchange for 100,000 preferred units. Certain expenses have been allocated by TardiMed and included in its statements of operations and statements of members’ and stockholders’ deficit as a contribution by TardiMed. These expenses are primarily comprised of TardiMed personnel and related expenses, rent and other office expenses which were paid by TardiMed on behalf of the Company. The Company allocated these expenses contributed on a 50% / 50% basis to research and development and selling, general and administrative. For the year ended December 31, 2020, approximately $51,000 was allocated to the Company as non-cash contribution from TardiMed in exchange of 101,514 preferred units and preferred shares, respectively. Cumulative Dividends and Distributions rights Preferred units are entitled to an eight percent cumulative annual return on the sum of such Preferred units outstanding, which shall accrue and compound annually, whether or not declared, and whether or not there are funds legally available for the payment thereof. Such preferred unit return is in preference to any distributions to common stockholders. On the date of issuance determined to be the commitment date the Company evaluated the fair value of the common stock into which the Preferred Units may be converted and the effective conversion price. This evaluation resulted in a beneficial conversion feature of approximately $1.5 million, and accordingly, the Company recorded a deemed dividend for the year ended December 31, 2020. For the year ended December 31, 2020, the Company accrued preferred dividends of $19,000 . Cumulative preferred dividends as of December 31, 2021 and 2020 were $62,000 . For the years ended December 31, 2021 and 2020, no dividends have been declared. Pursuant to the Amended and Restated Limited Liability Company Agreement (“LLC Agreement”) between TardiMed Sciences LLC (“TardiMed”) and Purinix, dated February 19, 2020, TardiMed agreed to commit $0.6 million of capital of the Company in exchange for Preferred units, at a purchase price of $0.87 per Preferred unit and are convertible in unregistered shares. On April 15, 2020, all of the outstanding Preferred units were converted into 2,696,439 shares of preferred stock. Liquidation The Company is intended to have perpetual existence. An event of withdrawal shall not cause a dissolution of the Company and the Company shall continue in existence subject to the terms and conditions of the LLC Agreement. “Event of Withdrawal” means the death, retirement, resignation, expulsion, bankruptcy or dissolution of a Member or the occurrence of any other event that terminates the continued membership of a Member in the Company. As promptly as practicable after dissolution, the liquidators shall (i) determine the Fair Market Value (the “of the Company’s remaining assets, (ii) determine the amounts to be distributed to each Unitholder in accordance and all preferred stockholders shall instead be given 1x Liquidation Preference including dividends. Preferred Stock On April 15, 2020, the Company authorized 2,696,439 shares of $.0001 par value preferred stock. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, or any deemed liquidation event, the holders of preferred stock shall be paid out of the funds of the assets available for distribution to stockholders before any payment is made to common stockholders. A deemed liquidation event includes a merger or consolidation, the sale lease, transfer, exclusive license or other disposition by the Company. The preferred stockholders would be paid at an amount equal to the greater of (i) the applicable original issue price plus any dividends declared but unpaid or (ii) the amount per share of preferred stock that would have been payable had all shares of preferred stock been converted to common stock prior to such liquidation, dissolution or winding up, or deemed liquidation event. Each holder of preferred stock has voting rights equal to the number of whole shares of common stock into which their preferred shares are convertible as of the record date. Each share of preferred stock is convertible at the option of the holder, at any time, into shares of the Company’s common stock, the number of which is determined by dividing the original issue price by the conversion price for that series of preferred stock in effect at the time of conversion. As of December 31, 2021, the Company had 2,696,439 shares of preferred stock issued and outstanding , and the preferred shares are convertible into 1,557,435 shares of common stock. Common stock Under the terms of the LLC Agreement 10,000,000 common units were issued to the founder, TardiMed, and are outstanding. These common units were issued for no consideration. As of April 15, 2020, these common units were converted to shares of common stock on a 1 :1 basis. On July 22, 2020, the Company effected a 1 - for-0.5775898 reverse stock split of its common stock. All share and per share information in the accompanying financial statements and footnotes has been retroactively adjusted for the effects of the reverse split for all periods presented. During the year ended December 31, 2021, in accordance with the original terms, the Company issued 1,137,594 shares of its common stock in connection with the conversion of $3.4 million of notes payable.

Stock-based compensation

Stock-based compensation	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Stock-based compensation.
Stock-based compensation	Note 7. Stock-based compensation Stock-based Compensation The following is a summary of stock-based compensation during the three and nine months ended September 30, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, Nine Months Ended September 30, ​ ​ 2022 2021 ​ 2022 2021 Canceled stock options ​ $ 119,829 ​ $ 272,124 ​ $ 449,840 ​ $ 1,110,874 Restricted stock units ​ 927,324 ​ — ​ 927,325 ​ — Total ​ $ 1,047,153 ​ $ 272,124 ​ $ 1,377,165 ​ $ 1,110,874 ​ Restricted Stock Units The following is a summary of the restricted stock units during the nine months ended September 30, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ Grant-Date ​ Number of Shares Fair Value Unvested as of December 31, 2021 — ​ $ — Granted 1,885,500 ​ $ 5.25 Forfeited (291,500) ​ $ 5.25 Vested ​ (11,780) ​ $ 5.26 Unvested as of September 30, 2022 1,582,220 ​ $ 5.25 ​ On May 15 , 2022 , the Company granted 35,333 restricted stock units (RSUs) with a fair value of approximately $0.2 million to a member of its board of directors. The RSUs are subject to service conditions (vesting of 33.34% on August 26, 2022 , the consummation date of the Company’s initial public offering, with the remaining units vesting 66.66% over the next two calendar years on each three-month anniversary thereafter). On January 1, 2022 , the Company granted 1,342,667 RSUs with a fair value of approximately $14.6 million to employees, officers and directors of the Company. The RSUs are subject to service conditions (vesting of 33.34% on May 1, 2022 , with the remaining units vesting on each three -month anniversary thereafter) and performance conditions in the form of a liquidity event. Vesting of the RSUs is subject to all grantees continuous service with the Company, and no vesting shall occur if the Company has not completed a Qualified Offering or a Change of Control on or before the vesting date. In the event that neither a Qualified Offering nor a Change of Control has occurred prior to December 31, 2022 , then all RSUs shall be forfeited for no consideration. Because a Qualified Offering or Change of Control is not considered probable of achievement until consummation, compensation cost measured at the grant date is not recognized until such event occurs. During the nine months ended September 30, 2022, 291,500 RSU’s (granted on January 1, 2022) were forfeited due to terminations of two of the Company’s employees and two of its board members. In August 2022, the Company modified the remaining 1,051,167 RSUs granted on January 1, 2022 to provide that 33.34% of each of those RSUs would vest on May 1, 2022 , with an additional 8.3325% of each grant vesting each quarter thereafter, provided that if neither (i) the expiration of the 6-month period following an initial public offering nor (ii) a change in control has occurred prior to the applicable vesting date, any RSUs that would have vested thereunder shall not vest until such expiration of the 6-month period following an initial public offering or change in control occurs (provided further that if neither an initial public offering nor a change in control occurs on or prior to December 31, 2022 , then all of the related RSUs will be forfeited). Vesting in all cases generally is subject to the grantee’s continued employment with the Company or a subsidiary thereof on the applicable vesting date. This improbable to improbable modification resulted in a new measurement of compensation cost based on the underlying fair value of the Company’s common stock on the date of the modification of approximately $5.5 million. On August 26, 2022 , the Company consummated its initial public offering and based on the modification above, 33.34% of each of the remaining 1,051,167 RSU’s would vest on February 26, 2023 , with an additional 8.3325% of each grant vesting each quarter thereafter. On July 16, 2022 , the Company granted 15,000 RSUs to its Chief Financial Officer with a fair value of approximately $0.1 million, all of which vest December 31, 2022. In August 2022, the Company granted 492,500 RSUs with a fair value of approximately $2.6 million to certain officers, directors and employees, one -third of which vest on the one-year anniversary of the Company’s initial public offering, with the remaining restricted stock units vesting on a quarterly basis over the following two years . On December 22, 2020, the Company granted 896,583 RSUs with a fair value of approximately $6.3 million to its officers and directors, in exchange for 787,499 vested and unvested stock options. The RSUs are subject to service conditions (vesting of 33.34% on May 1, 2021 , with the remaining units vesting on each three-month anniversary, thereafter, fully vesting on May 1, 2023 ) and performance conditions in the form of a liquidity event. Vesting of the RSUs is subject to all grantees continuous service with the Company, and no vesting shall occur if the Company has not completed a Qualified Offering or a Change of Control on or before the vesting date. In the event that neither an IPO no r change in control has occurred prior to December 31, 2021 , then all RSUs shall be forfeited for no consideration. Pursuant to the guidance of ASC 718- “Compensation - Stock Compensation”, the exchange of the options for the RSUs was accounted for as a probable (service only vesting) to improbable (performance and service with the performance criteria considered improbable since contingent upon a Qualified Offering or Change of Control) modification. As such, compensation cost for the original awards would be recognized if the awards would have vested pursuant to the original terms. In addition, since the original awards were modified, the incremental cost would be measured as the result of the most recent modification; that is, the fair value of the options after the modification to increase the exercise price to $8.98 . This fair value would be compared to the fair value of the RSUs to determine the incremental compensation cost. Incremental compensation cost related to the replacement awards would be recognized only if the modified vesting criteria are achieved. During the three and nine months ended September 30, 2022, the Company recorded stock-based compensation expense related to the RSUs of approximately $0.9 million, respectively. No stock-based compensation expense related to the RSUs was recognized during the three and nine months ended September 30, 2021. The unamortized stock-based compensation expense related to RSUs as of September 30, 2022 is approximately $7.4 million, which is expected to be recognized over a remaining weighted average vesting period of 1.3 years. Canceled Stock Options The Company previously granted options to purchase shares of the Company’s common stock and during the year ended December 31, 2020 these options were canceled. No stock options were outstanding as of September 30, 2022 and December 31, 2021. Compensation cost related to the canceled stock options of $4.3 million will continue to be recognized over the original vesting criteria. During the three months ended September 30, 2022 and 2021, the Company recorded stock-based compensation expense related to the canceled stock options of approximately $0.1 million and $0.3 million, respectively. During the nine months ended September 30, 2022 and 2021, the Company recorded stock-based compensation expense related to the canceled stock options of approximately $0.45 million and $1.1 million, respectively. The unamortized stock-based compensation expense related to canceled stock options as of September 30, 2022 is approximately $0.3 million.	Note 8. Stock-based compensation Stock Options On May 1, 2020, the Company granted 787,499 options to purchase shares of the Company’s common stock. The options had a fair value of approximately $ 4.3 million and vest over a period of 3 years . On August 22, 2020, the Company modified the option exercise price from $0.19 to $5.57 per share, which reduced the fair value of the options to $3.7 million. Pursuant to the guidance of ASC 718 — “Compensation — Stock Compensation”, total recognized compensation cost for an equity award that has been modified and for which the original service conditions are expected to be met shall at least equal the fair value of the award at the grant date. The original vesting conditions of the stock options were expected to be satisfied on the modification date, and therefore the compensation cost to be recognized for awards that ultimately vest cannot be less than the original grant-date fair value of the options of $4.3 million. On December 22, 2020, the Company canceled 787,499 vested and unvested stock options in exchange for 896,583 restricted stock units (see Restricted Stock Units). No stock options were granted during the year ended December 31, 2021, and as of December 31, 2021, there were no stock options outstanding. Restricted Stock Units The following is a summary of the restricted stock units during the years ended December 31, 2021 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ Grant-Date ​ ​ Number of Shares ​ Fair Value Unvested as of January 1, 2020 — ​ $ — Granted 1,377,999 ​ $ 8.98 Unvested as of December 31, 2020 1,377,999 ​ $ 8.98 Forfeited (1,377,999) ​ $ 8.98 Unvested as of December 31, 2021 — ​ $ — ​ On December 22, 2020, the Company granted 481,416 restricted stock units (“RSUs) with a fair value of approximately $4.3 million to employees, officers and directors of the Company. The RSUs are subject to service conditions (vesting of 33.34% on May 1, 2021, with the remaining units vesting on each three-month anniversary thereafter) and performance conditions in the form of a liquidity event. Vesting of the RSUs is subject to all grantees continuous service with the Company, and no vesting shall occur if the Company has not completed a Qualified Offering or a Change of Control on or before the vesting date. In the event that neither a Qualified Offering nor a Change of Control has occurred prior to December 31, 2021, then all RSUs shall be forfeited for no consideration. Because a Qualified Offering or Change of Control is not considered probable of achievement until consummation, compensation cost measured at the grant date is not recognized until such event occurs. On December 22, 2020, the Company granted 896,583 RSU’s with a fair value of approximately $ 6.3 million to its officers and directors, in exchange for 787,499 vested and unvested stock options. The RSUs are subject to service conditions (vesting of 33.34 % on May 1, 2021, with the remaining units vesting on each three-month anniversary, thereafter, fully vesting on May 1, 2023) and performance conditions in the form of a liquidity event. Vesting of the RSUs is subject to all grantees continuous service with the Company, and no vesting shall occur if the Company has not completed a Qualified Offering or a Change of Control on or before the vesting date. In the event that neither an IPO nor change in control has occurred prior to December 31, 2021, then all RSUs shall be forfeited for no consideration. Pursuant to the guidance of ASC 718- “Compensation — Stock Compensation”, the exchange of the options for the RSUs was accounted for as a probable (service only vesting) to improbable (performance and service with the performance criteria considered improbable since contingent upon a Qualified Offering or Change of Control) modification. As such, compensation cost for the original awards would be recognized if the awards would have vested pursuant to the original terms. In addition, since the original awards were modified, the incremental cost would be measured as the result of the most recent modification; that is, the fair value of the options after the modification to increase the exercise price to $ 8.98 . This fair value would be compared to the fair value of the RSUs to determine the incremental compensation cost. Incremental compensation cost related to the replacement awards would be recognized only if the modified vesting criteria are achieved. Compensation cost related to the canceled stock options of $ 4.3 million will continue to be recognized over the original vesting criteria. Because a Qualified Offering or Change of Control is not considered probable of achievement until consummation, the incremental compensation cost measured at the grant date of $1.9 million is not recognized until such event occurs. Since the Company failed to complete a Qualified Offering or a Change of Control prior to December 31, 2021, the RSU’s were forfeited as of December 31, 2021. During the years ended December 31, 2021 and 2020, the Company recorded stock-based compensation expense of approximately $ 1.3 million and $ 2.3 million, respectively. The unamortized stock-based compensation expense related to canceled stock options (as noted above), as of December 31, 2021 is approximately $ 0.7 million.

Income taxes

Income taxes	12 Months Ended
	Dec. 31, 2021
Income taxes
Income taxes	Note 9. Income taxes The provision for income taxes for the years ended December 31, 2021 and 2020 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Current Deferred Total Federal ​ $ — ​ $ — ​ $ — State ​ — ​ — ​ — Foreign ​ — ​ — ​ — Total ​ $ — ​ $ — ​ $ — ​ As of December 31, 2021, the Company has approximately $8.8 million of federal and state tax net operating loss carryforwards that may be available to offset future taxable income, if any. Under the Tax Cuts and Jobs Act, all federal NOLs incurred after December 31, 2017 are carried forward indefinitely. The Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) signed in to law on March 27, 2020, provided that NOLs generated in a taxable year beginning in 2018, 2019, or 2020, may now be carried back five years and forward indefinitely. In addition, the limitation of NOL utilization up to 80% of taxable income limitation was temporarily removed, allowing NOLs to fully offset taxable income. The state net operating loss carryforwards will begin to expire in 2041. Under the Internal Revenue Code (“IRC”) Section 382, annual use of the Company’s net operating loss carryforwards to offset taxable income may be limited based on cumulative changes in ownership. The Company has not completed an analysis to determine whether any such limitations have been triggered as of December 31, 2021. Any such limitation would have no net impact on the financial statements due to the recognition of a full valuation allowance on the recorded tax benefits related to loss carry forwards based on uncertainty surrounding realization of such assets. As required by ASC 740, management of the Company has evaluated the evidence bearing upon the realizability of its deferred tax assets. Based on the weight of available evidence, both positive and negative, management has determined that it is more likely than not that the Company will not realize the benefits of these assets. Accordingly, the Company recorded a valuation allowance of $2.7 million at December 31, 2021. The valuation allowance increased by $1.0 million during the year ended December 31, 2021, primarily as a result of the increase in net operating loss carryforwards generated in the current year. The tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consist of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ 2021 2020 Net operating loss carryforwards ​ $ 2,030 ​ $ 797 Research & development credits ​ 11 ​ 11 Accrued expenses ​ 166 ​ 144 Equity based compensation ​ — ​ 591 Other temporary differences ​ — ​ 20 Gross deferred tax assets ​ 2,207 ​ 1,563 Valuation allowance ​ (2,207) ​ (1,563) Net deferred tax asset ​ $ — ​ $ — ​ A reconciliation of the statutory income tax rates and the Company’s effective tax rate is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ For the years ended December 31, ​ 2021 2020 Tax provision at statutory rate 21.0 % 21.0 % State taxes, net of federal benefit 3.7 % 3.9 % Share based compensation (9.2) % — % Debt conversion (6.7) % — % Permanent items 0.4 % — % Other — % (0.7) % Warrant liability (0.9) % (4.2) % Change in valuation reserve (8.3) % (20.0) % Income taxes provision (benefit) — % — % ​ The Company has not identified any uncertain tax positions requiring a reserve as of December 31, 2021 and 2020. The Company’s policy is to recognize interest and penalties that would be assessed in relation to the settlement value of unrecognized tax benefits as a component of income tax expense. The Company did not accrue either interest or penalties for the years ended December 31, 2021 and 2020. The Company has not been under tax examination in any jurisdiction for the years ended December 31, 2021 and 2020.

Commitments and contingencies

Commitments and contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and contingencies
Commitments and contingencies	Note 9. Commitments and contingencies Litigation As of September 30, 2022 and 2021, there was no litigation against the Company. The Company may be involved in legal proceedings, claims and assessments arising from the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance.

Related party transactions

Related party transactions	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Related party transactions
Related party transactions	Note 10. Related party transactions Accounts payable - As of September 30, 2022, related party payables totaled approximately $132,000 and consisted of $80,000 owed to Tardimed for management fees, $27,000 owed to members of our board of directors and $25,000 owed to the Company’s Chief Financial Officer for consulting services. During the three months ended September 30, 2022 the Company expensed management fees of $60,000 , board of director fees of $20,000 and related party consulting services of $25,000 . During the nine months ended September 30, 2022 the Company expensed management fees of $180,000 , board of director fees of $74,000 and related party consulting services of $25,000 . Accrued expenses - As of September 30, 2022, there was approximately $50,000 accrued for payroll expenses owed to two terminated employees. During the nine months ended September 30, 2022, the Company reversed $155,000 of bonus expenses in connection with the termination of two of its executives.	Note 11. Related party transactions TardiMed Capital Contributions — TardiMed Sciences is a startup venture investment and operating firm in the life sciences space. The Chairman of the Board of the Company is also a Managing Member of TardiMed. The Chief Operating Officer is an employee of TardiMed. On April 5, 2018, the Company issued 5,775,898 founder common units to TardiMed. As of December 31, 2020 and 2021, TardiMed holds 5,775,898 shares of common stock which represents 100% of the total voting units outstanding. During the year ended December 31, 2020, TardiMed contributed approximately $0.5 million in exchange for approximately 0.9 million shares of preferred stock. Allocated Expenses — Certain expenses, allocated by TardiMed, have been incurred on behalf of the Company and included in its statements of operations and statements of members’ and stockholders’ deficit as a contribution by TardiMed. These expenses are primarily comprised of TardiMed personnel and related expenses, rent and other office expenses. The Company allocated these expenses contributed on a 50 %/ 50 % basis to research and development and selling, general and administrative. Management considers the allocation methodologies used to allocate expenses as reasonable and appropriate based on historical TardiMed expenses attributable to the Company and the Company’s operations. The expenses reflected in the financial statements may not be indicative of expenses that the Company will incur as an independent, publicly traded company and should not be relied upon as an indicator of its future results. No expenses were allocated during the year ended December 31, 2021. During the year ended December 31, 2020, approximately $25,000 was allocated to research and development expenses and approximately $25,000 was allocated to selling, general and administrative expenses. During the year ended December 31, 2021 the Company paid Tardimed $240,000 for management fees. Accounts payable — The related party payables as of December 31, 2021 were nominal. As of December 31, 2020, related party payables totaled approximately $ 100,000 and primarily consisted of $ 70,000 owed to TardiMed, and $ 30,000 owed to members of our board of directors and company executives. Accrued expenses — As of December 31, 2021, accrued expenses included bonus accruals of approximately $ 0.6 million owed to executives of the Company. As of December 31, 2020, accrued expenses included bonus, salary and payroll tax accruals of approximately $ 0.5 million owed to executives of the Company.

Subsequent events

Subsequent events	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Subsequent events
Subsequent events	Note 11. Subsequent events The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed financial statements. Time-Based Restricted Stock Units Subsequent to September 30, 2022, the Company granted 51,583 time-based RSUs with a fair value of approximately $124,000 to a member of its board of directors. The RSUs are subject to service conditions and vest 33.34% on the one year anniversary of the grant date, with the remaining units vesting on each three-month anniversary thereafter. Subsequent to September 30, 2022, the Company granted 12,000 time-based RSUs with a fair value of approximately $29,000 for consulting services. The RSUs will vest 100% on January 31, 2023. Performance-Based Restricted Stock Units Subsequent to September 30, 2022, the Company granted 25,000 performance-based RSUs with a fair value of approximately $60,000 for consulting services. The RSUs are subject to a performance condition, and will vest upon the Company signing a definitive agreement with a strategic partner. ​	Note 12. Subsequent events The Company has completed an evaluation of all subsequent events through June 10, 2022, the date the financial statements were available to be issued, to ensure that these financial statements include appropriate disclosure of events both recognized in the financial statements and events which occurred but were not recognized in the financial statements. Except as described below, the Company has concluded that no subsequent event has occurred that require disclosure within these financial statements. Convertible Promissory Notes In April 2022, the Company entered into senior secured convertible promissory notes with a principal balance totaling approximately $ 1.2 million. The notes contain an original issue discount totaling $ 0.1 million and the Company received net proceeds of approximately $ 1.1 million. The notes bear interest at 10 % per annum and mature 12 months from the issuance date. The notes are secured by all assets and personal property of the Company. The note holders have the right to convert all or any portion of the outstanding principal balance and accrued interest into shares of the Company’s common stock, up to a beneficial ownership limitation of 9.99 % of the number of shares of common stock outstanding at the time of conversion. The per share conversion price shall be equal to the lessor of (i) $ 7.00 or (ii) 80 % of the qualified offering price of the Company’s common stock resulting from the listing for trading of its common stock on a qualified exchange. In connection with the notes, the Company issued common stock warrants to purchase 164,284 shares of the Company’s common stock. The warrants have an exercise price of the lessor of (i) $ 7.00 or (ii) 80 % of the qualified offering price, and expire five years from the issuance date.

Significant accounting polici_2

Significant accounting policies (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Significant accounting policies
Basis of presentation	Basis of presentation The accompanying unaudited condensed financial statements are presented in U.S. dollars and in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected through December 31, 2022. The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the registration statement on Form S-1/A filed by the Company with the SEC on August 8, 2022.	Basis of presentation The Company’s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and include all adjustments necessary for the fair presentation of its balance sheets, results of operations and cash flows for the period presented.
Use of estimates	Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed financial statements relate to the valuation of convertible notes, valuation of warrants, valuation of the Simple Agreement For Equity (“SAFE”) liability and valuation of equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.	Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to the valuation of warrants, valuation of the SAFE liability and valuation of equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.
Cash, cash equivalents and short-term investments	Cash, cash equivalents and short-term investments The Company considers all highly liquid investments with an original maturity of three months or less at the date of acquisition to be cash equivalents. As of September 30, 2022 and December 31, 2021, the Company had no cash equivalents or short-term investments.	Cash, cash equivalents and short-term investments The Company considers all highly liquid investments with an original maturity of three months or less at the date of acquisition to be cash equivalents. As of December 31, 2021 and 2020, the Company had no cash equivalents or short-term investments .
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash high credit quality financial institutions, which may at times, be in excess of federal insured limits. The Company believes it is not exposed to any significant losses due to credit risk on cash.	Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash high credit quality financial institutions, which may at times, be in excess of federal insured limits. The Company believes it is not exposed to any significant losses due to credit risk on cash.
Risks and Uncertainties		Risks and Uncertainties The Company operates in a dynamic and highly competitive industry and is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, contract manufacturer and contract research organizations, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. The Company believes that changes in any of the following areas could have a material adverse effect on the Company’s future financial position, results of operations, or cash flows; ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Company’s products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company’s ability to attract and retain employees necessary to support its growth.
Fair value of financial instruments	Fair value of financial instruments The Company accounts for financial instruments under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification 820 (“ASC 820”), Fair Value Measurements. This statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements, ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels as follows: Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and Level 3 - assets and liabilities whose significant value drivers are unobservable. Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment. During the nine months ended September 30, 2022, the Company issued certain of the 2022 Notes and warrants in connection with the 2022 Notes. The 2022 Notes and warrants were classified as liabilities and measured at fair value on the issuance date, with changes in fair value recognized as other expense on the statements of operations and disclosed in the condensed financial statements During the year ended December 31, 2021, the Company entered into its SAFE agreement and classified the SAFE as a liability measured at cost on the issuance date, with changes in fair value recognized as other income on the statement of operations. The carrying amounts of the Company’s financial assets and liabilities, such as accounts payable, approximate fair value due to the short-term nature of these instruments.	Fair value of financial instruments The Company accounts for financial instruments under FASB Accounting Standards Codification 820 (“ASC 820”), Fair Value Measurements. This statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements, ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels as follows: Level 1 — quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 — observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and Level 3 — assets and liabilities whose significant value drivers are unobservable. Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment. During the year ended December 31, 2021, the Company entered into its SAFE agreement and classified the SAFE as a liability measured at cost on the issuance date, with changes in fair value recognized as other income on the statement of operations. During the year ended December 31, 2020, the Company issued convertible notes and warrants in connection with the notes. The notes and warrants were classified as liabilities and measured at fair value on the issuance date, with changes in fair value recognized as other expense on the statements of operations and disclosed in the financial statements. The carrying amounts of the Company’s financial assets and liabilities, such as accounts payable, approximate fair value due to the short-term nature of these instruments.
Convertible Notes	Convertible Notes In accordance with Accounting Standards Codification 825, Financial Instruments (“ASC 825”), the Company has elected the fair value option for recognition of its 2022 Notes. In accordance with ASC 825, the Company recognizes these 2022 Notes at fair value with changes in fair value recognized in the condensed statements of operations. The fair value option may be applied instrument by instrument, but it is irrevocable. As a result of applying the fair value option, direct costs and fees related to the convertible notes were recognized in general and administrative expense. Accrued interest for the 2022 Notes has been included in the change in fair value of convertible notes in the condensed statements of operations.
Warrant Liability	Warrant Liability The Company accounts for certain common stock warrants outstanding as a liability at fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statements of operations. The fair value of the warrants issued by the Company have been estimated using the Monte Carlo simulation. As of September 30, 2022, there are no warrant liabilities (See Note 3).	Warrant Liability The Company accounts for certain common stock warrants outstanding as a liability at fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statements of operations. The fair value of the warrants issued by the Company has been estimated using the Monte Carlo simulation.
Simple Agreement for Future Equity	Simple Agreement for Future Equity The Company accounts for a SAFE as a liability at fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until a triggering event, equity financing or a liquidity/dissolution occurs, and any change in fair value is recognized in the Company’s statements of operations. The fair value of the SAFE has been estimated using the Backsolve method which utilizes the Option Pricing Method. As of September 30, 2022, the SAFE liability has been converted to 100,000 shares of Series X preferred stock (See Note 8).	Simple Agreement for Future Equity The Company accounts for a SAFE as a liability at fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until a triggering event, equity financing or a liquidity/dissolution occurs, and any change in fair value is recognized in the Company’s statements of operations. The fair value of the SAFE has been estimated using the Backsolve method which utilizes the Option Pricing Method.
Derivative Financial Instruments		Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to interest rate, market, or foreign currency risks. The Company evaluates all of its financial instruments, including notes payable, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the statement of operations each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s balance sheet. During the year ended December 31, 2020, the Company entered into note agreements that were determined to have embedded derivative instruments in the form of contingent interest. The notes are recognized at the value of proceeds received after allocating issuance proceeds to the separable instruments issued with the notes and to the bifurcated contingent interest. The notes are subsequently measured at amortized cost using the effective interest method to accrete interest over their term to bring the notes’ initial carrying value to their principal balance at maturity. The bifurcated contingent interest is initially measured at fair value which is included in the notes payable balance on the accompanying balance sheets and subsequently measured at fair value with changes in fair value recognized as a component of other income (expense) in the statements of operations. The notes were converted during the year ended December 31, 2021 (See Note 5).
Research and development	Research and development Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.	Research and development Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.
Accrued Outsourcing Costs	Accrued Outsourcing Costs Substantial portions of the Company’s preclinical studies and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors (collectively “CROs”). These CROs generally bill monthly or quarterly for services performed, or bill based upon milestone achievement. For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining. Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources a substantial portion of its clinical trial activities, utilizing external entities such as CROs, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies. For each clinical trial that the Company conducts, certain clinical trial costs are expensed immediately, while others are expensed over time based on the number of patients in the trial, the attrition rate at which patients leave the trial, and/or the period over which clinical investigators or CROs are expected to provide services. The Company’s estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.	Accrued Outsourcing Costs Substantial portions of the Company’s preclinical studies and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors (collectively “CROs”). These CROs generally bill monthly or quarterly for services performed, or bill based upon milestone achievement. For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining. Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources a substantial portion of its clinical trial activities, utilizing external entities such as CROs, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies. For each clinical trial that the Company conducts, certain clinical trial costs are expensed immediately, while others are expensed over time based on the number of patients in the trial, the attrition rate at which patients leave the trial, and/or the period over which clinical investigators or CROs are expected to provide services. The Company’s estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.
Convertible Financial Instruments		Convertible Financial Instruments The Company bifurcates conversion options from their host instruments and accounts for them as free standing derivative financial instruments if certain criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable GAAP. When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, discounts are recorded for the intrinsic value of conversion options embedded in the instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the instrument.
Stock-Based Compensation	Stock-Based Compensation The Company expenses stock-based compensation to employees, non-employees and board members over the requisite service period based on the estimated grant-date fair value of the awards and actual forfeitures. The Company accounts for forfeitures as they occur. Stock-based awards with graded vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. All stock-based compensation costs are recorded in general and administrative costs in the statements of operations.	Stock-Based Compensation The Company expenses stock-based compensation to employees, non-employees and board members over the requisite service period based on the estimated grant-date fair value of the awards and actual forfeitures. The Company accounts for forfeitures as they occur. Stock-based awards with graded vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. All stock-based compensation costs are recorded in general and administrative costs in the statements of operations.
Loss Per Share	Loss Per Share Basic net loss per share (“EPS”) of common stock is computed by dividing net loss allocated to common shareholders by the weighted average number of common shares outstanding during the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity. The Company’s common stock equivalents have been excluded from the computation of diluted loss per share for the three and nine months ended September 30, 2022 and 2021, as the effect would be to reduce the loss per share. Therefore, the weighted average common stock outstanding used to calculate both basic and diluted loss per share is the same for the three and nine months ended September 30, 2022 and 2021. The following securities were excluded from the computation of diluted net loss per share attributable to common shareholders for the nine months ended September 30, 2022 and 2021, because including them would have been anti-dilutive: ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ 2022 2021 Preferred stock — 1,557,435 Series X preferred stock ​ 863,162 ​ — Unvested restricted stock units 1,582,220 1,377,999 Common stock warrants 587,497 1,034,176 SAFE investment — 414,808 Convertible notes 37,259 — Total 3,070,138 4,384,418	Loss Per Share Basic net loss per share (“EPS”) of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity. Since the Company has net losses, basic and diluted net loss per share is the same. Securities that could potentially dilute loss per share in the future were not included in the computation of diluted loss per share at December 31, 2021 and 2020, because their inclusion would be anti-dilutive are as follows: ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2021 2020 Preferred stock 1,557,435 1,557,435 Unvested restricted stock units — 1,377,999 Common stock warrants 1,034,176 1,034,176 Convertible notes — 1,034,177 SAFE investment (1) 414,808 — Total 3,006,419 5,003,787 (1) SAFE investment As of December 31, 2021, the Company’s price per share of $12.05 was calculated by dividing the post money valuation of $150 million by 12,444,251 shares of common stock outstanding. The 12,444,251 shares of common stock outstanding was calculated in accord with the agreement and includes 6,913,492 of common shares outstanding, 2,703,776 of IPO shares, 1,377,999 of restricted stock units, 1,034,176 of common stock warrants and 414,808 of SAFE shares. The SAFE investment shares of 414,808 (included in the table above) were calculated using the SAFE investment of $5.0 million divided by $12.05 per share.
Income taxes	Income taxes ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company’s condensed financial statements. The Company believes that its income tax positions and deductions would be sustained on audit and does not anticipate any adjustments that would result in material changes to its financial position.	Income taxes From April 5, 2018 (Inception) through April 14, 2020, the Company was organized as an LLC and subject to the provisions of Subchapter K of the Internal Revenue Code. As such, the Company was not viewed as a taxpaying entity in any jurisdiction and did not require a provision for income taxes for this period. Each member was responsible for the tax liability, if any, related to its proportionate share of the Company’s taxable losses for this period. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company’s financial statements. The Company believes that its income tax positions and deductions would be sustained on audit and does not anticipate any adjustments that would result in material changes to its financial position. The Company converted to a C-Corporation on April 15, 2020 and therefore the Company is subject to examination starting in 2020. The Company’s tax year, 2021 and 2020 federal tax returns remain subject to examination by the Internal Revenue Service. Given the Company’s historical losses, the conversion to a C-Corporation did not have a material impact on the Company financial statements.
Recent accounting pronouncements	Recent accounting pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This ASU is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company adopted this standard on January 1, 2022, and the adoption did not have a material impact on the Company’s condensed financial statements or disclosures. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The Company adopted this standard on January 1, 2022, and the adoption did not have a material impact on the Company’s condensed financial statements or disclosures.	Recent accounting pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This ASU is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company adopted this standard on January 1, 2022, and the adoption did not have a material impact on the Company’s financial statements or disclosures. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: (1) how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The Company adopted this standard on January 1, 2022, and the adoption did not have a material impact on the Company’s financial statements or disclosures.

Significant accounting polici_3

Significant accounting policies (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Significant accounting policies
Schedule of securities excluded from the computation of diluted loss per share	The following securities were excluded from the computation of diluted net loss per share attributable to common shareholders for the nine months ended September 30, 2022 and 2021, because including them would have been anti-dilutive: ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ 2022 2021 Preferred stock — 1,557,435 Series X preferred stock ​ 863,162 ​ — Unvested restricted stock units 1,582,220 1,377,999 Common stock warrants 587,497 1,034,176 SAFE investment — 414,808 Convertible notes 37,259 — Total 3,070,138 4,384,418	​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2021 2020 Preferred stock 1,557,435 1,557,435 Unvested restricted stock units — 1,377,999 Common stock warrants 1,034,176 1,034,176 Convertible notes — 1,034,177 SAFE investment (1) 414,808 — Total 3,006,419 5,003,787 (1) SAFE investment

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Summary of significant unobservable inputs (Level 3 inputs) used in measurement upon issuance dates		​ ​ ​ ​ ​ ​ Year Ended ​ ​ December 31, 2020 Contingent interest rate 15.0 % Interest rate 10.0 % Expected term 0.8 – 1.0 ​
Summary of Company's liabilities measured at fair value on a recurring basis into fair value hierarchy	The following tables classify the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of September 30, 2022 and December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value measured at September 30, 2022 ​ ​ ​ ​ Quoted prices in active ​ Significant other ​ Significant ​ ​ Total carrying value at ​ markets ​ observable inputs ​ unobservable inputs ​ September 30, 2022 (Level 1) (Level 2) (Level 3) Liabilities: ​ ​ ​ ​ Convertible notes ​ $ 156,486 ​ $ — ​ $ — ​ $ 156,486 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value measured at December 31, 2021 ​ ​ ​ ​ Quoted prices in active ​ Significant other ​ Significant ​ ​ Total carrying value at ​ markets ​ observable inputs ​ unobservable inputs ​ December 31, 2021 (Level 1) (Level 2) (Level 3) Liabilities: ​ ​ ​ ​ SAFE liability ​ $ 4,824,217 ​ $ — ​ $ — ​ $ 4,824,217 Warrant liability ​ $ 4,516,485 ​ $ — ​ $ — ​ $ 4,516,485	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value measured at December 31, 2021 ​ ​ Total carrying ​ Quoted prices in ​ Significant other ​ Significant ​ ​ value at ​ active markets ​ observable inputs ​ unobservable inputs ​ December 31, 2021 (Level 1) (Level 2) (Level 3) Liabilities: ​ ​ ​ ​ SAFE liability ​ $ 4,824,217 ​ $ — ​ $ — ​ $ 4,824,217 Warrant liability ​ $ 4,516,485 ​ $ — ​ $ — ​ $ 4,516,485 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value measured at December 31, 2020 ​ ​ Total carrying ​ Quoted prices in ​ Significant other ​ Significant ​ ​ value at ​ active markets ​ observable inputs ​ unobservable inputs ​ December 31, 2020 (Level 1) (Level 2) (Level 3) Liabilities: ​ ​ ​ ​ Warrant liability ​ $ 4,057,927 ​ $ — ​ $ — ​ $ 4,057,927 Contingent Interest ​ $ 59,890 ​ $ — ​ $ — ​ $ 59,890
Summary of changes in Level 3 liabilities measured at fair value	The following table presents changes in Level 3 liabilities measured at fair value for the nine months ended September 30, 2022. Unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to unobservable (e.g., changes in unobservable long-dated volatilities) inputs. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Convertible Notes SAFE Liability Warrant Liability Balance at December 31, 2021 ​ $ — ​ $ 4,824,217 ​ $ 4,516,485 Issuance of convertible notes and warrants ​ 1,353,720 ​ — ​ 278,494 Conversion of SAFE liability to Series X preferred stock ​ ​ — ​ ​ (10,000,000) ​ ​ — Issuance of common stock in connection with conversion of notes payable ​ ​ (1,159,500) ​ ​ — ​ ​ — Issuance of Series X preferred stock in connection with conversion of notes payable ​ ​ (296,819) ​ ​ — ​ ​ — Warrants exchanged for shares of common stock and Series X preferred stock ​ ​ — ​ ​ — ​ ​ (2,009,207) Loss on extinguishment of debt ​ ​ 3,940 ​ ​ — ​ ​ — Change in fair value ​ 255,145 ​ (163,025) ​ (1,873,192) Reclassification of warrants to equity ​ ​ — ​ ​ — ​ ​ (912,580) Loss on conversion of SAFE ​ ​ — ​ ​ 5,338,808 ​ ​ — Balance at September 30, 2022 ​ $ 156,486 ​ $ — ​ $ —	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ SAFE Liability Warrant Liability Contingent Interest Balance at December 31, 2019 ​ $ — ​ $ — ​ $ — Issuance of warrants in connection with convertible notes ​ — ​ 2,488,544 ​ — Contingent interest in connection with notes payable ​ — ​ — ​ 55,394 Change in fair value ​ — ​ 1,569,383 ​ 4,496 Balance at December 31, 2020 ​ $ — ​ $ 4,057,927 ​ $ 59,890 Gain on conversion of notes ​ — ​ — ​ (59,890) Issuance of SAFE ​ 5,000,000 ​ — ​ — Change in fair value ​ (175,783) ​ 458,558 ​ — Balance at December 31, 2021 ​ $ 4,824,217 ​ $ 4,516,485 ​ $ —
SAFE Agreement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Summary of significant unobservable inputs (Level 3 inputs) used in measurement upon issuance dates	A summary of significant unobservable inputs (Level 3 inputs) used in measuring the SAFE on the conversion date of August 2, 2022, and the period January 1, 2022 through August 2, 2022 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1, ​ ​ August 2, ​ 2022 - August ​ ​ 2022 2, 2022 Dividend yield 0 % 0 % Expected price volatility 50.0 % 50.0 % Risk free interest rate 3.08 % 1.35% - 3.08 % Expected term (in years) 1.5 0.8 - 1.5 ​	​ ​ ​ ​ ​ ​ Year Ended ​ ​ December 31, 2021 Dividend yield — ​ Expected price volatility 50.0 % Risk free interest rate 0.06 % – 0.07 % Expected term (in years) 1.0 – 5.0 ​
Warrant Exchange Agreement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Summary of significant unobservable inputs (Level 3 inputs) used in measurement upon issuance dates	A summary of significant unobservable inputs (Level 3 inputs) used in measuring warrants on issuance date, August 26, 2022, and during the period January 1, 2022 through August 26, 2022, is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1 2022 - ​ ​ July 2022 August 26, 2022 August 26, 2022 Dividend yield 0 % 0 % 0 % Expected price volatility 57.0 % 57.0 % 57.0% - 105.0 % Risk free interest rate 2.70 % - 2.82 % 2.39% - 3.40 % 0.17% - 3.40 % Expected term (in years) 5.0 ​ 0.1 - 4.9 0.1 - 4.0 ​	​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, ​ 2021 2020 Dividend yield ​ — ​ — ​ Expected price volatility 76.8 % – 112.1 % 108.7 % – 114.4 % Risk free interest rate 0.05 % – 1.09 % 0.10 % – 0.38 % Expected term (in years) 1.0 – 5.0 1.0 – 5.0 ​
2022 Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Summary of significant unobservable inputs (Level 3 inputs) used in measurement upon issuance dates	A summary of significant unobservable inputs (Level 3 inputs) used in measuring the 2022 Notes upon the issuance dates, conversion dates and during three and nine months ended September 30, 2022 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ​ ​ ​ ​ ​ ​ August 3, 2022 - ​ ended September ​ Nine months ended ​ ​ July 8, 2022 August 5, 2022 30, 2022 September 30, 2022 Dividend yield 0 % 0 % 0 % 0 % Expected price volatility 57.0 % 57.0 % 57.0 % 57.0% - 57.2 % Risk free interest rate 2.96 % 3.14 %- 3.29 % 2.8 %- 4.05 % 2.8 %- 4.05 % Expected term (in years) 1.0 1.0 0.7 - 0.9 ​ 0.7 - 0.9 ​

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Accrued Expenses
Schedule of Company's accrued expenses	The Company’s accrued expenses as of September 30, 2022 and December 31, 2021 consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2022 ​ 2021 ​ (Unaudited) ​ ​ Employee and related expenses ​ $ 50,335 ​ $ 680,026 Directors and officers insurance ​ ​ 385,362 ​ ​ — Professional fees ​ ​ 153,995 ​ ​ — Research and development ​ 24,758 ​ — Total accrued expenses ​ $ 614,450 ​ $ 680,026	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2021 2020 Accrued expenses: ​ ​ ​ ​ Employee and related expenses ​ $ 680,026 ​ $ 499,752 Research and development ​ — ​ 4,000 Professional fees ​ — ​ 74,772 Total accrued expenses ​ $ 680,026 ​ $ 578,524

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2021
Convertible promissory notes
Schedule of notes payable	Notes payable at December 31, 2020 consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unamortized Notes ​ ​ Principal ​ Contingent ​ Debt ​ Payable as of Issuance date ​ Balance ​ Interest ​ Discount ​ December 31, 2020 October 26, 2020 ​ $ 2,250,000 ​ $ 43,445 ​ $ (1,843,151) ​ $ 450,295 October 29, 2020 ​ 750,000 ​ 14,470 ​ (620,548) ​ 143,922 November 6, 2020 ​ 102,532 ​ 1,974 ​ (87,082) ​ 17,424 ​ ​ $ 3,102,532 ​ $ 59,890 ​ $ (2,550,780) ​ $ 611,641
Schedule of carrying value of the senior secured convertible notes	As of December 31, 2020, the carrying value of the senior secured convertible notes was comprised of the following: ​ ​ ​ ​ Principal value of convertible notes $ 3,102,532 Original issue discount ​ (172,500) Discount resulting from allocation of proceeds to warrant liability ​ (2,488,544) Discount resulting from beneficial conversion feature ​ (462,920) Amortization of discount ​ 551,752 Loss on issuance of debt ​ 53,541 Loss on extinguishment of debt ​ 23,284 Change in fair value of derivative ​ 4,496 Net carrying value of senior secured convertible notes ​ $ 611,641

Stock-based compensation (Table

Stock-based compensation (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Stock-based compensation.
Summary of stock based compensation	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, Nine Months Ended September 30, ​ ​ 2022 2021 ​ 2022 2021 Canceled stock options ​ $ 119,829 ​ $ 272,124 ​ $ 449,840 ​ $ 1,110,874 Restricted stock units ​ 927,324 ​ — ​ 927,325 ​ — Total ​ $ 1,047,153 ​ $ 272,124 ​ $ 1,377,165 ​ $ 1,110,874
Summary of the restricted stock units	The following is a summary of the restricted stock units during the nine months ended September 30, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ Grant-Date ​ Number of Shares Fair Value Unvested as of December 31, 2021 — ​ $ — Granted 1,885,500 ​ $ 5.25 Forfeited (291,500) ​ $ 5.25 Vested ​ (11,780) ​ $ 5.26 Unvested as of September 30, 2022 1,582,220 ​ $ 5.25	The following is a summary of the restricted stock units during the years ended December 31, 2021 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ Grant-Date ​ ​ Number of Shares ​ Fair Value Unvested as of January 1, 2020 — ​ $ — Granted 1,377,999 ​ $ 8.98 Unvested as of December 31, 2020 1,377,999 ​ $ 8.98 Forfeited (1,377,999) ​ $ 8.98 Unvested as of December 31, 2021 — ​ $ —

Income taxes (Tables)

Income taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income taxes
Summary of provision for income taxes	The provision for income taxes for the years ended December 31, 2021 and 2020 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Current Deferred Total Federal ​ $ — ​ $ — ​ $ — State ​ — ​ — ​ — Foreign ​ — ​ — ​ — Total ​ $ — ​ $ — ​ $ —
Summary tax effects of temporary differences and carry forwards that give rise to deferred tax assets consist	The tax effects of the temporary differences and carry forwards that give rise to deferred tax assets consist of the following (in thousands): ​ ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ 2021 2020 Net operating loss carryforwards ​ $ 2,030 ​ $ 797 Research & development credits ​ 11 ​ 11 Accrued expenses ​ 166 ​ 144 Equity based compensation ​ — ​ 591 Other temporary differences ​ — ​ 20 Gross deferred tax assets ​ 2,207 ​ 1,563 Valuation allowance ​ (2,207) ​ (1,563) Net deferred tax asset ​ $ — ​ $ —
Summary of reconciliation of statutory income tax rates and Company's effective tax rate	​ ​ ​ ​ ​ ​ ​ ​ ​ For the years ended December 31, ​ 2021 2020 Tax provision at statutory rate 21.0 % 21.0 % State taxes, net of federal benefit 3.7 % 3.9 % Share based compensation (9.2) % — % Debt conversion (6.7) % — % Permanent items 0.4 % — % Other — % (0.7) % Warrant liability (0.9) % (4.2) % Change in valuation reserve (8.3) % (20.0) % Income taxes provision (benefit) — % — %

Organization and description _2

Organization and description of business operations (Details)	Jul. 22, 2020	Apr. 15, 2020 item $ / shares shares	Sep. 30, 2022 $ / shares shares	Dec. 31, 2021 $ / shares shares	Dec. 31, 2020 $ / shares shares
Organization and description of business operations
Number of classes of stock | item		2
Common stock, par value (in dollars per share) | $ / shares		$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Preferred shares, par value (in dollars per share) | $ / shares		$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)		20,000,000	200,000,000	20,000,000	20,000,000
Preferred shares, shares authorized (in shares)		2,696,439	10,000,000	2,696,439	2,696,439
Conversion of preferred units to preferred stock		2,696,439
Common stock shares issuable upon conversion of preferred stock		1,557,435
Conversion of common units to common stock		5,775,898
Reverse stock split ratio	0.5775898

Organization and description _3

Organization and description of business operations - Going concern, liquidity and capital resources (Details) - USD ($)		3 Months Ended		9 Months Ended		12 Months Ended
	May 19, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Organization and description of business operations
Revenue				$ 0		$ 0
Accumulated deficit		$ (28,519,368)		(28,519,368)		(18,938,249)	$ (8,709,278)
Net income (loss)		$ (11,463,613)	$ (3,110,642)	(9,581,119)	$ (16,462,227)	(10,228,971)	(7,826,008)
Net cash used in operating activities				$ (3,004,175)	(4,264,250)	(5,512,639)	$ (2,348,822)
Proceeds from SAFE investment	$ 5,000,000				$ 5,000,000	$ 5,000,000

Significant accounting polici_4

Significant accounting policies - Cash, cash equivalents and short-term investments (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Significant accounting policies
Cash equivalents	$ 0	$ 0
Short-term investments	$ 0	$ 0

Significant accounting polici_5

Significant accounting policies - Anti-dilutive securities (Details) - shares	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Anti-dilutive securities
Anti-dilutive securities excluded from the computation of diluted net loss per share attributable to common shareholders	3,070,138	4,384,418	3,006,419	5,003,787
Preferred stock
Anti-dilutive securities
Anti-dilutive securities excluded from the computation of diluted net loss per share attributable to common shareholders		1,557,435	1,557,435	1,557,435
Series X preferred stock
Anti-dilutive securities
Anti-dilutive securities excluded from the computation of diluted net loss per share attributable to common shareholders	863,162
Unvested restricted stock units
Anti-dilutive securities
Anti-dilutive securities excluded from the computation of diluted net loss per share attributable to common shareholders	1,582,220	1,377,999		1,377,999
Common stock warrants
Anti-dilutive securities
Anti-dilutive securities excluded from the computation of diluted net loss per share attributable to common shareholders	587,497	1,034,176	1,034,176	1,034,176
SAFE investment
Anti-dilutive securities
Anti-dilutive securities excluded from the computation of diluted net loss per share attributable to common shareholders		414,808	414,808
Convertible notes
Anti-dilutive securities
Anti-dilutive securities excluded from the computation of diluted net loss per share attributable to common shareholders	37,259			1,034,177

Significant accounting polici_6

Significant accounting policies - SAFE Investment (Details) - USD ($) $ / shares in Units, $ in Millions		9 Months Ended
	Aug. 02, 2022	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Accounting Policies
Price per share (in dollars per share)			$ 12.05
Post money valuation			$ 150
Common stock, shares outstanding considered for determination of post money valuation			12,444,251
Common stock, shares outstanding (in shares)		6,913,492	6,913,492	5,775,898
IPO shares			2,703,776
Restricted stock units			1,377,999
Common stock warrants			1,034,176
SAFE shares			414,808
SAFE investment			$ 5
Series X preferred stock
Accounting Policies
Conversion of SAFE liability to Series X preferred stock (in shares)	100,000	100,000

Fair Value Measurements - Level

Fair Value Measurements - Level 3 Inputs (Details)	Sep. 30, 2022 item	Aug. 26, 2022 item	Aug. 05, 2022 item	Aug. 02, 2022 item	Jul. 08, 2022 item	Jul. 02, 2022 item	Dec. 31, 2021 Y	Dec. 31, 2020 Y
SAFE Liability | Dividend yield
Fair Value Measurement Inputs and Valuation Techniques
Measurement input				0
SAFE Liability | Expected price volatility
Fair Value Measurement Inputs and Valuation Techniques
Measurement input				0.500			0.500
SAFE Liability | Risk free interest rate
Fair Value Measurement Inputs and Valuation Techniques
Measurement input				0.0308
SAFE Liability | Risk free interest rate | Minimum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input				0.0135			0.0006
SAFE Liability | Risk free interest rate | Maximum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input				0.0308			0.0007
SAFE Liability | Expected term (in years)
Fair Value Measurement Inputs and Valuation Techniques
Measurement input				1.5
SAFE Liability | Expected term (in years) | Minimum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input				0.8			1
SAFE Liability | Expected term (in years) | Maximum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input				1.5			5
Warrant Liability | Dividend yield
Fair Value Measurement Inputs and Valuation Techniques
Measurement input		0				0
Warrant Liability | Expected price volatility
Fair Value Measurement Inputs and Valuation Techniques
Measurement input		0.570				0.570
Warrant Liability | Expected price volatility | Minimum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input		0.570					0.768	1.087
Warrant Liability | Expected price volatility | Maximum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input		1.050					1.121	1.144
Warrant Liability | Risk free interest rate | Minimum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input	0.0017	0.0239				0.0270	0.0005	0.0010
Warrant Liability | Risk free interest rate | Maximum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input	0.0340	0.0340				0.0282	0.0109	0.0038
Warrant Liability | Expected term (in years)
Fair Value Measurement Inputs and Valuation Techniques
Measurement input						5
Warrant Liability | Expected term (in years) | Minimum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input		0.1					1	1
Warrant Liability | Expected term (in years) | Maximum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input	4	4.9					5	5
Convertible Notes | Dividend yield
Fair Value Measurement Inputs and Valuation Techniques
Measurement input	0		0		0
Convertible Notes | Expected price volatility
Fair Value Measurement Inputs and Valuation Techniques
Measurement input	0.570		0.570		0.570
Convertible Notes | Expected price volatility | Minimum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input	0.570
Convertible Notes | Expected price volatility | Maximum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input	0.572
Convertible Notes | Risk free interest rate
Fair Value Measurement Inputs and Valuation Techniques
Measurement input					2.96
Convertible Notes | Risk free interest rate | Minimum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input	0.028		0.0314
Convertible Notes | Risk free interest rate | Maximum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input	0.0405		0.0329
Convertible Notes | Expected term (in years)
Fair Value Measurement Inputs and Valuation Techniques
Measurement input			1		1
Convertible Notes | Expected term (in years) | Minimum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input	0.007
Convertible Notes | Expected term (in years) | Maximum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input	0.9

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)						3 Months Ended	9 Months Ended	12 Months Ended
	Aug. 26, 2022	Aug. 03, 2022	Aug. 02, 2022	Mar. 19, 2022	Mar. 19, 2021	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Number of shares issued on conversion								1,137,594
Cash received					$ 5,000,000
Common stock warrants issued								1,034,176	1,034,176
Change in Level 3 liabilities measured at fair value								$ 300,000	$ 1,600,000
Reclassification of warrants to equity, shares	479,316
Warrant liability						$ 0	$ 0	4,516,485	$ 4,057,927
Contingent interest, consummation period of Qualified Offering from note issuance dates									9 months
Gain on derivative liability								60,000
Derivative liability								$ 0
Series X Preferred Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Conversion of SAFE liability to Series X preferred stock (in shares)			100,000				100,000
Warrants exchanged for shares of common stock	1,250
Common Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Number of shares issued on conversion	1,175,000
Warrants exchanged for shares of common stock	350,000
Minimum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Percentage of contingent interest rate per annum									10%
Maximum
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Percentage of contingent interest rate per annum									15%
2020 Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Warrants exchanged for shares of common stock	750,000
Convertible notes 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Number of shares issued on conversion	238,094							1,137,594
Convertible notes 2022 | Series X Preferred Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Issuance of Series X preferred stock in connection with conversion of notes payable (in shares)	2,555
SAFE Agreement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Change in Level 3 liabilities measured at fair value							$ (163,025)	$ (175,783)
SAFE Agreement | 2020 Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Cash received				$ 5,000,000
Common stock warrants issued							195,140	1,034,176
Number of warrants exchanged		750,000
Change in Level 3 liabilities measured at fair value						$ 3,300,000	$ 1,800,000
Warrants exchanged for shares of common stock		350,000

Fair Value Measurements - Assum

Fair Value Measurements - Assumptions used in the Monte Carlo simulation model (Details) - Convertible Debt [Member]	Dec. 31, 2020 Y
Contingent interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.150
Interest rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.100
Expected term (in years) | Minimum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.8
Expected term (in years) | Maximum
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	1

Fair Value Measurements - Liabi

Fair Value Measurements - Liabilities Measured at fair value (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Notes payable, net of discount of $0 and $2,550,780	$ 156,486		$ 611,641
Warrant liability	0	$ 4,516,485	4,057,927
SAFE Agreement | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Warrant liability		4,824,217
SAFE Agreement | Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Warrant liability		4,824,217
Warrant Exchange Agreement | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Warrant liability		4,516,485
Warrant Exchange Agreement | Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Warrant liability		4,516,485
2022 Notes | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Notes payable, net of discount of $0 and $2,550,780	156,486
2022 Notes | Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Notes payable, net of discount of $0 and $2,550,780	$ 156,486
2022 Notes | SAFE Agreement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Warrant liability		4,824,217
2022 Notes | SAFE Agreement | Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Warrant liability		4,824,217
2022 Notes | Warrant Exchange Agreement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Warrant liability		4,516,485	4,057,927
2022 Notes | Warrant Exchange Agreement | Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Warrant liability		$ 4,516,485	4,057,927
2022 Notes | Contingent Interest
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Warrant liability			59,890
2022 Notes | Contingent Interest | Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Warrant liability			$ 59,890

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Level 3 Liabilities (Details) - USD ($)	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
Conversion of SAFE liability to Series X preferred stock	$ 10,000,000	$ 10,000,000
Common stock issued in connection with conversion of notes payable	1,159,500	1,159,500	$ 3,412,782	$ 3,412,782
Issuance of Series X preferred stock in connection with conversion of notes payable	296,819	296,819
Warrants exchanged for shares of common stock and Series X preferred stock	2,009,207	2,009,207
Loss on extinguishment of debt	3,940	3,940			$ 23,284
Change in fair value				300,000	1,600,000
Reclassification of warrants to equity	(912,580)	(912,580)
Loss on conversion of SAFE	5,338,808	5,338,808
SAFE Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
Beginning Balance		4,824,217
Issuance of SAFE					5,000,000
Conversion of SAFE liability to Series X preferred stock		(10,000,000)
Change in fair value		(163,025)		(175,783)
Loss on conversion of SAFE		5,338,808
Ending Balance				4,824,217
Warrant Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
Beginning Balance		4,516,485	4,057,927	4,057,927
Issuance of convertible notes and warrants		278,494
Warrants exchanged for shares of common stock and Series X preferred stock		(2,009,207)
Change in fair value		(1,873,192)		458,558
Reclassification of warrants to equity		(912,580)
Ending Balance				4,516,485	4,057,927
Contingent Interest
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
Beginning Balance			$ 59,890	59,890
Gain on conversion of notes					(59,890)
Contingent interest in connection with notes payable					55,394
Ending Balance					59,890
Convertible Notes
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
Issuance of convertible notes and warrants		1,353,720
Contingent interest in connection with notes payable				$ 60,000
Common stock issued in connection with conversion of notes payable		(1,159,500)
Issuance of Series X preferred stock in connection with conversion of notes payable		(296,819)
Loss on extinguishment of debt		3,940
Change in fair value		255,145
Ending Balance	$ 156,486	$ 156,486
Convertible Notes | Warrant Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
Issuance of convertible notes and warrants					2,488,544
Change in fair value					1,569,383
Convertible Notes | Contingent Interest
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
Change in fair value					$ 4,496

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Accrued Expenses
Employee and related expenses	$ 50,335	$ 680,026	$ 499,752
Directors and officers insurance	385,362
Research and development	24,758		4,000
Professional fees	153,995		74,772
Total accrued expenses	$ 614,450	$ 680,026	$ 578,524

Notes Payable (Details)

Notes Payable (Details)	Dec. 31, 2020 USD ($)
Notes Payable
Principal Balance	$ 3,102,532
Contingent Interest	59,890
Unamortized Debt Discount	(2,550,780)
Notes Payable as of December 31, 2020	611,641
2022 Notes
Notes Payable
Principal Balance	3,102,532
Unamortized Debt Discount	(172,500)
Notes Payable as of December 31, 2020	611,641
October 26,2020
Notes Payable
Principal Balance	2,250,000
Contingent Interest	43,445
Unamortized Debt Discount	(1,843,151)
Notes Payable as of December 31, 2020	450,295
October 29, 2020
Notes Payable
Principal Balance	750,000
Contingent Interest	14,470
Unamortized Debt Discount	(620,548)
Notes Payable as of December 31, 2020	143,922
November 6, 2020
Notes Payable
Principal Balance	102,532
Contingent Interest	1,974
Unamortized Debt Discount	(87,082)
Notes Payable as of December 31, 2020	$ 17,424

Notes Payable - Unsecured Conve

Notes Payable - Unsecured Convertible Promissory Notes (Details) - Unsecured Convertible Promissory Notes	1 Months Ended
	Jul. 31, 2020 USD ($)
Notes Payable
2022 Notes, principal balance	$ 100,000
Interest rate per annum	8%
Maturity period	12 months
Percent of offering price	75%
Conversion price of per share purchase price in the event of Change in Control (in percent)	75%
Conversion price of per share purchase price in the event of Change in Control transaction wholly in cash (in percent)	75%

Notes Payable - Senior Secured

Notes Payable - Senior Secured Convertible Promissory Notes and Warrants (Details) - USD ($)					6 Months Ended	9 Months Ended	12 Months Ended
	Aug. 26, 2022	Nov. 06, 2020	Oct. 29, 2020	Oct. 26, 2020	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Notes Payable
Proceeds from issuance of convertible promissory notes, net of fees						$ 1,240,970
Carrying value of the senior secured convertible notes
Principal value of convertible notes								$ 3,102,532
Original issue discount								(2,550,780)
Notes Payable as of December 31, 2020								$ 611,641
Common stock purchase warrants
Notes Payable
Number of warrants issued								1,034,176
Warrants outstanding								517,088
Warrants term								5 years
Common stock warrants
Notes Payable
Warrants outstanding								517,088
2022 Notes
Notes Payable
Principal balance					$ 1,500,000	1,500,000
Original issue discount					200,000	$ 200,000
Proceeds from issuance of convertible promissory notes, net of fees					$ 1,200,000
Interest rate per annum					10%	10%
Conversion price (per share)	$ 4.20				$ 7	$ 7
Percent of offering price	80%				80%
Number of warrants issued					195,140	195,140
Warrants outstanding							0
Warrants term					5 years	5 years
Carrying value of the senior secured convertible notes
Principal value of convertible notes								$ 3,102,532
Original issue discount								(172,500)
Discount resulting from allocation of proceeds to warrant liability								(2,488,544)
Discount resulting from beneficial conversion feature								(462,920)
Amortization of discount								551,752
Loss on issuance of debt								53,541
Loss on extinguishment of debt								23,284
Change in fair value of derivative								4,496
Notes Payable as of December 31, 2020								611,641
Shares converted							1,137,594
Interest expense							$ 2,600,000
Gain related to contingent interest feature							$ 60,000
October 26,2020
Notes Payable
Principal balance				$ 2,250,000
Original issue discount				172,500
Proceeds from issuance of convertible promissory notes, net of fees				$ 2,077,500
Interest rate per annum				10%
Interest if not consummated a Qualified Offering (in percent)				15%
Conversion price (per share)				$ 3
Percent of offering price				90%
Carrying value of the senior secured convertible notes
Principal value of convertible notes								2,250,000
Original issue discount								(1,843,151)
Notes Payable as of December 31, 2020								450,295
October 29, 2020
Notes Payable
Principal balance			$ 750,000
Interest rate per annum			10%
Interest if not consummated a Qualified Offering (in percent)			15%
Conversion price (per share)			$ 3
Percent of offering price			90%
Carrying value of the senior secured convertible notes
Principal value of convertible notes								750,000
Original issue discount								(620,548)
Notes Payable as of December 31, 2020								143,922
November 6, 2020
Notes Payable
Principal balance		$ 102,500
Interest rate per annum		10%
Interest if not consummated a Qualified Offering (in percent)		15%
Conversion price (per share)		$ 3
Percent of offering price		90%
Carrying value of the senior secured convertible notes
Principal value of convertible notes								102,532
Original issue discount								(87,082)
Notes Payable as of December 31, 2020								$ 17,424

Simple Agreement for Future E_2

Simple Agreement for Future Equity ("SAFE") (Details) - USD ($)		3 Months Ended	9 Months Ended		12 Months Ended
	May 19, 2021	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Aug. 02, 2022
Simple Agreement for Future Equity ("SAFE")
Proceeds from SAFE investment	$ 5,000,000			$ 5,000,000	$ 5,000,000
Percentage of discount of pricing in the triggering equity financing (as a percent)					50%
Post money valuation					$ 150,000,000
Interest rate (as a percent)					0%
Loss recognized on conversion		$ 5,300,000	$ 5,300,000
Series X Preferred Stock
Simple Agreement for Future Equity ("SAFE")
SAFE, Outstanding amount converted						$ 4,700,000
Number of shares issued upon conversion						100,000

Stockholders' Deficit (Details)

Stockholders' Deficit (Details)						3 Months Ended	9 Months Ended		12 Months Ended
	Jul. 22, 2020	Apr. 15, 2020 $ / shares shares	Mar. 02, 2020 USD ($) shares	Feb. 19, 2020 USD ($) $ / shares	Apr. 05, 2018 shares	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2022 USD ($) $ / shares shares	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares
Preferred and common stock
Amount of contributions received | $										$ 470,000
Percentage of annual cumulative return									8%
Amount of beneficial conversion feature | $										1,500,000
Accrued preferred dividends | $										19,000
Cumulative dividends | $									$ 62,000	62,000
Amount of dividends declared | $									$ 0	$ 0
Price per share (in dollars per share) | $ / shares									$ 12.05
Preferred shares, shares authorized (in shares)		2,696,439				10,000,000	10,000,000		2,696,439	2,696,439
Preferred shares, par value (in dollars per share) | $ / shares		$ 0.0001				$ 0.0001	$ 0.0001		$ 0.0001	$ 0.0001
Preferred shares, shares issued (in shares)									2,696,439	2,696,439
Preferred shares, shares outstanding (in shares)									2,696,439	2,696,439
Number of preferred stock convertible into common stock									1,557,435
Common stock, shares issued (in shares)						11,779,475	11,779,475		6,913,492	5,775,898
Common stock, shares outstanding (in shares)						6,913,492	6,913,492		6,913,492	5,775,898
Consideration for shares issued | $						$ 300,000	$ 300,000
Conversion ratio for common units were converted to shares of common stock	1
Reverse stock split ratio	0.5775898
Number of shares issued on conversion									1,137,594
Common stock issued in connection with conversion of notes payable | $						$ 1,159,500	$ 1,159,500	$ 3,412,782	$ 3,412,782
Third-party investor
Preferred and common stock
Amount of contributions received | $			$ 50,000
Preferred Units
Preferred and common stock
Number of shares issued (in shares)										940,000
Common Units [Member]
Preferred and common stock
Conversion ratio for common units were converted to shares of common stock									1
Tardimed
Preferred and common stock
Amount of contributions received | $				$ 600,000					$ 0	$ 470,000
Number of shares issued (in shares)					5,775,898
Percentage of allocation of research and development			50%
Percentage of allocation of general and administrative			50%
Amount of non-cash contributions received | $										$ 51,000
Number of preferred units and preferred shares exchanged for non-cash contributions										101,514
Common stock, shares issued (in shares)									10,000,000
Common stock, shares outstanding (in shares)									5,775,898	5,775,898
Tardimed | Preferred Units
Preferred and common stock
Number of preferred units converted into common stock										542,934
Price per share (in dollars per share) | $ / shares				$ 0.87
Number of preferred units converted into preferred stock		2,696,439
Tardimed | Common Units [Member]
Preferred and common stock
Number of shares issued (in shares)			100,000
Consideration for shares issued | $									$ 0

Stock-based compensation - Rest

Stock-based compensation - Restricted Stock Units (Details) - $ / shares		1 Months Ended	9 Months Ended	12 Months Ended
	Aug. 26, 2022	Aug. 31, 2022	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Number of units outstanding
Beginning balance (shares)				1,377,999
Granted (shares)		1,051,167			1,377,999
Forfeited (shares)				(1,377,999)
Ending balance (shares)					1,377,999
Weighted Average Fair Value Per unit
Beginning balance (usd per share)					$ 8.98
Granted (usd per share)					8.98
Forfeited (usd per share)				$ 8.98
Ending balance (usd per share)					$ 8.98
Restricted stock units
Number of units outstanding
Granted (shares)	1,051,167		1,885,500
Forfeited (shares)			(291,500)
Vested (shares)			(11,780)
Ending balance (shares)			1,582,220
Weighted Average Fair Value Per unit
Beginning balance (usd per share)			$ 5.25
Granted (usd per share)			5.25
Forfeited (usd per share)			5.25
Vested (usd per share)			5.26
Ending balance (usd per share)			$ 5.25

Stock-based compensation - Addi

Stock-based compensation - Additional information (Details)											1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Dec. 22, 2022 USD ($) shares	Aug. 26, 2022 shares	Jul. 16, 2022 USD ($) shares	May 15, 2022 USD ($) shares	May 01, 2022	Jan. 01, 2022 USD ($) shares	May 01, 2021 $ / shares	Dec. 22, 2020 USD ($) shares	Aug. 22, 2020 USD ($) $ / shares	May 01, 2020 USD ($) shares	Aug. 31, 2022 USD ($) shares	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) employee director shares	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($) shares	Jun. 30, 2022 shares
Stock-based compensation
Number of units granted											1,051,167						1,377,999
Number of units forfeited																1,377,999
Compensation cost | $											$ 5,500,000
Stock options outstanding																0
Stock-based compensation expense | $												$ 1,047,153	$ 272,124	$ 1,377,165	$ 1,110,874
Stoct option granted																0
Member of its board of directors
Stock-based compensation
Number of board members terminated | director														2
Employees, officers and directors
Stock-based compensation
Number of employees terminated | employee														2
Restricted stock units
Stock-based compensation
Number of units granted		1,051,167												1,885,500
Fair value of units granted | $									$ 3,700,000
Vesting percentage		33.34%			33.34%
Vesting period		3 months			3 months
Number of units forfeited														291,500
Number of stock options exchanged for units								896,583
Stock-based compensation expense | $												927,324	0	$ 927,325	0	$ 1,300,000	$ 2,300,000
Unamortized stock-based compensation expense | $												7,400,000		$ 7,400,000		$ 700,000
Unamortized stock-based compensation period recognition														1 year 3 months 18 days
Stock options vested canceled								787,499
Restricted stock units | Minimum
Stock-based compensation
Exercise price | $ / shares									$ 0.19
Restricted stock units | Maximum
Stock-based compensation
Exercise price | $ / shares									$ 5.57
Restricted stock units | First three-month anniversary from Start Date
Stock-based compensation
Vesting percentage		8.3325%			8.3325%
Restricted stock units | Second three-month anniversary from Start Date
Stock-based compensation
Vesting percentage		8.3325%			8.3325%
Restricted stock units | Third three-month anniversary from Start Date
Stock-based compensation
Vesting percentage		8.3325%			8.3325%
Restricted stock units | Fourth three-month anniversary from Start Date
Stock-based compensation
Vesting percentage		8.3325%			8.3325%
Restricted stock units | Fifth three-month anniversary from Start Date
Stock-based compensation
Vesting percentage		8.3325%			8.3325%
Restricted stock units | Sixth three-month anniversary from Start Date
Stock-based compensation
Vesting percentage		8.3325%			8.3325%
Restricted stock units | Seventh three-month anniversary from Start Date
Stock-based compensation
Vesting percentage		8.3325%			8.3325%
Restricted stock units | Eighth three-month anniversary from Start Date
Stock-based compensation
Vesting percentage		8.3325%			8.3325%
Restricted stock units | Member of its board of directors
Stock-based compensation
Number of units granted				35,333
Fair value of units granted | $				$ 200,000						$ 4,300,000
Vesting percentage				33.34%
Vesting period				2 years						3 years
Restricted stock units | Member of its board of directors | First three-month anniversary from Start Date
Stock-based compensation
Vesting percentage		8.3325%
Restricted stock units | Member of its board of directors | Second three-month anniversary from Start Date
Stock-based compensation
Vesting percentage		8.3325%
Restricted stock units | Member of its board of directors | Third three-month anniversary from Start Date
Stock-based compensation
Vesting percentage		8.3325%
Restricted stock units | Member of its board of directors | Fourth three-month anniversary from Start Date
Stock-based compensation
Vesting percentage		8.3325%
Restricted stock units | Member of its board of directors | Fifth three-month anniversary from Start Date
Stock-based compensation
Vesting percentage		8.3325%
Restricted stock units | Member of its board of directors | Sixth three-month anniversary from Start Date
Stock-based compensation
Vesting percentage		8.3325%
Restricted stock units | Member of its board of directors | Seventh three-month anniversary from Start Date
Stock-based compensation
Vesting percentage		8.3325%
Restricted stock units | Member of its board of directors | Eighth three-month anniversary from Start Date
Stock-based compensation
Vesting percentage		8.3325%
Restricted stock units | Employees, officers and directors
Stock-based compensation
Number of units granted						1,342,667		896,583		787,499	492,500
Fair value of units granted | $						$ 14,600,000		$ 6,300,000			$ 2,600,000
Vesting percentage					33.34%		33.34%	33.34%			0.33%
Vesting period					3 months						2 years
Number of stock options exchanged for units								787,499
Exercise price | $ / shares							$ 8.98
Restricted stock units | Employees, officers and directors | First three-month anniversary from Start Date
Stock-based compensation
Vesting percentage					8.3325%		8.3325%				8.3325%
Restricted stock units | Employees, officers and directors | Second three-month anniversary from Start Date
Stock-based compensation
Vesting percentage					8.3325%		8.3325%				8.3325%
Restricted stock units | Employees, officers and directors | Third three-month anniversary from Start Date
Stock-based compensation
Vesting percentage					8.3325%		8.3325%				8.3325%
Restricted stock units | Employees, officers and directors | Fourth three-month anniversary from Start Date
Stock-based compensation
Vesting percentage					8.3325%		8.3325%				8.3325%
Restricted stock units | Employees, officers and directors | Fifth three-month anniversary from Start Date
Stock-based compensation
Vesting percentage					8.3325%		8.3325%				8.3325%
Restricted stock units | Employees, officers and directors | Sixth three-month anniversary from Start Date
Stock-based compensation
Vesting percentage					8.3325%		8.3325%				8.3325%
Restricted stock units | Employees, officers and directors | Seventh three-month anniversary from Start Date
Stock-based compensation
Vesting percentage					8.3325%		8.3325%				8.3325%
Restricted stock units | Employees, officers and directors | Eighth three-month anniversary from Start Date
Stock-based compensation
Vesting percentage					8.3325%		8.3325%				8.3325%
Restricted stock units | Officers and Directors
Stock-based compensation
Number of units granted	896,583
Fair value of units granted | $	$ 6,300,000
Vesting percentage							33.34%
Number of stock options exchanged for units	787,499
Exercise price | $ / shares							$ 8.98
Restricted stock units | Chief Financial Officer [Member]
Stock-based compensation
Number of units granted			15,000
Fair value of units granted | $			$ 100,000
Cancelled stock options
Stock-based compensation
Stock options outstanding																0		0
Canceled stock options and the related stock compensation | $									$ 4,300,000			4,300,000		$ 4,300,000		$ 4,300,000
Stock-based compensation expense | $												119,829	$ 272,124	449,840	$ 1,110,874
Unamortized stock-based compensation expense | $												$ 300,000		$ 300,000
Incremental compensation cost measured | $								$ 1,900,000

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - Domestic Tax Authority [Member] $ in Millions	12 Months Ended
	Dec. 31, 2021 USD ($)
Income taxes
Tax net operating loss carryforwards	$ 8.8
Valuation allowance of operating loss carryforwards	2.7
Increase in net operating loss carryforwards	$ 1

Income Taxes - Deferred tax ass

Income Taxes - Deferred tax assets (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Income taxes
Net operating loss carryforwards	$ 2,030	$ 797
Research & development credits	11	11
Accrued expenses	166	144
Equity based compensation		591
Other temporary differences		20
Gross deferred tax assets	2,207	1,563
Valuation allowance	$ (2,207)	$ (1,563)

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of statutory income tax rates and Company's effective tax rate (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income taxes
Tax provision at statutory rate	21%	21%
State taxes, net of federal benefit	3.70%	3.90%
Share based compensation	(9.20%)
Debt conversion	(6.70%)
Permanent items	0.40%
Other		(0.70%)
Warrant liability	(0.90%)	(4.20%)
Change in valuation reserve	(8.30%)	(20.00%)

Commitments and contingencies (

Commitments and contingencies (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020
Commitments and contingencies
Litigation against the Company	$ 0	$ 0	$ 0	$ 0

Related party transactions (Det

Related party transactions (Details)		3 Months Ended	9 Months Ended	12 Months Ended
	Apr. 05, 2018 shares	Sep. 30, 2022 USD ($) shares	Sep. 30, 2022 USD ($) employee shares	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($) shares
Related party transactions
Common stock, shares outstanding (in shares) | shares		6,913,492	6,913,492	6,913,492	5,775,898
Capital contributed value					$ 500,000
Capital contributed shares | shares					900,000
TardiMed Sciences is a startup venture investment
Related party transactions
Total voting units outstanding, percentage				100%	100%
Research and development expenses
Related party transactions
Expensed amount					$ 25,000
Selling, general and administrative expenses
Related party transactions
Expensed amount					25,000
Accounts payable
Related party transactions
Due to related party		$ 132,000	$ 132,000		100,000
Management fees | Accounts payable
Related party transactions
Expensed amount		60,000	180,000
Board of directors fees | Accounts payable
Related party transactions
Expensed amount		20,000	74,000
Bonus, salary and payroll tax accruals | Accrued expenses
Related party transactions
Due to related party					$ 500,000
Consulting services | Accounts payable
Related party transactions
Expensed amount		25,000	25,000
Accrued bonus | Accrued expenses
Related party transactions
Due to related party				$ 600,000
Expensed amount			155,000
Payroll expenses | Accrued expenses
Related party transactions
Due to related party		50,000	50,000
Tardimed
Related party transactions
Issuance of Series X preferred stock, net of fees (in shares) | shares	5,775,898
Common stock, shares outstanding (in shares) | shares				5,775,898	5,775,898
Management fees				$ 240,000
Tardimed | Research and development expenses
Related party transactions
Related party allocated expenses contributed basis of percentage.				50%
Tardimed | Selling, general and administrative expenses
Related party transactions
Related party allocated expenses contributed basis of percentage.				50%
Tardimed | Accounts payable
Related party transactions
Due to related party					$ 70,000
Tardimed | Management fees | Accounts payable
Related party transactions
Due to related party		80,000	80,000
Members of board of directors | Accounts payable
Related party transactions
Due to related party		27,000	27,000
Members of board of directors | Management fees | Accounts payable
Related party transactions
Due to related party					$ 30,000
Chief Financial Officer | Accounts payable
Related party transactions
Due to related party		$ 25,000	$ 25,000
Executives | Accrued expenses
Related party transactions
Number of executives terminated | employee			2

Subsequent events - Additional

Subsequent events - Additional Information (Details) - USD ($)			6 Months Ended	9 Months Ended
	Aug. 26, 2022	Apr. 30, 2022	Sep. 30, 2022	Sep. 30, 2022
Subsequent events
2022 Notes, net proceeds received				$ 1,240,970
2022 Notes
Subsequent events
2022 Notes, principal balance			$ 1,500,000	1,500,000
2022 Notes, original issue discount			300,000	$ 300,000
2022 Notes, net proceeds received			$ 1,200,000
Interest rate per annum			10%	10%
Maturity period			12 months
Percent of beneficial ownership limitation			9.99%	9.99%
Conversion price (per share)	$ 4.20		$ 7	$ 7
Percent of offering price	80%		80%
Number of warrants exchanged			195,140	195,140
Exercise price of warrants (in dollars per share)			$ 7	$ 7
Percent of qualified offering price			80%
Warrants expiry term			5 years	5 years
Subsequent event | 2022 Notes
Subsequent events
2022 Notes, principal balance		$ 1,200,000
2022 Notes, original issue discount		100,000
2022 Notes, net proceeds received		$ 1,100,000
Interest rate per annum		10%
Maturity period		12 months
Percent of beneficial ownership limitation		9.99%
Conversion price (per share)		$ 7
Percent of offering price		80%
Number of warrants exchanged		164,284
Exercise price of warrants (in dollars per share)		$ 7
Percent of qualified offering price		80%
Warrants expiry term		5 years

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets
Cash	$ 5,563,332	$ 444,087
Prepaid and other current assets	416,439
Total current assets	5,979,771	444,087
Deferred offering costs		204,779
Total assets	5,979,771	648,866
Current liabilities
Accounts payable	2,688,533	736,251
Accounts payable - related party	132,000	750
Accrued expenses	614,450	680,026
Notes payable - fair value	156,486
SAFE liability		4,824,217
Warrant liability	0	4,516,485
Total current liabilities	3,591,469	10,757,729
Total liabilities	3,591,469	10,757,729
Commitments and contingencies
Stockholders' Equity (Deficit)
Preferred stock		270
Common stock, par value $0.0001; 200,000,000 shares authorized at September 30, 2022 and 20,000,000 shares authorized at December 31, 2021; 11,779,475 and 6,913,492 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	1,178	691
Additional paid-in capital	30,906,477	8,828,425
Accumulated deficit	(28,519,368)	(18,938,249)
Total stockholders' equity (deficit)	2,388,302	(10,108,863)
Total liabilities, and stockholders' equity (deficit)	5,979,771	648,866
Series Seed
Stockholders' Equity (Deficit)
Preferred stock		270
Series X Preferred Stock
Stockholders' Equity (Deficit)
Preferred stock	$ 15

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parenthetical)	Dec. 31, 2021 USD ($) $ / shares shares
Preferred shares, par value (in dollars per share) | $ / shares	$ 0.0001
Preferred shares, shares authorized (in shares)	2,696,439
Preferred shares, shares issued (in shares)	2,696,439
Preferred shares, shares outstanding (in shares)	2,696,439
Preferred shares, aggregate liquidation preference | $	$ 2,808,148
Common stock, par value (in dollars per share) | $ / shares	$ 0.0001
Common stock, shares authorized (in shares)	20,000,000
Common stock, shares issued (in shares)	6,913,492
Common stock, shares outstanding (in shares)	6,913,492
Series Seed Preferred Stock [member]
Preferred shares, shares authorized (in shares)	2,696,439
Preferred shares, shares issued (in shares)	2,696,439
Preferred shares, shares outstanding (in shares)	2,696,439
Preferred shares, aggregate liquidation preference | $	$ 2,808,148
Series X Preferred Stock
Preferred shares, shares authorized (in shares)	0
Preferred shares, shares issued (in shares)	0
Preferred shares, shares outstanding (in shares)	0

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Operating expenses
General and administrative	$ 1,277,287	$ 3,651,218
Research and development	437,559	1,755,428
Total operating expenses	1,714,846	5,406,646
Loss from operations	(1,714,846)	(5,406,646)
Other income (expense):
Interest expense		(2,805,856)
Gain on conversion of notes		59,890
Change in fair value of SAFE	(622,212)	(3,806,374)
Change in fair value warrant liability	(789,419)	(4,498,146)
Other income (expense)	15,835	(5,095)
Total other expense	(1,395,796)	(11,055,581)
Net loss	$ (3,110,642)	$ (16,462,227)
Basic weighted average number of shares outstanding	6,913,492	6,582,602
Diluted weighted average number of shares outstanding	6,913,492	6,582,602
Basic net income (loss) per share	$ (0.45)	$ (2.50)
Diluted net income (loss) per share	$ (0.45)	$ (2.50)

CONDENSED STATEMENTS OF CHANGES

CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS' DEFICIT - USD ($)	Preferred Stock Series Seed Preferred Stock [member]	Preferred Stock Series X Preferred Stock	Preferred Stock	Common Stock Series Seed Preferred Stock [member]	Common Stock Series X Preferred Stock	Common Stock	Additional Paid-in Capital Series Seed Preferred Stock [member]	Additional Paid-in Capital Series X Preferred Stock	Additional Paid-in Capital	Accumulated Deficit	Series X Preferred Stock	Total
Beginning balance at Dec. 31, 2019										$ (863,828)		$ (863,828)
Increase (Decrease) in Stockholders' Equity
Net income (loss)										(7,826,008)		(7,826,008)
Stock-based compensation									$ 2,262,093			2,262,093
Ending balance at Dec. 31, 2020	$ 270		$ 270			$ 578			4,079,891	(8,709,278)		(4,628,539)
Ending balance (in shares) at Dec. 31, 2020	2,696,439		2,696,439			5,775,898
Increase (Decrease) in Stockholders' Equity
Issuance of common stock in connection with conversion of notes payable						$ 113			3,412,669			3,412,782
Issuance of common stock in connection with conversion of notes payable (in shares)						1,137,594
Net income (loss)										(16,462,227)		(16,462,227)
Stock-based compensation									1,110,874			1,110,874
Ending balance at Sep. 30, 2021	$ 270					$ 691			8,603,434	(25,171,505)		(16,567,110)
Ending balance (in shares) at Sep. 30, 2021	2,696,439					6,913,492
Beginning balance at Dec. 31, 2020	$ 270		$ 270			$ 578			4,079,891	(8,709,278)		(4,628,539)
Beginning balance (in shares) at Dec. 31, 2020	2,696,439		2,696,439			5,775,898
Increase (Decrease) in Stockholders' Equity
Issuance of common stock in connection with conversion of notes payable						$ 113			3,412,669			$ 3,412,782
Issuance of common stock in connection with conversion of notes payable (in shares)						1,137,594						1,137,594
Net income (loss)										(10,228,971)		$ (10,228,971)
Stock-based compensation									1,335,865			1,335,865
Ending balance at Dec. 31, 2021	$ 270		$ 270			$ 691			8,828,425	(18,938,249)		(10,108,863)
Ending balance (in shares) at Dec. 31, 2021	2,696,439		2,696,439			6,913,492
Beginning balance at Jun. 30, 2021	$ 270					$ 691			8,331,310	(22,060,863)		(13,728,592)
Beginning balance (in shares) at Jun. 30, 2021	2,696,439					6,913,492
Increase (Decrease) in Stockholders' Equity
Net income (loss)										(3,110,642)		(3,110,642)
Stock-based compensation									272,124			272,124
Ending balance at Sep. 30, 2021	$ 270					$ 691			8,603,434	(25,171,505)		(16,567,110)
Ending balance (in shares) at Sep. 30, 2021	2,696,439					6,913,492
Beginning balance at Dec. 31, 2021	$ 270		$ 270			$ 691			8,828,425	(18,938,249)		(10,108,863)
Beginning balance (in shares) at Dec. 31, 2021	2,696,439		2,696,439			6,913,492
Increase (Decrease) in Stockholders' Equity
Issuance of Series X preferred stock, net of fees		$ 1							299,999			300,000
Issuance of Series X preferred stock, net of fees (in shares)		3,200
Conversion of SAFE liability to Series X preferred stock		$ 20							9,999,980			10,000,000
Conversion of SAFE liability to Series X preferred stock (in shares)		100,000									100,000
Issuance of common stock and warrants, net of fees						$ 154			6,022,859			6,023,013
Issuance of common stock and warrants, net of fees (in shares)						1,545,454
Issuance of common stock in connection with conversion of notes payable						$ 24			1,159,476			1,159,500
Issuance of common stock in connection with conversion of notes payable (in shares)						238,094
Issuance of Series X preferred stock in connection with conversion of notes payable									296,819			296,819
Issuance of Series X preferred stock in connection with conversion of notes payable (in shares)		2,555
Conversion of preferred stock to common stock	$ (270)	$ (6)		$ 156	$ 118		$ 114	$ (112)
Conversion of preferred stock to common stock (in shares)	(2,696,439)	(61,689)		1,557,435	1,175,000
Warrants exchanged for shares of common stock and Series X preferred stock						$ 35			2,009,172			2,009,207
Warrants exchanged for shares of common stock and Series X preferred stock (in shares)		1,250				350,000
Reclassification of warrants to equity									912,580			912,580
Net income (loss)										(9,581,119)		(9,581,119)
Stock-based compensation									1,377,165			1,377,165
Ending balance at Sep. 30, 2022		$ 15				$ 1,178			30,906,477	(28,519,368)		2,388,302
Ending balance (in shares) at Sep. 30, 2022		45,316				11,779,475
Beginning balance at Jun. 30, 2022	$ 270					$ 691			9,158,437	(17,055,755)		(7,896,357)
Beginning balance (in shares) at Jun. 30, 2022	2,696,439					6,913,492
Increase (Decrease) in Stockholders' Equity
Issuance of Series X preferred stock, net of fees		$ 1							299,999			300,000
Issuance of Series X preferred stock, net of fees (in shares)		3,200
Conversion of SAFE liability to Series X preferred stock		$ 20							9,999,980			10,000,000
Conversion of SAFE liability to Series X preferred stock (in shares)		100,000
Issuance of common stock and warrants, net of fees						$ 154			6,022,859			6,023,013
Issuance of common stock and warrants, net of fees (in shares)						1,545,454
Issuance of common stock in connection with conversion of notes payable						$ 24			1,159,476			1,159,500
Issuance of common stock in connection with conversion of notes payable (in shares)						238,094
Issuance of Series X preferred stock in connection with conversion of notes payable									296,819			296,819
Issuance of Series X preferred stock in connection with conversion of notes payable (in shares)		2,555
Conversion of preferred stock to common stock	$ (270)	$ (6)		$ 156	$ 118		$ 114	$ (112)
Conversion of preferred stock to common stock (in shares)	(2,696,439)	(61,689)		1,557,435	1,175,000
Warrants exchanged for shares of common stock and Series X preferred stock						$ 35			2,009,172			2,009,207
Warrants exchanged for shares of common stock and Series X preferred stock (in shares)		1,250				350,000
Reclassification of warrants to equity									912,580			912,580
Net income (loss)										(11,463,613)		(11,463,613)
Stock-based compensation									1,047,153			1,047,153
Ending balance at Sep. 30, 2022		$ 15				$ 1,178			$ 30,906,477	$ (28,519,368)		$ 2,388,302
Ending balance (in shares) at Sep. 30, 2022		45,316				11,779,475

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Cash flows from operating activities
Net loss	$ (9,581,119)	$ (16,462,227)	$ (10,228,971)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	1,377,165	1,110,874	1,335,865
Amortization of debt discount		2,550,780	2,550,780
Change in fair value of notes	255,145
Change in fair value of SAFE	(163,025)	3,806,374	(175,783)
Loss on conversion of SAFE	5,338,808
Loss on issuance of debt	391,246
Loss on extinguishment of debt	3,940
Gain on conversion of notes		(59,890)	(59,890)
Change in fair value warrant liability	(1,873,192)	4,498,145	458,558
Non-cash interest expense		255,076	255,076
Changes in assets and liabilities:
Other current assets	(416,439)
Deferred offering costs	204,779
Accounts payable	(65,578)	140,935	352,277
Accounts payable - related party	131,250	(100,138)	(102,053)
Accrued expenses	1,392,845	(4,179)	101,502
Net cash used in operating activities	(3,004,175)	(4,264,250)	(5,512,639)
Cash flows from financing activities
Proceeds from issuance of common stock and warrants, net of fees	6,582,450
Proceeds from issuance of convertible promissory notes, net of fees	1,240,970
Proceeds from issuance of Series X preferred stock, net of fees	300,000
Proceeds from SAFE investment		5,000,000	5,000,000
Payment of deferred offering costs		(60,779)	(166,899)
Net cash provided by financing activities	8,123,420	4,939,221	4,833,101
Net increase in cash	5,119,245	674,971	(679,538)
Cash, beginning of period	444,087	1,123,625	1,123,625
Cash, end of period	5,563,332	1,798,596	444,087
Non-cash financing activities:
Series X preferred stock issued in connection with conversion of notes payable	296,819
Common stock issued in connection with conversion of notes payable	1,159,500	$ 3,412,782	3,412,782
Conversion of SAFE liability to Series X preferred stock	10,000,000
Warrants exchanged for shares of common stock and Series X preferred stock	2,009,207
Reclassification of warrants to equity	912,580
Unpaid offering costs	$ 559,437		$ 37,880

Organization and description _4

Organization and description of business operations	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Organization and description of business operations
Organization and description of business operations	Note 1. Organization and description of business operations PaxMedica, Inc. (the “Company”) is a clinical stage biopharmaceutical company organized as a Delaware limited liability company on April 5, 2018 (“Inception”) to focus on the development of drug candidates for the treatment of autism spectrum disorder (ASD), Fragile X syndrome tremor-ataxia (FXTAS) and Human African Trypanosomiasis (HAT). Initial Public Offering On August 9, 2022, the Company entered into an underwriting agreement relating to the public offering of its common stock, par value $0.0001 per share. The Company agreed to sell 1,545,454 shares of its common stock to the underwriters, at a purchase price per share of $4.83 (the offering price to the public of $5.25 per share minus the underwriters’ discount), pursuant to the Company’s registration statement on Form S-1 (File No. 333-239676), as amended, under the Securities Act of 1933, that was filed by the Company under Rule 462(b) under the Securities Act. The Company also granted the underwriters a 45 - day option to purchase up to 231,818 additional shares of common stock to cover over-allotments. On August 30, 2022, the Company received net proceeds from its public offering of approximately $6.0 million, net of underwriter fees and commissions of approximately $0.8 million, and offering costs of approximately $1.4 million. In connection with its public offering the Company issued 108,181 warrants to purchase shares of the Company’s common stock with an exercise price of $6.5625 per share. Going concern, liquidity and capital resources The Company has no product revenues, incurred operating losses since inception, and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. The Company had an accumulated deficit of approximately $28.5 million at September 30, 2022, a net loss of approximately $9.6 million, and approximately $3.0 million of net cash used in operating activities for the nine months ended September 30, 2022. 2022 Notes During the second and third quarters of 2022, the Company entered into senior secured convertible promissory notes (the “2022 Notes”) with a principal balance totaling approximately $1.5 million. The 2022 Notes contain an original issue discount totaling $0.3 million and the Company received net proceeds of approximately $1.2 million (See Note 6). Series X Preferred Stock On August 2, 2022, the Company issued 3,200 shares of Series X preferred stock, par value $0.0001 per share at a purchase price of $100 per share. The Company received net proceeds of approximately $0.3 million, net of fees. (See Note 8). Going Concern The accompanying condensed financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern. The Company’s future liquidity and capital funding requirements will depend on numerous factors, including: ● its ability to raise additional funds to finance its operations; ● the outcome, costs and timing of clinical trial results for the Company’s current or future product candidates; ● the emergence and effect of competing or complementary products; ● its ability to maintain, expand and defend the scope of its intellectual property portfolio, including the amount and timing of any payments the Company may be required to make, or that it may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights; ● its ability to retain its current employees and the need and ability to hire additional management and scientific and medical personnel; and ● the terms and timing of any collaborative, licensing or other arrangements that it has or may establish. The Company will likely need to raise substantial additional funds through one or more of the following: issuance of additional debt or equity, or the completion of a licensing transaction for one or more of the Company’s pipeline assets. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. This could affect future development and business activities and potential future clinical studies and/or other future ventures. Failure to obtain additional equity or debt financing will have a material, adverse impact on the Company’s business operations. There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or debt financings will likely have a dilutive effect on the holdings of the Company’s existing stockholders. Accordingly, there are material risks and uncertainties that raise substantial doubt about the Company’s ability to continue as a going concern for the next twelve months from the issuance of these condensed financial statements. The accompanying condensed financial statements do not include any adjustments that result from the outcome of these uncertainties. The COVID-19 global pandemic has been unprecedented and unpredictable, is likely to continue to result in significant national and global economic disruption, which may adversely affect our business. Based on the Company’s current assessment, the Company does not expect any material impact on its long-term development timeline and its liquidity due to the worldwide spread of the COVID-19 virus. However, the Company is continuing to assess the effect on its operations by monitoring the spread of COVID-19 and the resulting global pandemic and the actions implemented to combat the virus throughout the world.	Note 1. Organization and description of business operations PaxMedica, Inc. (Formerly Purinix Pharmaceuticals LLC) (the “Company”) is a clinical stage biopharmaceutical company organized as a Delaware limited liability company on April 5, 2018 (“Inception”) to focus on the development of drug candidates for the treatment of autism spectrum disorder (ASD), Fragile X syndrome tremor-ataxia (FXTAS) and Human African Trypanosomiasis (HAT). On April 15, 2020, Purinix Pharmaceuticals LLC converted from a limited liability company (“ LLC”) to a Delaware corporation and changed its name to PaxMedica, Inc., resulting in a new capital structure consisting of two classes of stock: common and preferred, each having a par value of $0.0001 . The Company has authorized 20,000,000 shares of common stock and 2,696,439 shares of preferred stock. This conversion resulted in conversion of the current members’ LLC interests into an aggregate of 2,696,439 shares of preferred stock, which are convertible into 1,557,435 shares of common stock, and 5,775,898 shares of common stock of the Company. On July 22, 2020, the Company filed with the state of Delaware a certificate of amendment for its certificate of incorporation and effected a 1-for- 0.5775898 reverse stock split of its common stock. All share and per share information in the accompanying financial statements and footnotes has been retroactively adjusted for the effects of the reverse split for all periods presented. Going concern, liquidity and capital resources The Company has no product revenues, incurred operating losses since inception, and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. The Company had an accumulated deficit of approximately $18.9 million at December 31, 2021, a net loss of approximately $10.2 million, and approximately $5.5 million of net cash used in operating activities for the year ended December 31, 2021. On March 19, 2021, the Company entered into a Simple Agreement for Future Equity (“SAFE”) with an investor and received proceeds of $5.0 million. Under the terms of the SAFE, the investor has rights to certain shares of the Company’s common and preferred stock at a discount to the price at which those securities might be issued (See Note 6). The accompanying financial statements have been prepared assuming the Company will continue to operate as a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from uncertainty related to its ability to continue as a going concern. The Company’s future liquidity and capital funding requirements will depend on numerous factors, including: ● its ability to raise additional funds to finance its operations; ● the outcome, costs and timing of clinical trial results for the Company’s current or future product candidates; ● the emergence and effect of competing or complementary products; ● its ability to maintain, expand and defend the scope of its intellectual property portfolio, including the amount and timing of any payments the Company may be required to make, or that it may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights; ● its ability to retain its current employees and the need and ability to hire additional management and scientific and medical personnel; and ● the terms and timing of any collaborative, licensing or other arrangements that it has or may establish. The Company will likely need to raise substantial additional funds through one or more of the following: issuance of additional debt or equity, or the completion of a licensing transaction for one or more of the Company’s pipeline assets. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. This could affect future development and business activities and potential future clinical studies and/or other future ventures. Failure to obtain additional equity or debt financing will have a material, adverse impact on the Company’s business operations. There can be no assurance that the Company will be able to obtain the needed financing on acceptable terms or at all. Additionally, equity or debt financings will likely have a dilutive effect on the holdings of the Company’s existing stockholders. Accordingly, there are material risks and uncertainties that raise substantial doubt about the Company’s ability to continue as a going concern for the next twelve months from the issuance of these financial statements. The accompanying financial statements do not include any adjustments that result from the outcome of these uncertainties. The COVID-19 global pandemic has been unprecedented and unpredictable, is likely to continue to result in significant national and global economic disruption, which may adversely affect our business. Based on the Company’s current assessment, the Company does not expect any material impact on its long-term development timeline and its liquidity due to the worldwide spread of the COVID-19 virus. However, the Company is continuing to assess the effect on its operations by monitoring the spread of COVID-19 and the resulting global pandemic and the actions implemented to combat the virus throughout the world.

Significant accounting polici_7

Significant accounting policies	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Significant accounting policies
Significant accounting policies	Note 2. Significant accounting policies Basis of presentation The accompanying unaudited condensed financial statements are presented in U.S. dollars and in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected through December 31, 2022. The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the registration statement on Form S-1/A filed by the Company with the SEC on August 8, 2022. Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed financial statements relate to the valuation of convertible notes, valuation of warrants, valuation of the Simple Agreement For Equity (“SAFE”) liability and valuation of equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. Cash, cash equivalents and short-term investments The Company considers all highly liquid investments with an original maturity of three months or less at the date of acquisition to be cash equivalents. As of September 30, 2022 and December 31, 2021, the Company had no cash equivalents or short-term investments. Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash high credit quality financial institutions, which may at times, be in excess of federal insured limits. The Company believes it is not exposed to any significant losses due to credit risk on cash. Fair value of financial instruments The Company accounts for financial instruments under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification 820 (“ASC 820”), Fair Value Measurements. This statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements, ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels as follows: Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and Level 3 - assets and liabilities whose significant value drivers are unobservable. Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment. During the nine months ended September 30, 2022, the Company issued certain of the 2022 Notes and warrants in connection with the 2022 Notes. The 2022 Notes and warrants were classified as liabilities and measured at fair value on the issuance date, with changes in fair value recognized as other expense on the statements of operations and disclosed in the condensed financial statements During the year ended December 31, 2021, the Company entered into its SAFE agreement and classified the SAFE as a liability measured at cost on the issuance date, with changes in fair value recognized as other income on the statement of operations. The carrying amounts of the Company’s financial assets and liabilities, such as accounts payable, approximate fair value due to the short-term nature of these instruments. Convertible Notes In accordance with Accounting Standards Codification 825, Financial Instruments (“ASC 825”), the Company has elected the fair value option for recognition of its 2022 Notes. In accordance with ASC 825, the Company recognizes these 2022 Notes at fair value with changes in fair value recognized in the condensed statements of operations. The fair value option may be applied instrument by instrument, but it is irrevocable. As a result of applying the fair value option, direct costs and fees related to the convertible notes were recognized in general and administrative expense. Accrued interest for the 2022 Notes has been included in the change in fair value of convertible notes in the condensed statements of operations. Warrant Liability The Company accounts for certain common stock warrants outstanding as a liability at fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statements of operations. The fair value of the warrants issued by the Company have been estimated using the Monte Carlo simulation. As of September 30, 2022, there are no warrant liabilities (See Note 3). Simple Agreement for Future Equity The Company accounts for a SAFE as a liability at fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until a triggering event, equity financing or a liquidity/dissolution occurs, and any change in fair value is recognized in the Company’s statements of operations. The fair value of the SAFE has been estimated using the Backsolve method which utilizes the Option Pricing Method. As of September 30, 2022, the SAFE liability has been converted to 100,000 shares of Series X preferred stock (See Note 8). Research and development Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Accrued Outsourcing Costs Substantial portions of the Company’s preclinical studies and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors (collectively “CROs”). These CROs generally bill monthly or quarterly for services performed, or bill based upon milestone achievement. For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining. Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources a substantial portion of its clinical trial activities, utilizing external entities such as CROs, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies. For each clinical trial that the Company conducts, certain clinical trial costs are expensed immediately, while others are expensed over time based on the number of patients in the trial, the attrition rate at which patients leave the trial, and/or the period over which clinical investigators or CROs are expected to provide services. The Company’s estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives. Stock-Based Compensation The Company expenses stock-based compensation to employees, non-employees and board members over the requisite service period based on the estimated grant-date fair value of the awards and actual forfeitures. The Company accounts for forfeitures as they occur. Stock-based awards with graded vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. All stock-based compensation costs are recorded in general and administrative costs in the statements of operations. Loss Per Share Basic net loss per share (“EPS”) of common stock is computed by dividing net loss allocated to common shareholders by the weighted average number of common shares outstanding during the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity. The Company’s common stock equivalents have been excluded from the computation of diluted loss per share for the three and nine months ended September 30, 2022 and 2021, as the effect would be to reduce the loss per share. Therefore, the weighted average common stock outstanding used to calculate both basic and diluted loss per share is the same for the three and nine months ended September 30, 2022 and 2021. The following securities were excluded from the computation of diluted net loss per share attributable to common shareholders for the nine months ended September 30, 2022 and 2021, because including them would have been anti-dilutive: ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ 2022 2021 Preferred stock — 1,557,435 Series X preferred stock ​ 863,162 ​ — Unvested restricted stock units 1,582,220 1,377,999 Common stock warrants 587,497 1,034,176 SAFE investment — 414,808 Convertible notes 37,259 — Total 3,070,138 4,384,418 ​ Income taxes ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company’s condensed financial statements. The Company believes that its income tax positions and deductions would be sustained on audit and does not anticipate any adjustments that would result in material changes to its financial position. Recent accounting pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This ASU is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company adopted this standard on January 1, 2022, and the adoption did not have a material impact on the Company’s condensed financial statements or disclosures. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The Company adopted this standard on January 1, 2022, and the adoption did not have a material impact on the Company’s condensed financial statements or disclosures.	Note 2. Significant accounting policies Basis of presentation The Company’s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and include all adjustments necessary for the fair presentation of its balance sheets, results of operations and cash flows for the period presented. Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to the valuation of warrants, valuation of the SAFE liability and valuation of equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected. Cash, cash equivalents and short-term investments The Company considers all highly liquid investments with an original maturity of three months or less at the date of acquisition to be cash equivalents. As of December 31, 2021 and 2020, the Company had no cash equivalents or short-term investments . Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash high credit quality financial institutions, which may at times, be in excess of federal insured limits. The Company believes it is not exposed to any significant losses due to credit risk on cash. Risks and Uncertainties The Company operates in a dynamic and highly competitive industry and is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, contract manufacturer and contract research organizations, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies and clinical trials and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting. The Company believes that changes in any of the following areas could have a material adverse effect on the Company’s future financial position, results of operations, or cash flows; ability to obtain future financing; advances and trends in new technologies and industry standards; results of clinical trials; regulatory approval and market acceptance of the Company’s products; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company’s ability to attract and retain employees necessary to support its growth. Fair value of financial instruments The Company accounts for financial instruments under FASB Accounting Standards Codification 820 (“ASC 820”), Fair Value Measurements. This statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements, ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels as follows: Level 1 — quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 — observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and Level 3 — assets and liabilities whose significant value drivers are unobservable. Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment. During the year ended December 31, 2021, the Company entered into its SAFE agreement and classified the SAFE as a liability measured at cost on the issuance date, with changes in fair value recognized as other income on the statement of operations. During the year ended December 31, 2020, the Company issued convertible notes and warrants in connection with the notes. The notes and warrants were classified as liabilities and measured at fair value on the issuance date, with changes in fair value recognized as other expense on the statements of operations and disclosed in the financial statements. The carrying amounts of the Company’s financial assets and liabilities, such as accounts payable, approximate fair value due to the short-term nature of these instruments. Warrant Liability The Company accounts for certain common stock warrants outstanding as a liability at fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statements of operations. The fair value of the warrants issued by the Company has been estimated using the Monte Carlo simulation. Simple Agreement for Future Equity The Company accounts for a SAFE as a liability at fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until a triggering event, equity financing or a liquidity/dissolution occurs, and any change in fair value is recognized in the Company’s statements of operations. The fair value of the SAFE has been estimated using the Backsolve method which utilizes the Option Pricing Method. Derivative Financial Instruments The Company does not use derivative instruments to hedge exposures to interest rate, market, or foreign currency risks. The Company evaluates all of its financial instruments, including notes payable, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the statement of operations each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s balance sheet. During the year ended December 31, 2020, the Company entered into note agreements that were determined to have embedded derivative instruments in the form of contingent interest. The notes are recognized at the value of proceeds received after allocating issuance proceeds to the separable instruments issued with the notes and to the bifurcated contingent interest. The notes are subsequently measured at amortized cost using the effective interest method to accrete interest over their term to bring the notes’ initial carrying value to their principal balance at maturity. The bifurcated contingent interest is initially measured at fair value which is included in the notes payable balance on the accompanying balance sheets and subsequently measured at fair value with changes in fair value recognized as a component of other income (expense) in the statements of operations. The notes were converted during the year ended December 31, 2021 (See Note 5). Research and development Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Accrued Outsourcing Costs Substantial portions of the Company’s preclinical studies and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors (collectively “CROs”). These CROs generally bill monthly or quarterly for services performed, or bill based upon milestone achievement. For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining. Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources a substantial portion of its clinical trial activities, utilizing external entities such as CROs, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies. For each clinical trial that the Company conducts, certain clinical trial costs are expensed immediately, while others are expensed over time based on the number of patients in the trial, the attrition rate at which patients leave the trial, and/or the period over which clinical investigators or CROs are expected to provide services. The Company’s estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives. Convertible Financial Instruments The Company bifurcates conversion options from their host instruments and accounts for them as free standing derivative financial instruments if certain criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable GAAP. When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, discounts are recorded for the intrinsic value of conversion options embedded in the instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the instrument. Stock-Based Compensation The Company expenses stock-based compensation to employees, non-employees and board members over the requisite service period based on the estimated grant-date fair value of the awards and actual forfeitures. The Company accounts for forfeitures as they occur. Stock-based awards with graded vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. All stock-based compensation costs are recorded in general and administrative costs in the statements of operations. Loss Per Share Basic net loss per share (“EPS”) of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity. Since the Company has net losses, basic and diluted net loss per share is the same. Securities that could potentially dilute loss per share in the future were not included in the computation of diluted loss per share at December 31, 2021 and 2020, because their inclusion would be anti-dilutive are as follows: ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2021 2020 Preferred stock 1,557,435 1,557,435 Unvested restricted stock units — 1,377,999 Common stock warrants 1,034,176 1,034,176 Convertible notes — 1,034,177 SAFE investment (1) 414,808 — Total 3,006,419 5,003,787 (1) SAFE investment As of December 31, 2021, the Company’s price per share of $12.05 was calculated by dividing the post money valuation of $150 million by 12,444,251 shares of common stock outstanding. The 12,444,251 shares of common stock outstanding was calculated in accord with the agreement and includes 6,913,492 of common shares outstanding, 2,703,776 of IPO shares, 1,377,999 of restricted stock units, 1,034,176 of common stock warrants and 414,808 of SAFE shares. The SAFE investment shares of 414,808 (included in the table above) were calculated using the SAFE investment of $5.0 million divided by $12.05 per share. Income taxes From April 5, 2018 (Inception) through April 14, 2020, the Company was organized as an LLC and subject to the provisions of Subchapter K of the Internal Revenue Code. As such, the Company was not viewed as a taxpaying entity in any jurisdiction and did not require a provision for income taxes for this period. Each member was responsible for the tax liability, if any, related to its proportionate share of the Company’s taxable losses for this period. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company’s financial statements. The Company believes that its income tax positions and deductions would be sustained on audit and does not anticipate any adjustments that would result in material changes to its financial position. The Company converted to a C-Corporation on April 15, 2020 and therefore the Company is subject to examination starting in 2020. The Company’s tax year, 2021 and 2020 federal tax returns remain subject to examination by the Internal Revenue Service. Given the Company’s historical losses, the conversion to a C-Corporation did not have a material impact on the Company financial statements. Recent accounting pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This ASU is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company adopted this standard on January 1, 2022, and the adoption did not have a material impact on the Company’s financial statements or disclosures. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: (1) how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The Company adopted this standard on January 1, 2022, and the adoption did not have a material impact on the Company’s financial statements or disclosures.

Fair Value Measurements_2

Fair Value Measurements	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Fair Value Measurements
Fair Value Measurements	Note 3. Fair Value Measurements Convertible Notes During the second and third quarters of 2022, the Company issued the 2022 Notes. The fair value of the 2022 Notes on the issuance dates and as of September 30, 2022 were estimated using a Monte Carlo simulation to capture the path dependencies intrinsic to their terms. The significant unobservable inputs used in the fair value measurement of the Company’s convertible notes are the common stock price, volatility, and risk-free interest rates. Significant changes in these inputs may result in significantly lower or higher fair value measurement. The Company elected the fair value option when recording its 2022 Notes (See Note 2) and the notes were classified as liabilities and measured at fair value on the issuance date, with changes in fair value recognized as other income (expense) on the statements of operations and disclosed in the condensed financial statements. On August 26, 2022, two holders of the 2022 Notes converted their notes to 238,094 shares of the Company’s common stock and one holder of the 2022 Notes converted its note to 2,555 shares of Series X preferred stock. A summary of significant unobservable inputs (Level 3 inputs) used in measuring the 2022 Notes upon the issuance dates, conversion dates and during three and nine months ended September 30, 2022 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ​ ​ ​ ​ ​ ​ August 3, 2022 - ​ ended September ​ Nine months ended ​ ​ July 8, 2022 August 5, 2022 30, 2022 September 30, 2022 Dividend yield 0 % 0 % 0 % 0 % Expected price volatility 57.0 % 57.0 % 57.0 % 57.0% - 57.2 % Risk free interest rate 2.96 % 3.14 %- 3.29 % 2.8 %- 4.05 % 2.8 %- 4.05 % Expected term (in years) 1.0 1.0 0.7 - 0.9 ​ 0.7 - 0.9 ​ ​ Simple Agreement for Future Equity On March 19, 2021, the Company entered into a SAFE agreement with an investor. At issuance date, the Company classified the cash received of $5.0 million as a liability, with changes in fair value recognized as other income (expense) on the statements of operations and disclosed in the condensed financial statements (See Note 5). On August 2, 2022 the SAFE was converted to 100,000 shares of Series X preferred stock (See Note 8). A summary of significant unobservable inputs (Level 3 inputs) used in measuring the SAFE on the conversion date of August 2, 2022, and the period January 1, 2022 through August 2, 2022 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1, ​ ​ August 2, ​ 2022 - August ​ ​ 2022 2, 2022 Dividend yield 0 % 0 % Expected price volatility 50.0 % 50.0 % Risk free interest rate 3.08 % 1.35% - 3.08 % Expected term (in years) 1.5 0.8 - 1.5 ​ ​ Warrants During the nine months ended September 30, 2022, the Company issued 195,140 common stock warrants in connection with its 2022 Notes (See Note 6). During the year ended December 31, 2020, the Company issued 1,034,176 common stock warrants in association with its 2020 convertible notes (the “2020 Notes”) issued during 2020. The warrants were classified as liabilities and measured at fair value on the grant date, with changes in fair value recognized as other income (expense) on the statements of operations and disclosed in the condensed financial statements. On August 26, 2022, 750,000 warrants issued in connection with the 2020 Notes were exchanged for 350,000 shares of common stock and 1,250 shares of Series X preferred stock (see below). On August 26, 2022, 479,316 liability classified warrants were reclassified to equity. As of September 30, 2022, there are no liability classified warrants. Warrant Exchange On August 3, 2022, the Company entered into a warrant exchange agreement (the “Warrant Exchange Agreement”) with a holder of certain warrants to purchase the Company’s common stock. The warrants were issued in connection with the Company’s 2020 Notes. Pursuant to the Warrant Exchange Agreement, the Company exchanged 750,000 warrants for 350,000 shares of common stock and 1,250 shares of Series X preferred stock at the consummation of the Company’s initial public offering (See Note 8). A summary of significant unobservable inputs (Level 3 inputs) used in measuring warrants on issuance date, August 26, 2022, and during the period January 1, 2022 through August 26, 2022, is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1 2022 - ​ ​ July 2022 August 26, 2022 August 26, 2022 Dividend yield 0 % 0 % 0 % Expected price volatility 57.0 % 57.0 % 57.0% - 105.0 % Risk free interest rate 2.70 % - 2.82 % 2.39% - 3.40 % 0.17% - 3.40 % Expected term (in years) 5.0 ​ 0.1 - 4.9 0.1 - 4.0 ​ ​ Significant changes in the expected price volatility and expected term would result in significantly lower or higher fair value measurement of the warrants, respectively. The following tables classify the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of September 30, 2022 and December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value measured at September 30, 2022 ​ ​ ​ ​ Quoted prices in active ​ Significant other ​ Significant ​ ​ Total carrying value at ​ markets ​ observable inputs ​ unobservable inputs ​ September 30, 2022 (Level 1) (Level 2) (Level 3) Liabilities: ​ ​ ​ ​ Convertible notes ​ $ 156,486 ​ $ — ​ $ — ​ $ 156,486 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value measured at December 31, 2021 ​ ​ ​ ​ Quoted prices in active ​ Significant other ​ Significant ​ ​ Total carrying value at ​ markets ​ observable inputs ​ unobservable inputs ​ December 31, 2021 (Level 1) (Level 2) (Level 3) Liabilities: ​ ​ ​ ​ SAFE liability ​ $ 4,824,217 ​ $ — ​ $ — ​ $ 4,824,217 Warrant liability ​ $ 4,516,485 ​ $ — ​ $ — ​ $ 4,516,485 ​ For the three and nine months ended September 30, 2022, there was a change of approximately $3.3 million and $1.8 million in Level 3 liabilities measured at fair value, respectively. The fair value of the convertible notes may change significantly as additional data is obtained, impacting the Company’s assumptions used to estimate the fair value of the liabilities. In evaluating this information, considerable judgment is required to interpret the data used to develop the assumptions and estimates. The estimates of fair value may not be indicative of the amounts that could be realized in a current market exchange. Accordingly, the use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts, and such changes could materially impact the Company’s results of operations in future periods. The following table presents changes in Level 3 liabilities measured at fair value for the nine months ended September 30, 2022. Unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to unobservable (e.g., changes in unobservable long-dated volatilities) inputs. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Convertible Notes SAFE Liability Warrant Liability Balance at December 31, 2021 ​ $ — ​ $ 4,824,217 ​ $ 4,516,485 Issuance of convertible notes and warrants ​ 1,353,720 ​ — ​ 278,494 Conversion of SAFE liability to Series X preferred stock ​ ​ — ​ ​ (10,000,000) ​ ​ — Issuance of common stock in connection with conversion of notes payable ​ ​ (1,159,500) ​ ​ — ​ ​ — Issuance of Series X preferred stock in connection with conversion of notes payable ​ ​ (296,819) ​ ​ — ​ ​ — Warrants exchanged for shares of common stock and Series X preferred stock ​ ​ — ​ ​ — ​ ​ (2,009,207) Loss on extinguishment of debt ​ ​ 3,940 ​ ​ — ​ ​ — Change in fair value ​ 255,145 ​ (163,025) ​ (1,873,192) Reclassification of warrants to equity ​ ​ — ​ ​ — ​ ​ (912,580) Loss on conversion of SAFE ​ ​ — ​ ​ 5,338,808 ​ ​ — Balance at September 30, 2022 ​ $ 156,486 ​ $ — ​ $ — ​	Note 3. Fair Value Measurements Simple Agreement for Future Equity On March 19, 2021, the Company entered into a SAFE agreement with an investor. At issuance date, the Company classified the cash received of $5.0 million as a liability, with changes in fair value recognized as other expense on the statements of operations and disclosed in the financial statements. (See Note 6). A summary of significant unobservable inputs (Level 3 inputs) used in measuring the SAFE during the year ended December 31, 2021, is as follows: ​ ​ ​ ​ ​ ​ Year Ended ​ ​ December 31, 2021 Dividend yield — ​ Expected price volatility 50.0 % Risk free interest rate 0.06 % – 0.07 % Expected term (in years) 1.0 – 5.0 ​ ​ Warrants During the year ended December 31, 2020, the Company issued 1,034,176 common stock warrants in association with its convertible notes. As of December 31, 2021, 1,034,176 warrants were outstanding. The warrants were classified as liabilities and measured at fair value on the grant date, with changes in fair value recognized as other expense on the statements of operations and disclosed in the financial statements. A summary of significant unobservable inputs (Level 3 inputs) used in measuring warrants during the years ended December 31, 2021 and 2020, is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, ​ 2021 2020 Dividend yield ​ — ​ — ​ Expected price volatility 76.8 % – 112.1 % 108.7 % – 114.4 % Risk free interest rate 0.05 % – 1.09 % 0.10 % – 0.38 % Expected term (in years) 1.0 – 5.0 1.0 – 5.0 ​ ​ Significant changes in the expected price volatility and expected term would result in significantly lower or higher fair value measurement of the warrants, respectively. Contingent Interest During the year ended December 31, 2020, the Company recorded a derivative liability resulting from the contingent interest feature within its convertible notes. The Company recorded contingent interest on its convertible notes due to the interest rate increasing from 10% to 15% per annum, if the Company has not consummated a Qualified Offering on or before the date that is 9 months from the note issuance dates (See Note 5). The fair value of the contingent interest was estimated using the Monte Carlo simulation model on the dates the notes were issued and was subsequently revalued. During the year ended December 31, 2021, all of the Company’s notes were converted into 1,137,594 shares of the Company’s common stock, and the Company recognized a gain on the derivative liability of approximately $60,000 . As of December 31, 2021, there is no derivative liability. The following table reflects the assumptions used in the Monte Carlo simulation model at the notes issuance dates and during the year ended December 31, 2020: ​ ​ ​ ​ ​ ​ Year Ended ​ ​ December 31, 2020 Contingent interest rate 15.0 % Interest rate 10.0 % Expected term 0.8 – 1.0 ​ ​ Significant changes in the expected term and contingent interest rate would result in significantly lower or higher fair value measurement of the contingent interest derivative, respectively. The following tables classify the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of December 31, 2021 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value measured at December 31, 2021 ​ ​ Total carrying ​ Quoted prices in ​ Significant other ​ Significant ​ ​ value at ​ active markets ​ observable inputs ​ unobservable inputs ​ December 31, 2021 (Level 1) (Level 2) (Level 3) Liabilities: ​ ​ ​ ​ SAFE liability ​ $ 4,824,217 ​ $ — ​ $ — ​ $ 4,824,217 Warrant liability ​ $ 4,516,485 ​ $ — ​ $ — ​ $ 4,516,485 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value measured at December 31, 2020 ​ ​ Total carrying ​ Quoted prices in ​ Significant other ​ Significant ​ ​ value at ​ active markets ​ observable inputs ​ unobservable inputs ​ December 31, 2020 (Level 1) (Level 2) (Level 3) Liabilities: ​ ​ ​ ​ Warrant liability ​ $ 4,057,927 ​ $ — ​ $ — ​ $ 4,057,927 Contingent Interest ​ $ 59,890 ​ $ — ​ $ — ​ $ 59,890 ​ For the years ended December 31, 2021 and 2020, there was a change of approximately $0.3 million and $1.6 million, respectively, in Level 3 liabilities measured at fair value. The fair value of the warrant liability and SAFE liability may change significantly as additional data is obtained, impacting the Company’s assumptions used to estimate the fair value of the liabilities. In evaluating this information, considerable judgment is required to interpret the data used to develop the assumptions and estimates. The estimates of fair value may not be indicative of the amounts that could be realized in a current market exchange. Accordingly, the use of different market assumptions and/or different valuation techniques may have a material effect on the estimated fair value amounts, and such changes could materially impact the Company’s results of operations in future periods. The following table presents changes in Level 3 liabilities measured at fair value for the years ended December 31, 2021 and 2020. Unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to unobservable (e.g., changes in unobservable long-dated volatilities) inputs. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ SAFE Liability Warrant Liability Contingent Interest Balance at December 31, 2019 ​ $ — ​ $ — ​ $ — Issuance of warrants in connection with convertible notes ​ — ​ 2,488,544 ​ — Contingent interest in connection with notes payable ​ — ​ — ​ 55,394 Change in fair value ​ — ​ 1,569,383 ​ 4,496 Balance at December 31, 2020 ​ $ — ​ $ 4,057,927 ​ $ 59,890 Gain on conversion of notes ​ — ​ — ​ (59,890) Issuance of SAFE ​ 5,000,000 ​ — ​ — Change in fair value ​ (175,783) ​ 458,558 ​ — Balance at December 31, 2021 ​ $ 4,824,217 ​ $ 4,516,485 ​ $ — ​

Accrued Expenses_2

Accrued Expenses	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Accrued Expenses
Accrued Expenses	Note 4. Accrued Expenses The Company’s accrued expenses as of September 30, 2022 and December 31, 2021 consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2022 ​ 2021 ​ (Unaudited) ​ ​ Employee and related expenses ​ $ 50,335 ​ $ 680,026 Directors and officers insurance ​ ​ 385,362 ​ ​ — Professional fees ​ ​ 153,995 ​ ​ — Research and development ​ 24,758 ​ — Total accrued expenses ​ $ 614,450 ​ $ 680,026 ​	Note 4. Accrued Expenses The Company’s accrued expenses as of December 31, 2021 and 2020 consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2021 2020 Accrued expenses: ​ ​ ​ ​ Employee and related expenses ​ $ 680,026 ​ $ 499,752 Research and development ​ — ​ 4,000 Professional fees ​ — ​ 74,772 Total accrued expenses ​ $ 680,026 ​ $ 578,524 ​

Simple Agreement for Future E_3

Simple Agreement for Future Equity ("SAFE")	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Simple Agreement for Future Equity ("SAFE").
Simple Agreement for Future Equity ("SAFE")	Note 5. Simple Agreement for Future Equity (“SAFE”) During the year ended December 31, 2021, the Company entered into a SAFE with an investor, and received proceeds of $5.0 million. Under the terms of the SAFE, the investor has the right to participate in future equity financings of the Company. The number of shares to be received by the SAFE investor was based on a 50% discount of the pricing in the triggering equity financing and includes a post money valuation cap of $150.0 million. In a liquidity or dissolution event, the investors right to receive cash out was junior to payment of outstanding indebtedness and creditor claims, on par for other SAFE agreements and/or preferred stock, and senior to payments for common stock. The SAFE had no interest rate or maturity date, the SAFE investor had no voting rights prior to conversion, and if the Company paid a dividend on outstanding shares of common stock while the SAFE was outstanding, the SAFE investor would have received the same dividend. On August 2, 2022, the fair value of the SAFE was approximately $ 4.7 million and the SAFE was converted into 100,000 shares of Series X preferred stock. During the three and nine months ended September 30, 2022, the Company recognized a $5.3 million loss on conversion of the SAFE (See Note 8).	Note 6. Simple Agreement for Future Equity (“SAFE”) During the year ended December 31, 2021, the Company entered into a SAFE with an investor, and received proceeds of $5.0 million. Under the terms of the SAFE, the investor has the right to participate in future equity financings of the Company. The number of shares to be received by the SAFE investor is based on a 50% discount of the pricing in the triggering equity financing and includes a post money valuation cap of $150.0 million. In a liquidity or dissolution event, the investors right to receive cash out is junior to payment of outstanding indebtedness and creditor claims, on par for other SAFE agreements and/or preferred stock, and senior to payments for common stock. The SAFE has no interest rate or maturity date, the SAFE investor has no voting rights prior to conversion, and if the Company pays a dividend on outstanding shares of common stock while the SAFE is outstanding, the SAFE investor will receive the same dividend. As of December 31, 2021, the SAFE had not yet converted as a qualifying financing had not yet occurred. Pursuant to the guidance under ASC 480, Distinguishing Liabilities from Equity , the Company determined that the value of the SAFE should be recorded as a liability in the accompanying balance sheets (See Note 3).

Convertible promissory notes

Convertible promissory notes	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Convertible promissory notes
Convertible promissory notes	Note 6. Convertible promissory notes During the second and third quarters of 2022, the Company entered into its 2022 Notes with a principal balance totaling approximately $1.5 million. The 2022 Notes contain an original issue discount totaling $0.2 million and the Company received net proceeds of approximately $1.2 million (net of financing fees of approximately $0.1 million). The 2022 Notes bear interest at 10% per annum and mature 12 months from the issuance date. The notes are secured by all assets and personal property of the Company. The note holders have the right to convert all or any portion of the outstanding principal balance and accrued interest into shares of the Company’s common stock, up to a beneficial ownership limitation of 9.99% of the number of shares of common stock outstanding at the time of conversion. The per share conversion price is equal to the lessor of (i) $7.00 or (ii) 80% of the qualified offering price of the Company’s common stock resulting from the listing for trading of its common stock on a qualified exchange. In connection with the notes, the Company issued common stock warrants to purchase 195,140 shares of the Company’s common stock. The warrants have an exercise price of the lessor of (i) $7.00 or (ii) 80% of the qualified offering price and expire five years from the issuance date. As a result of the issuance of the common stock warrants, the exercise price of the Company’s existing warrants was adjusted to an exercise of $3.00 per share. On August 26, 2022, upon the consummation of the Company’s initial public offering, the conversion price of the 2022 Notes and the exercise price of the warrants is calculated at 80% of $5.25 per share (the offering price) or $4.20 per share. On August 3, 2022, the Company entered into a conversion agreement with certain holders of the 2022 Notes, pursuant to which the holders agreed to convert $1.0 million of the principal balance at the consummation of the Company’s initial public offering at the conversion price of $4.20 per share. On August 26, 2022, the holders of the 2022 Notes converted the notes fair value of approximately $1.2 million to 238,094 shares of the Company’s common stock. On August 3, 2022, the Company entered into a conversion agreement with an additional holder of the 2022 Notes, pursuant to which the holder agreed to convert $255,555 of the principal balance at the consummation of the Company’s initial public offering into 2,555 shares of Series X preferred stock. On August 26, 2022, the note holder converted the notes fair value of $0.3 million to 2,555 shares of Series X preferred stock (See Note 8). As of September 30, 2022, the outstanding principal balance of the 2022 Notes was approximately $0.2 million. For the nine months ended September 30, 2022, the Company recorded a loss on issuance of debt of $0.4 million, and a fair value loss of $0.25 million that is included in the change in fair value of notes, in the accompanying condensed statements of operations. The Company recognized interest expense as a component of the change in fair value of the notes during the nine months ended September 30, 2022 (See Note 2).	Note 5. Notes Payable Notes payable at December 31, 2020 consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Unamortized Notes ​ ​ Principal ​ Contingent ​ Debt ​ Payable as of Issuance date ​ Balance ​ Interest ​ Discount ​ December 31, 2020 October 26, 2020 ​ $ 2,250,000 ​ $ 43,445 ​ $ (1,843,151) ​ $ 450,295 October 29, 2020 ​ 750,000 ​ 14,470 ​ (620,548) ​ 143,922 November 6, 2020 ​ 102,532 ​ 1,974 ​ (87,082) ​ 17,424 ​ ​ $ 3,102,532 ​ $ 59,890 ​ $ (2,550,780) ​ $ 611,641 ​ Unsecured Convertible Promissory Notes In July, 2020, the Company issued unsecured convertible promissory notes in an aggregate principal amount of $100,000 with an interest rate of 8% per annum. The notes mature 12 months from the date of issuance and provide for conversion into shares of the Company’s common stock on the earlier of a Qualified Financing or if the Company engages in a Change of Control. Upon a Qualified Offering, the notes will convert into shares of the Company’s common stock at a conversion price equal to 75% of the per share purchase price in such Qualified Financing. The principal amount and accrued but unpaid interest under each note will automatically convert into shares of the Company’s common stock at the stated conversion price per share. If the Company engages in a Change of Control, the principal amount and all accrued but unpaid interest on the notes will automatically be converted into shares of the Company’s common stock at a conversion price equal to 75% of the price per share of the common stock set forth in the definitive agreements related to the Change of Control. Further, in the event that the Change of Control is a transaction wholly for cash, all principal and accrued but unpaid interest will convert into shares of the Company’s common stock at a price per share equal to 75% of the Company’s Enterprise Value as set forth and agreed to in the definitive agreements related to the Change of Control. During the year ended December 31, 2020, the unsecured convertible promissory notes were converted into senior secured convertible promissory notes (see below). Senior Secured Convertible Promissory Notes and Warrants On October 26, 2020, the Company issued a senior secured convertible promissory note with a principal balance of $2,250,000 . The Company recorded an original issue discount of $172,500 and received net proceeds totaling $2,077,500 . The note accrues interest at a rate of 10% per annum (which increases to 15% per annum if the Company has not consummated a Qualified Offering on or before July 26, 2021), and matures on October 26, 2021. The note holder has the right to convert all or any portion of the outstanding principal and interest into shares of the Company’s common stock at a conversion price equal to the lesser of (i) $3.00 or (ii) 90% of the stock price in a Qualified Offering. On October 29, 2020, the Company issued a senior secured convertible promissory note with a principal balance of $750,000 . The note accrues interest at a rate of 10% per annum (which increases to 15% per annum if the Company has not consummated a Qualified Offering on or before July 29, 2021), and matures on October 29, 2021. The note holder has the right to convert all or any portion of the outstanding principal and interest into shares of the Company’s common stock at a conversion price equal to the lesser of (i) $3.00 or (ii) 90% of the stock price in a Qualified Offering. On November 6, 2020, the Company entered into note exchange agreements with the holders of the unsecured convertible promissory notes. The note holders surrendered the July 2020 notes and entered into senior secured convertible promissory notes dated November 6, 2020. The senior secured convertible promissory notes have a principal balance of approximately $102,500 , accrue interest at a rate of 10% per annum (which increases to 15% per annum if the Company has not consummated a Qualified Offering on or before August 6, 2021), and mature on November 6, 2021. The note holders have the right to convert all or any portion of the outstanding principal and interest into shares of the Company’s common stock at a conversion price equal to the lesser of (i) $3.00 or (ii) 90% of the stock price in a Qualified Offering. In connection with the issuance of the senior secured convertible promissory notes, the Company issued the note holders common stock purchase warrants, providing the holders with the right to purchase 1,034,176 shares of the Company’s common stock at December 31, 2020. The purchase price of one share of common stock under the warrant shall be the same as the conversion price of the senior secured convertible promissory notes, and 517,088 of the common stock purchase warrants expire five years from the issuance date, and 517,088 of the common stock warrants expire thirty calendar days after the consummation of a Qualified Offering. As of December 31, 2020, the carrying value of the senior secured convertible notes was comprised of the following: ​ ​ ​ ​ Principal value of convertible notes $ 3,102,532 Original issue discount ​ (172,500) Discount resulting from allocation of proceeds to warrant liability ​ (2,488,544) Discount resulting from beneficial conversion feature ​ (462,920) Amortization of discount ​ 551,752 Loss on issuance of debt ​ 53,541 Loss on extinguishment of debt ​ 23,284 Change in fair value of derivative ​ 4,496 Net carrying value of senior secured convertible notes ​ $ 611,641 ​ During the year ended December 31, 2021, the Company converted all of its senior secured promissory notes into 1,137,594 shares of its common stock. In connection with the note conversions, the Company recorded interest expense totaling $2.6 million, and recognized a gain of approximately $60,000 related to the contingent interest feature (see Note 3). As of December 31, 2021, there were no convertible notes outstanding.

Stock-based compensation_2

Stock-based compensation	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Stock-based compensation.
Stock-based compensation	Note 7. Stock-based compensation Stock-based Compensation The following is a summary of stock-based compensation during the three and nine months ended September 30, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, Nine Months Ended September 30, ​ ​ 2022 2021 ​ 2022 2021 Canceled stock options ​ $ 119,829 ​ $ 272,124 ​ $ 449,840 ​ $ 1,110,874 Restricted stock units ​ 927,324 ​ — ​ 927,325 ​ — Total ​ $ 1,047,153 ​ $ 272,124 ​ $ 1,377,165 ​ $ 1,110,874 ​ Restricted Stock Units The following is a summary of the restricted stock units during the nine months ended September 30, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ Grant-Date ​ Number of Shares Fair Value Unvested as of December 31, 2021 — ​ $ — Granted 1,885,500 ​ $ 5.25 Forfeited (291,500) ​ $ 5.25 Vested ​ (11,780) ​ $ 5.26 Unvested as of September 30, 2022 1,582,220 ​ $ 5.25 ​ On May 15 , 2022 , the Company granted 35,333 restricted stock units (RSUs) with a fair value of approximately $0.2 million to a member of its board of directors. The RSUs are subject to service conditions (vesting of 33.34% on August 26, 2022 , the consummation date of the Company’s initial public offering, with the remaining units vesting 66.66% over the next two calendar years on each three-month anniversary thereafter). On January 1, 2022 , the Company granted 1,342,667 RSUs with a fair value of approximately $14.6 million to employees, officers and directors of the Company. The RSUs are subject to service conditions (vesting of 33.34% on May 1, 2022 , with the remaining units vesting on each three -month anniversary thereafter) and performance conditions in the form of a liquidity event. Vesting of the RSUs is subject to all grantees continuous service with the Company, and no vesting shall occur if the Company has not completed a Qualified Offering or a Change of Control on or before the vesting date. In the event that neither a Qualified Offering nor a Change of Control has occurred prior to December 31, 2022 , then all RSUs shall be forfeited for no consideration. Because a Qualified Offering or Change of Control is not considered probable of achievement until consummation, compensation cost measured at the grant date is not recognized until such event occurs. During the nine months ended September 30, 2022, 291,500 RSU’s (granted on January 1, 2022) were forfeited due to terminations of two of the Company’s employees and two of its board members. In August 2022, the Company modified the remaining 1,051,167 RSUs granted on January 1, 2022 to provide that 33.34% of each of those RSUs would vest on May 1, 2022 , with an additional 8.3325% of each grant vesting each quarter thereafter, provided that if neither (i) the expiration of the 6-month period following an initial public offering nor (ii) a change in control has occurred prior to the applicable vesting date, any RSUs that would have vested thereunder shall not vest until such expiration of the 6-month period following an initial public offering or change in control occurs (provided further that if neither an initial public offering nor a change in control occurs on or prior to December 31, 2022 , then all of the related RSUs will be forfeited). Vesting in all cases generally is subject to the grantee’s continued employment with the Company or a subsidiary thereof on the applicable vesting date. This improbable to improbable modification resulted in a new measurement of compensation cost based on the underlying fair value of the Company’s common stock on the date of the modification of approximately $5.5 million. On August 26, 2022 , the Company consummated its initial public offering and based on the modification above, 33.34% of each of the remaining 1,051,167 RSU’s would vest on February 26, 2023 , with an additional 8.3325% of each grant vesting each quarter thereafter. On July 16, 2022 , the Company granted 15,000 RSUs to its Chief Financial Officer with a fair value of approximately $0.1 million, all of which vest December 31, 2022. In August 2022, the Company granted 492,500 RSUs with a fair value of approximately $2.6 million to certain officers, directors and employees, one -third of which vest on the one-year anniversary of the Company’s initial public offering, with the remaining restricted stock units vesting on a quarterly basis over the following two years . On December 22, 2020, the Company granted 896,583 RSUs with a fair value of approximately $6.3 million to its officers and directors, in exchange for 787,499 vested and unvested stock options. The RSUs are subject to service conditions (vesting of 33.34% on May 1, 2021 , with the remaining units vesting on each three-month anniversary, thereafter, fully vesting on May 1, 2023 ) and performance conditions in the form of a liquidity event. Vesting of the RSUs is subject to all grantees continuous service with the Company, and no vesting shall occur if the Company has not completed a Qualified Offering or a Change of Control on or before the vesting date. In the event that neither an IPO no r change in control has occurred prior to December 31, 2021 , then all RSUs shall be forfeited for no consideration. Pursuant to the guidance of ASC 718- “Compensation - Stock Compensation”, the exchange of the options for the RSUs was accounted for as a probable (service only vesting) to improbable (performance and service with the performance criteria considered improbable since contingent upon a Qualified Offering or Change of Control) modification. As such, compensation cost for the original awards would be recognized if the awards would have vested pursuant to the original terms. In addition, since the original awards were modified, the incremental cost would be measured as the result of the most recent modification; that is, the fair value of the options after the modification to increase the exercise price to $8.98 . This fair value would be compared to the fair value of the RSUs to determine the incremental compensation cost. Incremental compensation cost related to the replacement awards would be recognized only if the modified vesting criteria are achieved. During the three and nine months ended September 30, 2022, the Company recorded stock-based compensation expense related to the RSUs of approximately $0.9 million, respectively. No stock-based compensation expense related to the RSUs was recognized during the three and nine months ended September 30, 2021. The unamortized stock-based compensation expense related to RSUs as of September 30, 2022 is approximately $7.4 million, which is expected to be recognized over a remaining weighted average vesting period of 1.3 years. Canceled Stock Options The Company previously granted options to purchase shares of the Company’s common stock and during the year ended December 31, 2020 these options were canceled. No stock options were outstanding as of September 30, 2022 and December 31, 2021. Compensation cost related to the canceled stock options of $4.3 million will continue to be recognized over the original vesting criteria. During the three months ended September 30, 2022 and 2021, the Company recorded stock-based compensation expense related to the canceled stock options of approximately $0.1 million and $0.3 million, respectively. During the nine months ended September 30, 2022 and 2021, the Company recorded stock-based compensation expense related to the canceled stock options of approximately $0.45 million and $1.1 million, respectively. The unamortized stock-based compensation expense related to canceled stock options as of September 30, 2022 is approximately $0.3 million.	Note 8. Stock-based compensation Stock Options On May 1, 2020, the Company granted 787,499 options to purchase shares of the Company’s common stock. The options had a fair value of approximately $ 4.3 million and vest over a period of 3 years . On August 22, 2020, the Company modified the option exercise price from $0.19 to $5.57 per share, which reduced the fair value of the options to $3.7 million. Pursuant to the guidance of ASC 718 — “Compensation — Stock Compensation”, total recognized compensation cost for an equity award that has been modified and for which the original service conditions are expected to be met shall at least equal the fair value of the award at the grant date. The original vesting conditions of the stock options were expected to be satisfied on the modification date, and therefore the compensation cost to be recognized for awards that ultimately vest cannot be less than the original grant-date fair value of the options of $4.3 million. On December 22, 2020, the Company canceled 787,499 vested and unvested stock options in exchange for 896,583 restricted stock units (see Restricted Stock Units). No stock options were granted during the year ended December 31, 2021, and as of December 31, 2021, there were no stock options outstanding. Restricted Stock Units The following is a summary of the restricted stock units during the years ended December 31, 2021 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ Grant-Date ​ ​ Number of Shares ​ Fair Value Unvested as of January 1, 2020 — ​ $ — Granted 1,377,999 ​ $ 8.98 Unvested as of December 31, 2020 1,377,999 ​ $ 8.98 Forfeited (1,377,999) ​ $ 8.98 Unvested as of December 31, 2021 — ​ $ — ​ On December 22, 2020, the Company granted 481,416 restricted stock units (“RSUs) with a fair value of approximately $4.3 million to employees, officers and directors of the Company. The RSUs are subject to service conditions (vesting of 33.34% on May 1, 2021, with the remaining units vesting on each three-month anniversary thereafter) and performance conditions in the form of a liquidity event. Vesting of the RSUs is subject to all grantees continuous service with the Company, and no vesting shall occur if the Company has not completed a Qualified Offering or a Change of Control on or before the vesting date. In the event that neither a Qualified Offering nor a Change of Control has occurred prior to December 31, 2021, then all RSUs shall be forfeited for no consideration. Because a Qualified Offering or Change of Control is not considered probable of achievement until consummation, compensation cost measured at the grant date is not recognized until such event occurs. On December 22, 2020, the Company granted 896,583 RSU’s with a fair value of approximately $ 6.3 million to its officers and directors, in exchange for 787,499 vested and unvested stock options. The RSUs are subject to service conditions (vesting of 33.34 % on May 1, 2021, with the remaining units vesting on each three-month anniversary, thereafter, fully vesting on May 1, 2023) and performance conditions in the form of a liquidity event. Vesting of the RSUs is subject to all grantees continuous service with the Company, and no vesting shall occur if the Company has not completed a Qualified Offering or a Change of Control on or before the vesting date. In the event that neither an IPO nor change in control has occurred prior to December 31, 2021, then all RSUs shall be forfeited for no consideration. Pursuant to the guidance of ASC 718- “Compensation — Stock Compensation”, the exchange of the options for the RSUs was accounted for as a probable (service only vesting) to improbable (performance and service with the performance criteria considered improbable since contingent upon a Qualified Offering or Change of Control) modification. As such, compensation cost for the original awards would be recognized if the awards would have vested pursuant to the original terms. In addition, since the original awards were modified, the incremental cost would be measured as the result of the most recent modification; that is, the fair value of the options after the modification to increase the exercise price to $ 8.98 . This fair value would be compared to the fair value of the RSUs to determine the incremental compensation cost. Incremental compensation cost related to the replacement awards would be recognized only if the modified vesting criteria are achieved. Compensation cost related to the canceled stock options of $ 4.3 million will continue to be recognized over the original vesting criteria. Because a Qualified Offering or Change of Control is not considered probable of achievement until consummation, the incremental compensation cost measured at the grant date of $1.9 million is not recognized until such event occurs. Since the Company failed to complete a Qualified Offering or a Change of Control prior to December 31, 2021, the RSU’s were forfeited as of December 31, 2021. During the years ended December 31, 2021 and 2020, the Company recorded stock-based compensation expense of approximately $ 1.3 million and $ 2.3 million, respectively. The unamortized stock-based compensation expense related to canceled stock options (as noted above), as of December 31, 2021 is approximately $ 0.7 million.

Preferred and common stock

Preferred and common stock	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Preferred and common stock
Preferred and common stock	Note 8. Preferred and common stock Amendment to Certificate of Incorporation On August 30, 2022, the Company filed an amendment (the “Amendment”) to its certificate of incorporation (the “Certificate”) with the Secretary of State of the State of Delaware in connection with the completion of the Company’s initial public offering. The Amendment amends the Company’s Certificate to, among other things: (i) authorize 200,000,000 shares of common stock and (ii) authorize 10,000,000 shares of preferred stock, 500,000 of which are designated as Series X Preferred Stock. In connection with the initial public offering, the Board waived any lock-up restrictions contained in the Series X Certificate of Designations. Series X Preferred Stock On August 1, 2022, the Company authorized 500,000 shares of Series X preferred stock, par value 0.0001 per share. The stated value of the Series X preferred stock is $100 per share. The holders of the Series X preferred stock have no voting rights and are not entitled to dividends. The Series X preferred stock is convertible into shares of the Company’s common stock and is subject to a beneficial ownership limitation of 9.99% of the number of shares of common stock outstanding at the time of conversion. On August 2, 2022, the Company issued 3,200 shares of Series X preferred stock in a private placement, at a purchase price of $100 per share, and received net proceeds of approximately $0.3 million, after deducting expenses (the “Series X Private Placement”). The Series X Private Placement constituted a qualified offering under the terms of the SAFE and the $5.0 million outstanding under the SAFE automatically converted into 100,000 shares of Series X preferred stock (See Note 5). On August 26, 2022, the Company issued 2,555 shares of its Series X preferred stock in connection with the conversion of certain 2022 Notes (See Note 6). The 2,555 shares of Series X preferred stock are convertible into shares of common stock at the initial offering price of $5.25 per share, subject to the beneficial ownership limitation. On the August 26, 2022, in connection with its Warrant Exchange Agreement (See Note 3), the Company exchanged 750,000 warrants for 350,000 shares of its common stock and 1,250 shares of its Series X preferred stock. On August 26, 2022, upon the consummation of the Company’s initial public offering, 61,689 shares of the Series X preferred stock were converted into 1,175,000 shares of the Company’s common stock. As of September 30, 2022, 45,316 shares of Series X preferred stock remain outstanding. Series Seed Preferred Stock On August 5, 2022, the Company entered into exchange agreements with the holders of the Company’s Series Seed preferred stock, par value $0.0001 per share. The Company and the holders exchanged all shares of outstanding Series Seed preferred stock into 1,557,435 shares of common stock immediately prior to the effectiveness of its registration statement filed in connection with the Company’s initial public offering.	Note 7. Stockholders’ Deficit Preferred Units During the year ended December 31, 2020, TardiMed contributed approximately $470,000 in exchange for 940,000 preferred units, which are convertible into 542,934 shares of the Company’s common stock. During the year ended December 31, 2021, there were no contributions from TardiMed. On March 2, 2020, a third-party investor contributed $50,000 in exchange for 100,000 preferred units. Certain expenses have been allocated by TardiMed and included in its statements of operations and statements of members’ and stockholders’ deficit as a contribution by TardiMed. These expenses are primarily comprised of TardiMed personnel and related expenses, rent and other office expenses which were paid by TardiMed on behalf of the Company. The Company allocated these expenses contributed on a 50% / 50% basis to research and development and selling, general and administrative. For the year ended December 31, 2020, approximately $51,000 was allocated to the Company as non-cash contribution from TardiMed in exchange of 101,514 preferred units and preferred shares, respectively. Cumulative Dividends and Distributions rights Preferred units are entitled to an eight percent cumulative annual return on the sum of such Preferred units outstanding, which shall accrue and compound annually, whether or not declared, and whether or not there are funds legally available for the payment thereof. Such preferred unit return is in preference to any distributions to common stockholders. On the date of issuance determined to be the commitment date the Company evaluated the fair value of the common stock into which the Preferred Units may be converted and the effective conversion price. This evaluation resulted in a beneficial conversion feature of approximately $1.5 million, and accordingly, the Company recorded a deemed dividend for the year ended December 31, 2020. For the year ended December 31, 2020, the Company accrued preferred dividends of $19,000 . Cumulative preferred dividends as of December 31, 2021 and 2020 were $62,000 . For the years ended December 31, 2021 and 2020, no dividends have been declared. Pursuant to the Amended and Restated Limited Liability Company Agreement (“LLC Agreement”) between TardiMed Sciences LLC (“TardiMed”) and Purinix, dated February 19, 2020, TardiMed agreed to commit $0.6 million of capital of the Company in exchange for Preferred units, at a purchase price of $0.87 per Preferred unit and are convertible in unregistered shares. On April 15, 2020, all of the outstanding Preferred units were converted into 2,696,439 shares of preferred stock. Liquidation The Company is intended to have perpetual existence. An event of withdrawal shall not cause a dissolution of the Company and the Company shall continue in existence subject to the terms and conditions of the LLC Agreement. “Event of Withdrawal” means the death, retirement, resignation, expulsion, bankruptcy or dissolution of a Member or the occurrence of any other event that terminates the continued membership of a Member in the Company. As promptly as practicable after dissolution, the liquidators shall (i) determine the Fair Market Value (the “of the Company’s remaining assets, (ii) determine the amounts to be distributed to each Unitholder in accordance and all preferred stockholders shall instead be given 1x Liquidation Preference including dividends. Preferred Stock On April 15, 2020, the Company authorized 2,696,439 shares of $.0001 par value preferred stock. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, or any deemed liquidation event, the holders of preferred stock shall be paid out of the funds of the assets available for distribution to stockholders before any payment is made to common stockholders. A deemed liquidation event includes a merger or consolidation, the sale lease, transfer, exclusive license or other disposition by the Company. The preferred stockholders would be paid at an amount equal to the greater of (i) the applicable original issue price plus any dividends declared but unpaid or (ii) the amount per share of preferred stock that would have been payable had all shares of preferred stock been converted to common stock prior to such liquidation, dissolution or winding up, or deemed liquidation event. Each holder of preferred stock has voting rights equal to the number of whole shares of common stock into which their preferred shares are convertible as of the record date. Each share of preferred stock is convertible at the option of the holder, at any time, into shares of the Company’s common stock, the number of which is determined by dividing the original issue price by the conversion price for that series of preferred stock in effect at the time of conversion. As of December 31, 2021, the Company had 2,696,439 shares of preferred stock issued and outstanding , and the preferred shares are convertible into 1,557,435 shares of common stock. Common stock Under the terms of the LLC Agreement 10,000,000 common units were issued to the founder, TardiMed, and are outstanding. These common units were issued for no consideration. As of April 15, 2020, these common units were converted to shares of common stock on a 1 :1 basis. On July 22, 2020, the Company effected a 1 - for-0.5775898 reverse stock split of its common stock. All share and per share information in the accompanying financial statements and footnotes has been retroactively adjusted for the effects of the reverse split for all periods presented. During the year ended December 31, 2021, in accordance with the original terms, the Company issued 1,137,594 shares of its common stock in connection with the conversion of $3.4 million of notes payable.

Commitments and contingencies_2

Commitments and contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and contingencies
Commitments and contingencies	Note 9. Commitments and contingencies Litigation As of September 30, 2022 and 2021, there was no litigation against the Company. The Company may be involved in legal proceedings, claims and assessments arising from the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance.

Related party transactions_2

Related party transactions	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Related party transactions
Related party transactions	Note 10. Related party transactions Accounts payable - As of September 30, 2022, related party payables totaled approximately $132,000 and consisted of $80,000 owed to Tardimed for management fees, $27,000 owed to members of our board of directors and $25,000 owed to the Company’s Chief Financial Officer for consulting services. During the three months ended September 30, 2022 the Company expensed management fees of $60,000 , board of director fees of $20,000 and related party consulting services of $25,000 . During the nine months ended September 30, 2022 the Company expensed management fees of $180,000 , board of director fees of $74,000 and related party consulting services of $25,000 . Accrued expenses - As of September 30, 2022, there was approximately $50,000 accrued for payroll expenses owed to two terminated employees. During the nine months ended September 30, 2022, the Company reversed $155,000 of bonus expenses in connection with the termination of two of its executives.	Note 11. Related party transactions TardiMed Capital Contributions — TardiMed Sciences is a startup venture investment and operating firm in the life sciences space. The Chairman of the Board of the Company is also a Managing Member of TardiMed. The Chief Operating Officer is an employee of TardiMed. On April 5, 2018, the Company issued 5,775,898 founder common units to TardiMed. As of December 31, 2020 and 2021, TardiMed holds 5,775,898 shares of common stock which represents 100% of the total voting units outstanding. During the year ended December 31, 2020, TardiMed contributed approximately $0.5 million in exchange for approximately 0.9 million shares of preferred stock. Allocated Expenses — Certain expenses, allocated by TardiMed, have been incurred on behalf of the Company and included in its statements of operations and statements of members’ and stockholders’ deficit as a contribution by TardiMed. These expenses are primarily comprised of TardiMed personnel and related expenses, rent and other office expenses. The Company allocated these expenses contributed on a 50 %/ 50 % basis to research and development and selling, general and administrative. Management considers the allocation methodologies used to allocate expenses as reasonable and appropriate based on historical TardiMed expenses attributable to the Company and the Company’s operations. The expenses reflected in the financial statements may not be indicative of expenses that the Company will incur as an independent, publicly traded company and should not be relied upon as an indicator of its future results. No expenses were allocated during the year ended December 31, 2021. During the year ended December 31, 2020, approximately $25,000 was allocated to research and development expenses and approximately $25,000 was allocated to selling, general and administrative expenses. During the year ended December 31, 2021 the Company paid Tardimed $240,000 for management fees. Accounts payable — The related party payables as of December 31, 2021 were nominal. As of December 31, 2020, related party payables totaled approximately $ 100,000 and primarily consisted of $ 70,000 owed to TardiMed, and $ 30,000 owed to members of our board of directors and company executives. Accrued expenses — As of December 31, 2021, accrued expenses included bonus accruals of approximately $ 0.6 million owed to executives of the Company. As of December 31, 2020, accrued expenses included bonus, salary and payroll tax accruals of approximately $ 0.5 million owed to executives of the Company.

Subsequent events_2

Subsequent events	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Subsequent events
Subsequent events	Note 11. Subsequent events The Company evaluated subsequent events and transactions that occurred after the balance sheet date up to the date that the condensed financial statements were issued. Based upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the condensed financial statements. Time-Based Restricted Stock Units Subsequent to September 30, 2022, the Company granted 51,583 time-based RSUs with a fair value of approximately $124,000 to a member of its board of directors. The RSUs are subject to service conditions and vest 33.34% on the one year anniversary of the grant date, with the remaining units vesting on each three-month anniversary thereafter. Subsequent to September 30, 2022, the Company granted 12,000 time-based RSUs with a fair value of approximately $29,000 for consulting services. The RSUs will vest 100% on January 31, 2023. Performance-Based Restricted Stock Units Subsequent to September 30, 2022, the Company granted 25,000 performance-based RSUs with a fair value of approximately $60,000 for consulting services. The RSUs are subject to a performance condition, and will vest upon the Company signing a definitive agreement with a strategic partner. ​	Note 12. Subsequent events The Company has completed an evaluation of all subsequent events through June 10, 2022, the date the financial statements were available to be issued, to ensure that these financial statements include appropriate disclosure of events both recognized in the financial statements and events which occurred but were not recognized in the financial statements. Except as described below, the Company has concluded that no subsequent event has occurred that require disclosure within these financial statements. Convertible Promissory Notes In April 2022, the Company entered into senior secured convertible promissory notes with a principal balance totaling approximately $ 1.2 million. The notes contain an original issue discount totaling $ 0.1 million and the Company received net proceeds of approximately $ 1.1 million. The notes bear interest at 10 % per annum and mature 12 months from the issuance date. The notes are secured by all assets and personal property of the Company. The note holders have the right to convert all or any portion of the outstanding principal balance and accrued interest into shares of the Company’s common stock, up to a beneficial ownership limitation of 9.99 % of the number of shares of common stock outstanding at the time of conversion. The per share conversion price shall be equal to the lessor of (i) $ 7.00 or (ii) 80 % of the qualified offering price of the Company’s common stock resulting from the listing for trading of its common stock on a qualified exchange. In connection with the notes, the Company issued common stock warrants to purchase 164,284 shares of the Company’s common stock. The warrants have an exercise price of the lessor of (i) $ 7.00 or (ii) 80 % of the qualified offering price, and expire five years from the issuance date.

Significant accounting polici_8

Significant accounting policies (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Significant accounting policies
Basis of presentation	Basis of presentation The accompanying unaudited condensed financial statements are presented in U.S. dollars and in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results that may be expected through December 31, 2022. The accompanying unaudited condensed financial statements should be read in conjunction with the audited financial statements and notes thereto included in the registration statement on Form S-1/A filed by the Company with the SEC on August 8, 2022.	Basis of presentation The Company’s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”) as determined by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and include all adjustments necessary for the fair presentation of its balance sheets, results of operations and cash flows for the period presented.
Use of estimates	Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed financial statements relate to the valuation of convertible notes, valuation of warrants, valuation of the Simple Agreement For Equity (“SAFE”) liability and valuation of equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.	Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s financial statements relate to the valuation of warrants, valuation of the SAFE liability and valuation of equity-based awards. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.
Cash, cash equivalents and short-term investments	Cash, cash equivalents and short-term investments The Company considers all highly liquid investments with an original maturity of three months or less at the date of acquisition to be cash equivalents. As of September 30, 2022 and December 31, 2021, the Company had no cash equivalents or short-term investments.	Cash, cash equivalents and short-term investments The Company considers all highly liquid investments with an original maturity of three months or less at the date of acquisition to be cash equivalents. As of December 31, 2021 and 2020, the Company had no cash equivalents or short-term investments .
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash high credit quality financial institutions, which may at times, be in excess of federal insured limits. The Company believes it is not exposed to any significant losses due to credit risk on cash.	Concentrations of Credit Risk Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash high credit quality financial institutions, which may at times, be in excess of federal insured limits. The Company believes it is not exposed to any significant losses due to credit risk on cash.
Fair value of financial instruments	Fair value of financial instruments The Company accounts for financial instruments under Financial Accounting Standards Board (“FASB”) Accounting Standards Codification 820 (“ASC 820”), Fair Value Measurements. This statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements, ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels as follows: Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 - observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and Level 3 - assets and liabilities whose significant value drivers are unobservable. Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment. During the nine months ended September 30, 2022, the Company issued certain of the 2022 Notes and warrants in connection with the 2022 Notes. The 2022 Notes and warrants were classified as liabilities and measured at fair value on the issuance date, with changes in fair value recognized as other expense on the statements of operations and disclosed in the condensed financial statements During the year ended December 31, 2021, the Company entered into its SAFE agreement and classified the SAFE as a liability measured at cost on the issuance date, with changes in fair value recognized as other income on the statement of operations. The carrying amounts of the Company’s financial assets and liabilities, such as accounts payable, approximate fair value due to the short-term nature of these instruments.	Fair value of financial instruments The Company accounts for financial instruments under FASB Accounting Standards Codification 820 (“ASC 820”), Fair Value Measurements. This statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements, ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels as follows: Level 1 — quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 — observable inputs other than Level 1, quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, and model-derived prices whose inputs are observable or whose significant value drivers are observable; and Level 3 — assets and liabilities whose significant value drivers are unobservable. Observable inputs are based on market data obtained from independent sources, while unobservable inputs are based on the Company’s market assumptions. Unobservable inputs require significant management judgment or estimation. In some cases, the inputs used to measure an asset or liability may fall into different levels of the fair value hierarchy. In those instances, the fair value measurement is required to be classified using the lowest level of input that is significant to the fair value measurement. Such determination requires significant management judgment. During the year ended December 31, 2021, the Company entered into its SAFE agreement and classified the SAFE as a liability measured at cost on the issuance date, with changes in fair value recognized as other income on the statement of operations. During the year ended December 31, 2020, the Company issued convertible notes and warrants in connection with the notes. The notes and warrants were classified as liabilities and measured at fair value on the issuance date, with changes in fair value recognized as other expense on the statements of operations and disclosed in the financial statements. The carrying amounts of the Company’s financial assets and liabilities, such as accounts payable, approximate fair value due to the short-term nature of these instruments.
Convertible Notes	Convertible Notes In accordance with Accounting Standards Codification 825, Financial Instruments (“ASC 825”), the Company has elected the fair value option for recognition of its 2022 Notes. In accordance with ASC 825, the Company recognizes these 2022 Notes at fair value with changes in fair value recognized in the condensed statements of operations. The fair value option may be applied instrument by instrument, but it is irrevocable. As a result of applying the fair value option, direct costs and fees related to the convertible notes were recognized in general and administrative expense. Accrued interest for the 2022 Notes has been included in the change in fair value of convertible notes in the condensed statements of operations.
Warrant Liability	Warrant Liability The Company accounts for certain common stock warrants outstanding as a liability at fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statements of operations. The fair value of the warrants issued by the Company have been estimated using the Monte Carlo simulation. As of September 30, 2022, there are no warrant liabilities (See Note 3).	Warrant Liability The Company accounts for certain common stock warrants outstanding as a liability at fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s statements of operations. The fair value of the warrants issued by the Company has been estimated using the Monte Carlo simulation.
Simple Agreement for Future Equity	Simple Agreement for Future Equity The Company accounts for a SAFE as a liability at fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until a triggering event, equity financing or a liquidity/dissolution occurs, and any change in fair value is recognized in the Company’s statements of operations. The fair value of the SAFE has been estimated using the Backsolve method which utilizes the Option Pricing Method. As of September 30, 2022, the SAFE liability has been converted to 100,000 shares of Series X preferred stock (See Note 8).	Simple Agreement for Future Equity The Company accounts for a SAFE as a liability at fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until a triggering event, equity financing or a liquidity/dissolution occurs, and any change in fair value is recognized in the Company’s statements of operations. The fair value of the SAFE has been estimated using the Backsolve method which utilizes the Option Pricing Method.
Research and development	Research and development Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.	Research and development Research and development costs are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made.
Accrued Outsourcing Costs	Accrued Outsourcing Costs Substantial portions of the Company’s preclinical studies and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors (collectively “CROs”). These CROs generally bill monthly or quarterly for services performed, or bill based upon milestone achievement. For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining. Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources a substantial portion of its clinical trial activities, utilizing external entities such as CROs, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies. For each clinical trial that the Company conducts, certain clinical trial costs are expensed immediately, while others are expensed over time based on the number of patients in the trial, the attrition rate at which patients leave the trial, and/or the period over which clinical investigators or CROs are expected to provide services. The Company’s estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.	Accrued Outsourcing Costs Substantial portions of the Company’s preclinical studies and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors (collectively “CROs”). These CROs generally bill monthly or quarterly for services performed, or bill based upon milestone achievement. For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining. Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company outsources a substantial portion of its clinical trial activities, utilizing external entities such as CROs, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies. For each clinical trial that the Company conducts, certain clinical trial costs are expensed immediately, while others are expensed over time based on the number of patients in the trial, the attrition rate at which patients leave the trial, and/or the period over which clinical investigators or CROs are expected to provide services. The Company’s estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.
Stock-Based Compensation	Stock-Based Compensation The Company expenses stock-based compensation to employees, non-employees and board members over the requisite service period based on the estimated grant-date fair value of the awards and actual forfeitures. The Company accounts for forfeitures as they occur. Stock-based awards with graded vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. All stock-based compensation costs are recorded in general and administrative costs in the statements of operations.	Stock-Based Compensation The Company expenses stock-based compensation to employees, non-employees and board members over the requisite service period based on the estimated grant-date fair value of the awards and actual forfeitures. The Company accounts for forfeitures as they occur. Stock-based awards with graded vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. All stock-based compensation costs are recorded in general and administrative costs in the statements of operations.
Income (Loss) Per Share	Loss Per Share Basic net loss per share (“EPS”) of common stock is computed by dividing net loss allocated to common shareholders by the weighted average number of common shares outstanding during the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity. The Company’s common stock equivalents have been excluded from the computation of diluted loss per share for the three and nine months ended September 30, 2022 and 2021, as the effect would be to reduce the loss per share. Therefore, the weighted average common stock outstanding used to calculate both basic and diluted loss per share is the same for the three and nine months ended September 30, 2022 and 2021. The following securities were excluded from the computation of diluted net loss per share attributable to common shareholders for the nine months ended September 30, 2022 and 2021, because including them would have been anti-dilutive: ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ 2022 2021 Preferred stock — 1,557,435 Series X preferred stock ​ 863,162 ​ — Unvested restricted stock units 1,582,220 1,377,999 Common stock warrants 587,497 1,034,176 SAFE investment — 414,808 Convertible notes 37,259 — Total 3,070,138 4,384,418	Loss Per Share Basic net loss per share (“EPS”) of common stock is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted EPS reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the entity. Since the Company has net losses, basic and diluted net loss per share is the same. Securities that could potentially dilute loss per share in the future were not included in the computation of diluted loss per share at December 31, 2021 and 2020, because their inclusion would be anti-dilutive are as follows: ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2021 2020 Preferred stock 1,557,435 1,557,435 Unvested restricted stock units — 1,377,999 Common stock warrants 1,034,176 1,034,176 Convertible notes — 1,034,177 SAFE investment (1) 414,808 — Total 3,006,419 5,003,787 (1) SAFE investment As of December 31, 2021, the Company’s price per share of $12.05 was calculated by dividing the post money valuation of $150 million by 12,444,251 shares of common stock outstanding. The 12,444,251 shares of common stock outstanding was calculated in accord with the agreement and includes 6,913,492 of common shares outstanding, 2,703,776 of IPO shares, 1,377,999 of restricted stock units, 1,034,176 of common stock warrants and 414,808 of SAFE shares. The SAFE investment shares of 414,808 (included in the table above) were calculated using the SAFE investment of $5.0 million divided by $12.05 per share.
Income taxes	Income taxes ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim period, disclosure and transition. Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company’s condensed financial statements. The Company believes that its income tax positions and deductions would be sustained on audit and does not anticipate any adjustments that would result in material changes to its financial position.	Income taxes From April 5, 2018 (Inception) through April 14, 2020, the Company was organized as an LLC and subject to the provisions of Subchapter K of the Internal Revenue Code. As such, the Company was not viewed as a taxpaying entity in any jurisdiction and did not require a provision for income taxes for this period. Each member was responsible for the tax liability, if any, related to its proportionate share of the Company’s taxable losses for this period. ASC 740 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. Based on the Company’s evaluation, it has been concluded that there are no significant uncertain tax positions requiring recognition in the Company’s financial statements. The Company believes that its income tax positions and deductions would be sustained on audit and does not anticipate any adjustments that would result in material changes to its financial position. The Company converted to a C-Corporation on April 15, 2020 and therefore the Company is subject to examination starting in 2020. The Company’s tax year, 2021 and 2020 federal tax returns remain subject to examination by the Internal Revenue Service. Given the Company’s historical losses, the conversion to a C-Corporation did not have a material impact on the Company financial statements.
Recent accounting pronouncements	Recent accounting pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This ASU is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company adopted this standard on January 1, 2022, and the adoption did not have a material impact on the Company’s condensed financial statements or disclosures. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The Company adopted this standard on January 1, 2022, and the adoption did not have a material impact on the Company’s condensed financial statements or disclosures.	Recent accounting pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt — Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging — Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. The ASU removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. This ASU is effective for annual reporting periods beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. This update permits the use of either the modified retrospective or fully retrospective method of transition. The Company adopted this standard on January 1, 2022, and the adoption did not have a material impact on the Company’s financial statements or disclosures. In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40). This ASU reduces diversity in an issuer’s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. This ASU provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. It specifically addresses: (1) how an entity should treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; (2) how an entity should measure the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange; and (3) how an entity should recognize the effect of a modification or an exchange of a freestanding equity-classified written call option that remains equity classified after modification or exchange. This ASU will be effective for all entities for fiscal years beginning after December 15, 2021. An entity should apply the amendments prospectively to modifications or exchanges occurring on or after the effective date of the amendments. Early adoption is permitted, including adoption in an interim period. The Company adopted this standard on January 1, 2022, and the adoption did not have a material impact on the Company’s financial statements or disclosures.

Significant accounting polici_9

Significant accounting policies (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Significant accounting policies
Schedule of securities excluded from the computation of diluted net loss per share attributable to common shareholders	The following securities were excluded from the computation of diluted net loss per share attributable to common shareholders for the nine months ended September 30, 2022 and 2021, because including them would have been anti-dilutive: ​ ​ ​ ​ ​ ​ ​ September 30, ​ ​ 2022 2021 Preferred stock — 1,557,435 Series X preferred stock ​ 863,162 ​ — Unvested restricted stock units 1,582,220 1,377,999 Common stock warrants 587,497 1,034,176 SAFE investment — 414,808 Convertible notes 37,259 — Total 3,070,138 4,384,418	​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2021 2020 Preferred stock 1,557,435 1,557,435 Unvested restricted stock units — 1,377,999 Common stock warrants 1,034,176 1,034,176 Convertible notes — 1,034,177 SAFE investment (1) 414,808 — Total 3,006,419 5,003,787 (1) SAFE investment

Fair Value Measurements (Tabl_2

Fair Value Measurements (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Summary of significant unobservable inputs (Level 3 inputs) used in measurement upon issuance dates		​ ​ ​ ​ ​ ​ Year Ended ​ ​ December 31, 2020 Contingent interest rate 15.0 % Interest rate 10.0 % Expected term 0.8 – 1.0 ​
Summary of Company's liabilities measured at fair value on a recurring basis into fair value hierarchy	The following tables classify the Company’s liabilities measured at fair value on a recurring basis into the fair value hierarchy as of September 30, 2022 and December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value measured at September 30, 2022 ​ ​ ​ ​ Quoted prices in active ​ Significant other ​ Significant ​ ​ Total carrying value at ​ markets ​ observable inputs ​ unobservable inputs ​ September 30, 2022 (Level 1) (Level 2) (Level 3) Liabilities: ​ ​ ​ ​ Convertible notes ​ $ 156,486 ​ $ — ​ $ — ​ $ 156,486 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value measured at December 31, 2021 ​ ​ ​ ​ Quoted prices in active ​ Significant other ​ Significant ​ ​ Total carrying value at ​ markets ​ observable inputs ​ unobservable inputs ​ December 31, 2021 (Level 1) (Level 2) (Level 3) Liabilities: ​ ​ ​ ​ SAFE liability ​ $ 4,824,217 ​ $ — ​ $ — ​ $ 4,824,217 Warrant liability ​ $ 4,516,485 ​ $ — ​ $ — ​ $ 4,516,485	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value measured at December 31, 2021 ​ ​ Total carrying ​ Quoted prices in ​ Significant other ​ Significant ​ ​ value at ​ active markets ​ observable inputs ​ unobservable inputs ​ December 31, 2021 (Level 1) (Level 2) (Level 3) Liabilities: ​ ​ ​ ​ SAFE liability ​ $ 4,824,217 ​ $ — ​ $ — ​ $ 4,824,217 Warrant liability ​ $ 4,516,485 ​ $ — ​ $ — ​ $ 4,516,485 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair value measured at December 31, 2020 ​ ​ Total carrying ​ Quoted prices in ​ Significant other ​ Significant ​ ​ value at ​ active markets ​ observable inputs ​ unobservable inputs ​ December 31, 2020 (Level 1) (Level 2) (Level 3) Liabilities: ​ ​ ​ ​ Warrant liability ​ $ 4,057,927 ​ $ — ​ $ — ​ $ 4,057,927 Contingent Interest ​ $ 59,890 ​ $ — ​ $ — ​ $ 59,890
Summary of changes in Level 3 liabilities measured at fair value	The following table presents changes in Level 3 liabilities measured at fair value for the nine months ended September 30, 2022. Unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to unobservable (e.g., changes in unobservable long-dated volatilities) inputs. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Convertible Notes SAFE Liability Warrant Liability Balance at December 31, 2021 ​ $ — ​ $ 4,824,217 ​ $ 4,516,485 Issuance of convertible notes and warrants ​ 1,353,720 ​ — ​ 278,494 Conversion of SAFE liability to Series X preferred stock ​ ​ — ​ ​ (10,000,000) ​ ​ — Issuance of common stock in connection with conversion of notes payable ​ ​ (1,159,500) ​ ​ — ​ ​ — Issuance of Series X preferred stock in connection with conversion of notes payable ​ ​ (296,819) ​ ​ — ​ ​ — Warrants exchanged for shares of common stock and Series X preferred stock ​ ​ — ​ ​ — ​ ​ (2,009,207) Loss on extinguishment of debt ​ ​ 3,940 ​ ​ — ​ ​ — Change in fair value ​ 255,145 ​ (163,025) ​ (1,873,192) Reclassification of warrants to equity ​ ​ — ​ ​ — ​ ​ (912,580) Loss on conversion of SAFE ​ ​ — ​ ​ 5,338,808 ​ ​ — Balance at September 30, 2022 ​ $ 156,486 ​ $ — ​ $ —	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ SAFE Liability Warrant Liability Contingent Interest Balance at December 31, 2019 ​ $ — ​ $ — ​ $ — Issuance of warrants in connection with convertible notes ​ — ​ 2,488,544 ​ — Contingent interest in connection with notes payable ​ — ​ — ​ 55,394 Change in fair value ​ — ​ 1,569,383 ​ 4,496 Balance at December 31, 2020 ​ $ — ​ $ 4,057,927 ​ $ 59,890 Gain on conversion of notes ​ — ​ — ​ (59,890) Issuance of SAFE ​ 5,000,000 ​ — ​ — Change in fair value ​ (175,783) ​ 458,558 ​ — Balance at December 31, 2021 ​ $ 4,824,217 ​ $ 4,516,485 ​ $ —
SAFE Agreement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Summary of significant unobservable inputs (Level 3 inputs) used in measurement upon issuance dates	A summary of significant unobservable inputs (Level 3 inputs) used in measuring the SAFE on the conversion date of August 2, 2022, and the period January 1, 2022 through August 2, 2022 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1, ​ ​ August 2, ​ 2022 - August ​ ​ 2022 2, 2022 Dividend yield 0 % 0 % Expected price volatility 50.0 % 50.0 % Risk free interest rate 3.08 % 1.35% - 3.08 % Expected term (in years) 1.5 0.8 - 1.5 ​	​ ​ ​ ​ ​ ​ Year Ended ​ ​ December 31, 2021 Dividend yield — ​ Expected price volatility 50.0 % Risk free interest rate 0.06 % – 0.07 % Expected term (in years) 1.0 – 5.0 ​
Warrant Exchange Agreement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Summary of significant unobservable inputs (Level 3 inputs) used in measurement upon issuance dates	A summary of significant unobservable inputs (Level 3 inputs) used in measuring warrants on issuance date, August 26, 2022, and during the period January 1, 2022 through August 26, 2022, is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ January 1 2022 - ​ ​ July 2022 August 26, 2022 August 26, 2022 Dividend yield 0 % 0 % 0 % Expected price volatility 57.0 % 57.0 % 57.0% - 105.0 % Risk free interest rate 2.70 % - 2.82 % 2.39% - 3.40 % 0.17% - 3.40 % Expected term (in years) 5.0 ​ 0.1 - 4.9 0.1 - 4.0 ​	​ ​ ​ ​ ​ ​ ​ ​ ​ Years Ended December 31, ​ 2021 2020 Dividend yield ​ — ​ — ​ Expected price volatility 76.8 % – 112.1 % 108.7 % – 114.4 % Risk free interest rate 0.05 % – 1.09 % 0.10 % – 0.38 % Expected term (in years) 1.0 – 5.0 1.0 – 5.0 ​
2022 Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Summary of significant unobservable inputs (Level 3 inputs) used in measurement upon issuance dates	A summary of significant unobservable inputs (Level 3 inputs) used in measuring the 2022 Notes upon the issuance dates, conversion dates and during three and nine months ended September 30, 2022 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three months ​ ​ ​ ​ ​ ​ August 3, 2022 - ​ ended September ​ Nine months ended ​ ​ July 8, 2022 August 5, 2022 30, 2022 September 30, 2022 Dividend yield 0 % 0 % 0 % 0 % Expected price volatility 57.0 % 57.0 % 57.0 % 57.0% - 57.2 % Risk free interest rate 2.96 % 3.14 %- 3.29 % 2.8 %- 4.05 % 2.8 %- 4.05 % Expected term (in years) 1.0 1.0 0.7 - 0.9 ​ 0.7 - 0.9 ​

Accrued Expenses (Tables)_2

Accrued Expenses (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Accrued Expenses
Schedule of Company's accrued expenses	The Company’s accrued expenses as of September 30, 2022 and December 31, 2021 consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ September 30, ​ December 31, ​ ​ 2022 ​ 2021 ​ (Unaudited) ​ ​ Employee and related expenses ​ $ 50,335 ​ $ 680,026 Directors and officers insurance ​ ​ 385,362 ​ ​ — Professional fees ​ ​ 153,995 ​ ​ — Research and development ​ 24,758 ​ — Total accrued expenses ​ $ 614,450 ​ $ 680,026	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2021 2020 Accrued expenses: ​ ​ ​ ​ Employee and related expenses ​ $ 680,026 ​ $ 499,752 Research and development ​ — ​ 4,000 Professional fees ​ — ​ 74,772 Total accrued expenses ​ $ 680,026 ​ $ 578,524

Stock-based compensation (Tab_2

Stock-based compensation (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Stock-based compensation.
Summary of stock based compensation	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, Nine Months Ended September 30, ​ ​ 2022 2021 ​ 2022 2021 Canceled stock options ​ $ 119,829 ​ $ 272,124 ​ $ 449,840 ​ $ 1,110,874 Restricted stock units ​ 927,324 ​ — ​ 927,325 ​ — Total ​ $ 1,047,153 ​ $ 272,124 ​ $ 1,377,165 ​ $ 1,110,874
Summary of the restricted stock units	The following is a summary of the restricted stock units during the nine months ended September 30, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ Grant-Date ​ Number of Shares Fair Value Unvested as of December 31, 2021 — ​ $ — Granted 1,885,500 ​ $ 5.25 Forfeited (291,500) ​ $ 5.25 Vested ​ (11,780) ​ $ 5.26 Unvested as of September 30, 2022 1,582,220 ​ $ 5.25	The following is a summary of the restricted stock units during the years ended December 31, 2021 and 2020: ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ Grant-Date ​ ​ Number of Shares ​ Fair Value Unvested as of January 1, 2020 — ​ $ — Granted 1,377,999 ​ $ 8.98 Unvested as of December 31, 2020 1,377,999 ​ $ 8.98 Forfeited (1,377,999) ​ $ 8.98 Unvested as of December 31, 2021 — ​ $ —

Organization and description _5

Organization and description of business operations - Initial Public Offering (Details) $ / shares in Units, $ in Millions	Aug. 30, 2022 USD ($) $ / shares shares	Aug. 09, 2022 D $ / shares shares	Sep. 30, 2022 $ / shares	Dec. 31, 2021 $ / shares	Dec. 31, 2020 $ / shares	Apr. 15, 2020 $ / shares
Initial Public Offering
Common stock, par value (in dollars per share)			$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Price per share				$ 12.05
Initial public offering
Initial Public Offering
Common stock, par value (in dollars per share)		$ 0.0001
Shares agreed to sell (in shares) | shares		1,545,454
Purchase price per share (in dollars per share)		$ 4.83
Price per share		$ 5.25
Net proceeds from issuance | $	$ 6
Underwriter fees and commissions | $	0.8
Offering costs | $	$ 1.4
Number of warrants issued (in shares) | shares	108,181
Exercise price of warrants (in dollars per share)	$ 6.5625
Overallotment option
Initial Public Offering
Shares agreed to sell (in shares) | shares		231,818
Number of days option provided | D		45

Organization and description _6

Organization and description of business operations - Going concern, liquidity and capital resources (Details) - USD ($)			3 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended
	Aug. 02, 2022	Apr. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020	Aug. 01, 2022	Apr. 15, 2020
Organization And Description Of Business Operation
Revenue						$ 0		$ 0
Accumulated deficit			$ (28,519,368)		$ (28,519,368)	(28,519,368)		(18,938,249)	$ (8,709,278)
Net loss			$ (11,463,613)	$ (3,110,642)		(9,581,119)	$ (16,462,227)	(10,228,971)	(7,826,008)
Net cash used in operating activities						(3,004,175)	$ (4,264,250)	$ (5,512,639)	$ (2,348,822)
2022 Notes, net proceeds received						$ 1,240,970
Par value per share (in dollars per share)			$ 0.0001		$ 0.0001	$ 0.0001		$ 0.0001	$ 0.0001		$ 0.0001
Net proceeds						$ 300,000
Series X preferred stock
Organization And Description Of Business Operation
Number of shares issued (in shares)	3,200
Par value per share (in dollars per share)	$ 0.0001									$ 0.0001
Purchase price per share (in dollars per share)	$ 100
Net proceeds	$ 300,000
2022 Notes
Organization And Description Of Business Operation
2022 Notes, principal balance			$ 1,500,000		$ 1,500,000	1,500,000
2022 Notes, original issue discount			$ 300,000		300,000	$ 300,000
2022 Notes, net proceeds received					$ 1,200,000
Subsequent event | 2022 Notes
Organization And Description Of Business Operation
2022 Notes, principal balance		$ 1,200,000
2022 Notes, original issue discount		100,000
2022 Notes, net proceeds received		$ 1,100,000

Significant accounting polic_10

Significant accounting policies - Cash, cash equivalents and short-term investments (Details) - USD ($)	Jun. 30, 2022	Dec. 31, 2021
Significant accounting policies
Cash equivalents	$ 0	$ 0
Short-term investments	$ 0	$ 0

Significant accounting polic_11

Significant accounting policies - Anti-dilutive securities (Details) - shares	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Anti-dilutive securities
Anti-dilutive securities excluded from the computation of diluted net loss per share attributable to common shareholders	3,070,138	4,384,418	3,006,419	5,003,787
Preferred stock
Anti-dilutive securities
Anti-dilutive securities excluded from the computation of diluted net loss per share attributable to common shareholders		1,557,435	1,557,435	1,557,435
Series X preferred stock
Anti-dilutive securities
Anti-dilutive securities excluded from the computation of diluted net loss per share attributable to common shareholders	863,162
Unvested restricted stock units
Anti-dilutive securities
Anti-dilutive securities excluded from the computation of diluted net loss per share attributable to common shareholders	1,582,220	1,377,999		1,377,999
Common stock warrants
Anti-dilutive securities
Anti-dilutive securities excluded from the computation of diluted net loss per share attributable to common shareholders	587,497	1,034,176	1,034,176	1,034,176
SAFE investment
Anti-dilutive securities
Anti-dilutive securities excluded from the computation of diluted net loss per share attributable to common shareholders		414,808	414,808
Convertible notes
Anti-dilutive securities
Anti-dilutive securities excluded from the computation of diluted net loss per share attributable to common shareholders	37,259			1,034,177

Significant accounting polic_12

Significant accounting policies - SAFE Investment (Details) - shares		9 Months Ended
	Aug. 02, 2022	Sep. 30, 2022
Series X preferred stock
Accounting Policies
Conversion of SAFE liability to Series X preferred stock (in shares)	100,000	100,000

Fair Value Measurements - Lev_2

Fair Value Measurements - Level 3 Inputs (Details)	Sep. 30, 2022 item	Aug. 26, 2022 item	Aug. 05, 2022 item	Aug. 02, 2022 item	Jul. 08, 2022 item	Jul. 02, 2022 item	Dec. 31, 2021 Y	Dec. 31, 2020 Y
SAFE Liability | Dividend yield
Fair Value Measurement Inputs and Valuation Techniques
Measurement input				0
SAFE Liability | Expected price volatility
Fair Value Measurement Inputs and Valuation Techniques
Measurement input				0.500			0.500
SAFE Liability | Risk free interest rate
Fair Value Measurement Inputs and Valuation Techniques
Measurement input				0.0308
SAFE Liability | Risk free interest rate | Minimum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input				0.0135			0.0006
SAFE Liability | Risk free interest rate | Maximum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input				0.0308			0.0007
SAFE Liability | Expected term (in years)
Fair Value Measurement Inputs and Valuation Techniques
Measurement input				1.5
SAFE Liability | Expected term (in years) | Minimum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input				0.8			1
SAFE Liability | Expected term (in years) | Maximum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input				1.5			5
Warrant Liability | Dividend yield
Fair Value Measurement Inputs and Valuation Techniques
Measurement input		0				0
Warrant Liability | Expected price volatility
Fair Value Measurement Inputs and Valuation Techniques
Measurement input		0.570				0.570
Warrant Liability | Expected price volatility | Minimum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input		0.570					0.768	1.087
Warrant Liability | Expected price volatility | Maximum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input		1.050					1.121	1.144
Warrant Liability | Risk free interest rate | Minimum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input	0.0017	0.0239				0.0270	0.0005	0.0010
Warrant Liability | Risk free interest rate | Maximum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input	0.0340	0.0340				0.0282	0.0109	0.0038
Warrant Liability | Expected term (in years)
Fair Value Measurement Inputs and Valuation Techniques
Measurement input						5
Warrant Liability | Expected term (in years) | Minimum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input		0.1					1	1
Warrant Liability | Expected term (in years) | Maximum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input	4	4.9					5	5
Convertible Notes | Dividend yield
Fair Value Measurement Inputs and Valuation Techniques
Measurement input	0		0		0
Convertible Notes | Expected price volatility
Fair Value Measurement Inputs and Valuation Techniques
Measurement input	0.570		0.570		0.570
Convertible Notes | Expected price volatility | Minimum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input	0.570
Convertible Notes | Expected price volatility | Maximum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input	0.572
Convertible Notes | Risk free interest rate
Fair Value Measurement Inputs and Valuation Techniques
Measurement input					2.96
Convertible Notes | Risk free interest rate | Minimum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input	0.028		0.0314
Convertible Notes | Risk free interest rate | Maximum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input	0.0405		0.0329
Convertible Notes | Expected term (in years)
Fair Value Measurement Inputs and Valuation Techniques
Measurement input			1		1
Convertible Notes | Expected term (in years) | Minimum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input	0.007
Convertible Notes | Expected term (in years) | Maximum
Fair Value Measurement Inputs and Valuation Techniques
Measurement input	0.9

Fair Value Measurements - Add_2

Fair Value Measurements - Additional Information (Details) - USD ($)						3 Months Ended	9 Months Ended	12 Months Ended
	Aug. 26, 2022	Aug. 03, 2022	Aug. 02, 2022	Mar. 19, 2022	Mar. 19, 2021	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Number of shares issued on conversion								1,137,594
Cash received					$ 5,000,000
Common stock warrants issued								1,034,176	1,034,176
Change in Level 3 liabilities measured at fair value								$ 300,000	$ 1,600,000
Reclassification of warrants to equity, shares	479,316
Warrant liability						$ 0	$ 0	$ 4,516,485	$ 4,057,927
Series X Preferred Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Conversion of SAFE liability to Series X preferred stock (in shares)			100,000				100,000
Warrants exchanged for shares of common stock	1,250
Common Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Number of shares issued on conversion	1,175,000
Warrants exchanged for shares of common stock	350,000
2020 Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Warrants exchanged for shares of common stock	750,000
Convertible notes 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Number of shares issued on conversion	238,094							1,137,594
Convertible notes 2022 | Series X Preferred Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Issuance of Series X preferred stock in connection with conversion of notes payable (in shares)	2,555
SAFE Agreement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Change in Level 3 liabilities measured at fair value							$ (163,025)	$ (175,783)
SAFE Agreement | 2020 Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Cash received				$ 5,000,000
Common stock warrants issued							195,140	1,034,176
Number of warrants exchanged		750,000
Change in Level 3 liabilities measured at fair value						$ 3,300,000	$ 1,800,000
Warrants exchanged for shares of common stock		350,000

Fair Value Measurements - Lia_2

Fair Value Measurements - Liabilities Measured at fair value (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Notes payable - fair value	$ 156,486		$ 611,641
Warrant liability	0	$ 4,516,485	4,057,927
SAFE Agreement | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Warrant liability		4,824,217
SAFE Agreement | Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Warrant liability		4,824,217
Warrant Exchange Agreement | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Warrant liability		4,516,485
Warrant Exchange Agreement | Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Warrant liability		4,516,485
2022 Notes | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Notes payable - fair value	156,486
2022 Notes | Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Notes payable - fair value	$ 156,486
2022 Notes | SAFE Agreement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Warrant liability		4,824,217
2022 Notes | SAFE Agreement | Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Warrant liability		4,824,217
2022 Notes | Warrant Exchange Agreement
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Warrant liability		4,516,485	4,057,927
2022 Notes | Warrant Exchange Agreement | Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis
Warrant liability		$ 4,516,485	$ 4,057,927

Fair Value Measurements - Cha_2

Fair Value Measurements - Changes in Level 3 Liabilities (Details) - USD ($)	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
Conversion of SAFE liability to Series X preferred stock	$ 10,000,000	$ 10,000,000
Issuance of common stock in connection with conversion of notes payable	1,159,500	1,159,500	$ 3,412,782	$ 3,412,782
Issuance of Series X preferred stock in connection with conversion of notes payable	296,819	296,819
Warrants exchanged for shares of common stock and Series X preferred stock	2,009,207	2,009,207
Loss on extinguishment of debt	3,940	3,940			$ 23,284
Change in fair value				300,000	1,600,000
Reclassification of warrants to equity	(912,580)	(912,580)
Loss on conversion of SAFE	5,338,808	5,338,808
SAFE Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
Beginning Balance		4,824,217
Issuance of SAFE					5,000,000
Conversion of SAFE liability to Series X preferred stock		(10,000,000)
Change in fair value		(163,025)		(175,783)
Loss on conversion of SAFE		5,338,808
Ending Balance				4,824,217
Warrant Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
Beginning Balance		4,516,485	$ 4,057,927	4,057,927
Issuance of convertible notes and warrants		278,494
Warrants exchanged for shares of common stock and Series X preferred stock		(2,009,207)
Change in fair value		(1,873,192)		458,558
Reclassification of warrants to equity		(912,580)
Ending Balance				$ 4,516,485	4,057,927
Convertible Notes
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
Issuance of convertible notes and warrants		1,353,720
Issuance of common stock in connection with conversion of notes payable		(1,159,500)
Issuance of Series X preferred stock in connection with conversion of notes payable		(296,819)
Loss on extinguishment of debt		3,940
Change in fair value		255,145
Ending Balance	$ 156,486	$ 156,486
Convertible Notes | Warrant Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
Issuance of convertible notes and warrants					2,488,544
Change in fair value					$ 1,569,383

Accrued Expenses (Details)_2

Accrued Expenses (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Accrued Expenses
Employee and related expenses	$ 50,335	$ 680,026	$ 499,752
Directors and officers insurance	385,362
Professional fees	153,995		74,772
Research and development	24,758		4,000
Total accrued expenses	$ 614,450	$ 680,026	$ 578,524

Simple Agreement for Future E_4

Simple Agreement for Future Equity ("SAFE") (Details) - USD ($)		3 Months Ended	9 Months Ended		12 Months Ended
	May 19, 2021	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Aug. 02, 2022
Simple Agreement for Future Equity ("SAFE")
Proceeds From SAFE Investment	$ 5,000,000			$ 5,000,000	$ 5,000,000
Percentage of discount of pricing in the triggering equity financing (as a percent)					50%
Post money valuation					$ 150,000,000
Interest rate (as a percent)					0%
Loss recognized on conversion		$ 5,300,000	$ 5,300,000
Series X Preferred Stock
Simple Agreement for Future Equity ("SAFE")
SAFE, Outstanding amount converted						$ 4,700,000
Number of shares issued upon conversion						100,000

Convertible promissory notes (D

Convertible promissory notes (Details) - USD ($)			3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Aug. 26, 2022	Aug. 03, 2022	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Proceeds from issuance of convertible promissory notes, net of fees					$ 1,240,970
Common stock warrants issued						1,034,176	1,034,176
Loss on issuance of debt			$ (88,234)		(391,246)		$ (53,541)
Fair value loss			(151,195)		(255,145)
Conversion agreement with certain holders of 2022 Notes
Debt Instrument [Line Items]
Principal balance		$ 1,000,000
Conversion price (per share)		$ 4.20
Convertible notes outstanding	$ 1,200,000
Shares converted	238,094
Conversion agreement with an additional holder of 2022 Notes
Debt Instrument [Line Items]
Principal balance		$ 255,555
Convertible notes outstanding	$ 300,000
Conversion agreement with an additional holder of 2022 Notes | Series X Preferred Stock
Debt Instrument [Line Items]
Shares converted	2,555	2,555
2022 Notes
Debt Instrument [Line Items]
Principal balance			1,500,000	$ 1,500,000	1,500,000
Financing fee			100,000	100,000	100,000
Original issue discount			$ 200,000	200,000	$ 200,000
Proceeds from issuance of convertible promissory notes, net of fees				$ 1,200,000
Interest rate per annum			10%	10%	10%
Maturity period				12 months
Percent of beneficial ownership limitation			9.99%	9.99%	9.99%
Conversion price (per share)	$ 4.20		$ 7	$ 7	$ 7
Percent of offering price	80%			80%
Number of warrants exchanged			195,140	195,140	195,140
Exercise price of warrants (in dollars per share)			$ 7	$ 7	$ 7
Percent of qualified offering price				80%
Warrants expiry term			5 years	5 years	5 years
Adjusted exercise price per share				$ 3
2022 Notes, original issue discount			$ 300,000	$ 300,000	$ 300,000
Offering price per share	$ 5.25
Convertible notes outstanding					200,000
Shares converted						1,137,594
Loss on issuance of debt					400,000
Fair value loss					$ 250,000

Stock-based compensation - Summ

Stock-based compensation - Summary of Stock based Compensation (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Stock-based compensation
Stock-based compensation expense	$ 1,047,153	$ 272,124	$ 1,377,165	$ 1,110,874
Cancelled stock options
Stock-based compensation
Stock-based compensation expense	119,829	272,124	449,840	1,110,874
Restricted stock units
Stock-based compensation
Stock-based compensation expense	$ 927,324	$ 0	$ 927,325	$ 0	$ 1,300,000	$ 2,300,000

Stock-based compensation - Re_2

Stock-based compensation - Restricted Stock Units (Details) - $ / shares		1 Months Ended	9 Months Ended	12 Months Ended
	Aug. 26, 2022	Aug. 31, 2022	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Number of units outstanding
Beginning balance (shares)				1,377,999
Granted (shares)		1,051,167			1,377,999
Forfeited (shares)				(1,377,999)
Ending balance (shares)					1,377,999
Weighted Average Fair Value Per unit
Beginning balance (usd per share)					$ 8.98
Granted (usd per share)					8.98
Forfeited (usd per share)				$ 8.98
Ending balance (usd per share)					$ 8.98
Restricted stock units
Number of units outstanding
Granted (shares)	1,051,167		1,885,500
Forfeited (shares)			(291,500)
Vested (shares)			(11,780)
Ending balance (shares)			1,582,220
Weighted Average Fair Value Per unit
Beginning balance (usd per share)			$ 5.25
Granted (usd per share)			5.25
Forfeited (usd per share)			5.25
Vested (usd per share)			5.26
Ending balance (usd per share)			$ 5.25

Stock-based compensation - Ad_2

Stock-based compensation - Additional information (Details)										1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Aug. 26, 2022 shares	Jul. 16, 2022 USD ($) shares	May 15, 2022 USD ($) shares	May 01, 2022	Jan. 01, 2022 USD ($) shares	May 01, 2021 $ / shares	Dec. 22, 2020 USD ($) shares	Aug. 22, 2020 USD ($)	May 01, 2020 USD ($) shares	Aug. 31, 2022 USD ($) shares	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) employee director shares	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($) shares	Dec. 31, 2020 USD ($) shares	Jun. 30, 2022 shares
Stock-based compensation
Number of units granted | shares										1,051,167						1,377,999
Number of units forfeited | shares															1,377,999
Compensation cost | $										$ 5,500,000
Stock options outstanding | shares															0
Stock-based compensation expense | $											$ 1,047,153	$ 272,124	$ 1,377,165	$ 1,110,874
Member of its board of directors
Stock-based compensation
Number of board members terminated | director													2
Employees, officers and directors
Stock-based compensation
Number of employees terminated | employee													2
Restricted stock units
Stock-based compensation
Number of units granted | shares	1,051,167												1,885,500
Fair value of units granted | $								$ 3,700,000
Vesting percentage	33.34%			33.34%
Vesting period	3 months			3 months
Number of units forfeited | shares													291,500
Number of stock options exchanged for units | shares							896,583
Stock-based compensation expense | $											927,324	0	$ 927,325	0	$ 1,300,000	$ 2,300,000
Unamortized stock-based compensation expense | $											7,400,000		$ 7,400,000		$ 700,000
Unamortized stock-based compensation period recognition													1 year 3 months 18 days
Restricted stock units | First three-month anniversary from Start Date
Stock-based compensation
Vesting percentage	8.3325%			8.3325%
Restricted stock units | Second three-month anniversary from Start Date
Stock-based compensation
Vesting percentage	8.3325%			8.3325%
Restricted stock units | Third three-month anniversary from Start Date
Stock-based compensation
Vesting percentage	8.3325%			8.3325%
Restricted stock units | Fourth three-month anniversary from Start Date
Stock-based compensation
Vesting percentage	8.3325%			8.3325%
Restricted stock units | Fifth three-month anniversary from Start Date
Stock-based compensation
Vesting percentage	8.3325%			8.3325%
Restricted stock units | Sixth three-month anniversary from Start Date
Stock-based compensation
Vesting percentage	8.3325%			8.3325%
Restricted stock units | Seventh three-month anniversary from Start Date
Stock-based compensation
Vesting percentage	8.3325%			8.3325%
Restricted stock units | Eighth three-month anniversary from Start Date
Stock-based compensation
Vesting percentage	8.3325%			8.3325%
Restricted stock units | Member of its board of directors
Stock-based compensation
Number of units granted | shares			35,333
Fair value of units granted | $			$ 200,000						$ 4,300,000
Vesting percentage			33.34%
Vesting period			2 years						3 years
Restricted stock units | Member of its board of directors | First three-month anniversary from Start Date
Stock-based compensation
Vesting percentage	8.3325%
Restricted stock units | Member of its board of directors | Second three-month anniversary from Start Date
Stock-based compensation
Vesting percentage	8.3325%
Restricted stock units | Member of its board of directors | Third three-month anniversary from Start Date
Stock-based compensation
Vesting percentage	8.3325%
Restricted stock units | Member of its board of directors | Fourth three-month anniversary from Start Date
Stock-based compensation
Vesting percentage	8.3325%
Restricted stock units | Member of its board of directors | Fifth three-month anniversary from Start Date
Stock-based compensation
Vesting percentage	8.3325%
Restricted stock units | Member of its board of directors | Sixth three-month anniversary from Start Date
Stock-based compensation
Vesting percentage	8.3325%
Restricted stock units | Member of its board of directors | Seventh three-month anniversary from Start Date
Stock-based compensation
Vesting percentage	8.3325%
Restricted stock units | Member of its board of directors | Eighth three-month anniversary from Start Date
Stock-based compensation
Vesting percentage	8.3325%
Restricted stock units | Employees, officers and directors
Stock-based compensation
Number of units granted | shares					1,342,667		896,583		787,499	492,500
Fair value of units granted | $					$ 14,600,000		$ 6,300,000			$ 2,600,000
Vesting percentage				33.34%		33.34%	33.34%			0.33%
Vesting period				3 months						2 years
Number of stock options exchanged for units | shares							787,499
Exercise price | $ / shares						$ 8.98
Restricted stock units | Employees, officers and directors | First three-month anniversary from Start Date
Stock-based compensation
Vesting percentage				8.3325%		8.3325%				8.3325%
Restricted stock units | Employees, officers and directors | Second three-month anniversary from Start Date
Stock-based compensation
Vesting percentage				8.3325%		8.3325%				8.3325%
Restricted stock units | Employees, officers and directors | Third three-month anniversary from Start Date
Stock-based compensation
Vesting percentage				8.3325%		8.3325%				8.3325%
Restricted stock units | Employees, officers and directors | Fourth three-month anniversary from Start Date
Stock-based compensation
Vesting percentage				8.3325%		8.3325%				8.3325%
Restricted stock units | Employees, officers and directors | Fifth three-month anniversary from Start Date
Stock-based compensation
Vesting percentage				8.3325%		8.3325%				8.3325%
Restricted stock units | Employees, officers and directors | Sixth three-month anniversary from Start Date
Stock-based compensation
Vesting percentage				8.3325%		8.3325%				8.3325%
Restricted stock units | Employees, officers and directors | Seventh three-month anniversary from Start Date
Stock-based compensation
Vesting percentage				8.3325%		8.3325%				8.3325%
Restricted stock units | Employees, officers and directors | Eighth three-month anniversary from Start Date
Stock-based compensation
Vesting percentage				8.3325%		8.3325%				8.3325%
Restricted stock units | Chief Financial Officer [Member]
Stock-based compensation
Number of units granted | shares		15,000
Fair value of units granted | $		$ 100,000
Cancelled stock options
Stock-based compensation
Stock options outstanding | shares															0		0
Canceled stock options and the related stock compensation | $								$ 4,300,000			4,300,000		$ 4,300,000		$ 4,300,000
Stock-based compensation expense | $											119,829	$ 272,124	449,840	$ 1,110,874
Unamortized stock-based compensation expense | $											$ 300,000		$ 300,000

Preferred and common stock (Det

Preferred and common stock (Details) - USD ($)					12 Months Ended
	Aug. 30, 2022	Aug. 26, 2022	Aug. 05, 2022	Aug. 02, 2022	Dec. 31, 2021	Sep. 30, 2022	Aug. 01, 2022	Dec. 31, 2020	Apr. 15, 2020
Preferred and common stock
Preferred shares, shares authorized (in shares)					2,696,439	10,000,000		2,696,439	2,696,439
Preferred shares, par value (in dollars per share)					$ 0.0001	$ 0.0001		$ 0.0001	$ 0.0001
Preferred shares, shares outstanding (in shares)					2,696,439			2,696,439
Preferred stock value outstanding					$ 270			$ 270
Number of shares issued on conversion					1,137,594
Preferred stock outstanding					2,696,439			2,696,439
Common stock, shares authorized (in shares)					20,000,000	200,000,000		20,000,000	20,000,000
Warrant Exchange Agreement
Preferred and common stock
Number of warrants exchanged		750,000
Exchange agreements with holders of Seed preferred stock
Preferred and common stock
Preferred shares, par value (in dollars per share)			$ 0.0001
Private placement | SAFE
Preferred and common stock
Preferred stock value outstanding				$ 5,000,000
Initial public offering
Preferred and common stock
Net proceeds from issuance	$ 6,000,000
Preferred Stock
Preferred and common stock
Preferred shares, shares authorized (in shares)	10,000,000
Series X preferred stock
Preferred and common stock
Preferred shares, shares authorized (in shares)	500,000				0	500,000	500,000
Preferred shares, par value (in dollars per share)				$ 0.0001			$ 0.0001
Preferred stock, stated value, (per share)							$ 100
Percentage on number of shares of common stock for beneficial ownership limitation							9.99%
Preferred shares, shares outstanding (in shares)		45,316			0	45,316
Preferred stock value outstanding						$ 15
Preferred stock outstanding		45,316			0	45,316
Series X preferred stock | 2022 Notes
Preferred and common stock
Number of shares issued on conversion		2,555
Conversion price (per share)		$ 5.25
Series X preferred stock | SAFE
Preferred and common stock
Number of shares on conversion of preferred stock				100,000
Series X preferred stock | Warrant Exchange Agreement
Preferred and common stock
Number of shares issued on conversion		1,250
Series X preferred stock | Private placement
Preferred and common stock
Number of shares issued				3,200
Price per share				$ 100
Net proceeds from issuance				$ 300,000
Series X preferred stock | Initial public offering
Preferred and common stock
Number of shares exchanged		61,689
Common Stock
Preferred and common stock
Number of shares issued on conversion		1,175,000
Common stock, shares authorized (in shares)	200,000,000
Common Stock | Warrant Exchange Agreement
Preferred and common stock
Number of shares issued on conversion		350,000
Common Stock | Exchange agreements with holders of Seed preferred stock
Preferred and common stock
Number of shares on conversion of preferred stock			1,557,435

Commitments and contingencies_3

Commitments and contingencies (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020
Commitments and contingencies
Litigation against the Company	$ 0	$ 0	$ 0	$ 0

Related party transactions (D_2

Related party transactions (Details)	3 Months Ended	9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2022 USD ($) employee	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Accounts payable
Related party transactions
Due to related party	$ 132,000	$ 132,000		$ 100,000
Management fees | Accounts payable
Related party transactions
Expensed amount	60,000	180,000
Board of directors fees | Accounts payable
Related party transactions
Expensed amount	20,000	74,000
Consulting services | Accounts payable
Related party transactions
Expensed amount	25,000	25,000
Accrued bonus | Accrued expenses
Related party transactions
Due to related party			$ 600,000
Expensed amount		155,000
Payroll expenses | Accrued expenses
Related party transactions
Due to related party	50,000	50,000
Tardimed | Accounts payable
Related party transactions
Due to related party				70,000
Tardimed | Management fees | Accounts payable
Related party transactions
Due to related party	80,000	80,000
Members of board of directors | Accounts payable
Related party transactions
Due to related party	27,000	27,000
Members of board of directors | Management fees | Accounts payable
Related party transactions
Due to related party				$ 30,000
Chief Financial Officer | Accounts payable
Related party transactions
Due to related party	$ 25,000	$ 25,000
Executives | Accrued expenses
Related party transactions
Number of executives terminated | employee		2

Subsequent events - Additiona_2

Subsequent events - Additional Information (Details) - USD ($)	1 Months Ended	12 Months Ended
	Oct. 31, 2022	Dec. 31, 2021
Subsequent Event [Line Items]
Grants (in shares)		0
Subsequent event | Time-Based Restricted Stock Units | Consulting Services [Member]
Subsequent Event [Line Items]
Grants (in shares)	12,000
Fai value	$ 29,000
Vesting percentage	100%
Subsequent event | Time-Based Restricted Stock Units | Board of Directors Chairman [Member]
Subsequent Event [Line Items]
Grants (in shares)	51,583
Fai value	$ 124,000
Vesting percentage	33.34%
Vesting period	3 months
Subsequent event | Time-Based Restricted Stock Units | Board of Directors Chairman [Member] | Maximum
Subsequent Event [Line Items]
Vesting period	1 year
Subsequent event | Performance-Based Restricted Stock Units | Consulting Services [Member]
Subsequent Event [Line Items]
Grants (in shares)	25,000
Fai value	$ 60,000